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SUMMARY
The influence of pharmacokinetic parameters on the hepatic 
biochemical responses to the peroxisome prolif erators,
ciprofibrate, bezafibrate and clofibrate, was studied in the 
Fischer rat following a 2 6-week treatment period. With once 
daily dosing, the induction profiles of these compounds were 
dissimilar and the order of response was ciprofibrate > 
bezafibrate > clofibrate. By adjusting the frequency of dosing 
with respect to drug half life, i.e. clofibrate and 
bezafibrate twice daily and ciprofibrate once every 48 hours, 
the differences in response were ablated.
The effect of short term ciprofibrate administration on 
hepatic enzyme parameters was studied in different rat strains 
and species. The rat (all strains), mouse, hamster and rabbit 
were termed responsive due to a coordinate induction of 
cytochrome P-452, carnitine acetyltransf erase and peroxisomal 
beta-oxidation. No treatment related changes were observed in 
the guinea pig* In the marmoset a slight increase in 
peroxisomal beta-oxidation was demonstrated with no induction 
of cytochrome P-452 and carnitine acetyltransf erase. In 
responsive species increased 12-hydroxylation of lauric acid 
correlated with an increase in mRNA hybridising to a 
cytochrome P-452 cDNA probe. The guinea pig and marmoset were 
designated non-responsive.
In the marmoset and Fischer rat the hepatic enzyme responses 
to a 14-day and 2 6-week ciprofibrate administration were
similar. A 4-week recovery group was included in the marmoset 
chronic study and the increase in peroxisomal beta-oxidation 
was found to be readily reversible whereas mitochondrial and 
microsomal changes were not. Electron microscopy revealed no 
peroxisome proliferation in the marmoset.
Renal enzyme parameters were examined in ciprofibrate treated 
animals and considerable rat strain and species differences 
were observed. Renal enzyme changes were minimal. The response 
to ciprofibrate appeared to be largely specific for the liver 
in responsive species.
From these results it is clear that the rat is not a suitable 
animal model to predict the hepatic response in the marmoset. 
If it is assumed that the marmoset resembles man more closely 
than the rat, extrapolation would indicate that peroxisome 
prolif erators are not a toxicological hazard to man.
3CHAPTER 1
INTRODUCTION
Peroxisome prolif erators are a group of structurally diverse 
chemicals which on administration to rodents cause a increase 
in peroxisome number and a decrease in plasma triglyceride and 
cholesterol levels (Reddy et al.,1975). This group of 
compounds may be broadly classified into hypolipidaemic agents 
and phthalate ester plasticisers. The term "hypolipidaemic
drug" is used in this thesis to denote hypolipidaemic agents 
approved for clinical therapy either in the United States of 
America or in Europe. In addition to these two categories of 
peroxisome prolif erators, it has been found that certain 
nutritional states stimulate the proliferation of peroxisomes 
with induction of peroxisomal beta-oxidation enzymes, namely a 
high fat diet and a vitamin E deficient diet (Ishii et
al.,1980, Reddy et al.,1981). The phenoxy acid herbicides,
2,4-dichlorophenoxy acetic acid (2,4-D), 2,4,5-trichloro- 
phenoxy acetic acid (2,4,5-T) and 4-chloro-2-methyl-phenoxy
acetic acid (MCPA) have also been found to induce hepatic 
peroxisomal proliferation in rodents in a manner similar to 
clofibrate (Vainio et al.,1983, Kawashima et al.,1984a).
Peroxisome proliferator drugs are used to treat
hyperlipidaemia, a lipid disorder characterised by elevated 
levels of lipoproteins and/or lipids in the blood
(Lewis,1976). Elevated cholesterol and triglyceride levels
have been defined as risk factors for ischaemic heart disease. 
Whether the relationship between hypertriglyceridaemia and
atherosclerosis is causal or casual has yet to be 
unequivocally ascertained, however the evidence is sufficient 
to justify long term treatment as a preventative measure in 
severe cases. With familial hyperlipidaemias, drug treatment 
probably offers the only prospect of successful therapy. The 
prolonged use of lipid lowering drugs has been associated with 
occasional side effects (such as nausea, diarrhoea, vomiting 
and infrequently, cardiac arrhythmias) of varying magnitude 
(Rogers and Spector,1983). There is little information 
available on the long term effects of drug therapy with these 
hypolipidaemic drugs. However, two trials with prolonged 
clofibrate treatment have been completed. In the US Coronary 
Drug Project (treatment period of 5 years) it was found that 
with patients who already have had a myocardial infarction, 
there was no significant reduction in overall mortality, death 
from ischaemic heart disease or further infarctions (Coronary 
Drug Project Research Group, 1975). There was a small but 
significant increase in the incidence of arrhythmias and 
angina in patients with no previous history of this clinical 
condition. In the WHO coordinated trial with a treatment
duration of 4-6 years, there was a decrease in non-fatal 
myocardial infarctions in the treated groups (Oliver, 1978). 
However, in this group there was a higher non-cardiac
mortality rate than with the control subjects, due mainly to 
an increased incidence of malignant neoplasms and 
complications of cholecystectomy. The current use of
clofibrate has become increasingly restricted reflecting the 
doubt of effectiveness of its therapeutic action and the 
possibility of latent side effects.
Two classes of hypolipidaemic agents are recognised as 
inducers of peroxisome proliferation; clofibrate and its
structural analogues and compounds structurally unrelated to 
clofibrate. Examples of these groups are shown in figure 1 
together with examples of phthalate esters inducing
peroxisomal proliferation.
In recent years growing concern has developed regarding the 
possible effects of long term exposure of man to
hypolipidaemic drugs (i.e. therapeutic use) and to industrial 
plasticisers (as a result of leouching from medicinal and food 
packaging) on human health. The concern is based largely on 
the ever increasing evidence that compounds capable of 
inducing peroxisome proliferation in rodent liver also induce 
hepatocellular carcinomas in rats and mice (Reddy, J.K. et 
al.,1980).
From the onset it must be emphasized that although the rodent 
responses to peroxisome prolif erators are amply documented, 
there is intense controversy regarding the relevance of rodent 
data to other species, particularly non-human primates and 
man.
1.1. HEPATIC RESPONSES TO ADMINISTRATION OF PEROXISOME
PROLIFERATORS
The administration of clofibrate and other peroxisome 
proliferators to rodents results in several characteristic 
changes. The induced hepatic responses have been studied
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extensively and can be sub-divided into ;
1. hepatomegaly,
2. proliferation of smooth endoplasmic reticulum and 
induction of cytochrome P-450,
3. peroxisome proliferation and associated changes in 
enzyme composition, and
4. alteration in mitochondrial number and structure with 
concomitant increases in certain enzyme levels.
1.1.1 Hepatomegaly
Hepatomegaly is liver enlargement measured as an increase in 
the liver to body weight ratio and it appears to be a
characteristic response in laboratory animals exposed to a
variety of xenobiotics (Reddy and Lalwani, 1983).
The administration of peroxisome prolif erators to rodents is 
predictably associated with hepatomegaly, the extent of which 
is dependent upon the agent involved (Lake et al.,1975, 
Reddy, J.K., 1980). Liver enlargement is observed in both male 
and female rats and this has been attributed, in part, to an 
increase in phospholipid and total protein levels with an 
associated increase in microsomal and cell sap protein 
concentration (Azarnoff et al.,1965, Platt and Cockrill,1969). 
It is the result of hypertrophy and hyperplasia which 
correlates to increased hepatic DNA content and may be
dependent on the dose and duration of treatment (Beckett et
al.,1972). The hypertrophy is associated with a marked
10
proliferation of the smooth endoplasmic reticulum and 
peroxisomes (Reddy et al.,1973). Chronic administration 
results in an accumulation of protein, phospholipids and RNA 
with the absence of cholesterol or triglycerides indicating an 
adaptive hepatomegaly as opposed to a pathological condition 
associated with fat droplets and high cholesterol and/or
triglyceride levels (Dalton et al.,1974). This liver
enlargement may be associated with mid zonal and periportal 
accumulation of lipid droplets (Mann et al.,1985). Persistent 
hepatomegaly has been observed in rats dosed over a 25 month 
period with nafenopin (Reddy and Rao,1977).
Short-term administration of Wy-14,643 stimulated DNA 
replication and cell division and the increase in tritiated 
thymidine incorporation was apparent at 24 hrs following a 
single dose (Reddy et al.,1979). Treatment of primary cultures 
of rat hepatocytes with nafenopin caused an increased level of 
thymidine incorporation into cultures as a consequence of 
replicative DNA synthesis rather than DNA repair (Bieri et 
al.,1984). Semi-conservative DNA synthesis and not unscheduled 
DNA synthesis was stimulated with replicative DNA synthesis 
occurring between the 2nd and 3rd day in all cultures (Bieri 
et al.,1984). A single treatment of primary neonatal rat 
hepatocytes with nafenopin enhanced hepatocyte DNA synthesis 
irrespective of the environmental calcium level, whereas in 
normal untreated cells the Gl/S transition is physiologically 
controlled by the level of extracellular calcium (Armato et 
al.,1984). This would infer that the mitogenic effect exerted
by nafenopin occurred independently of normal physiologically
11
controlled replication.
Liver enlargement occurs rapidly in response to administration 
reaching a steady state level within 10-14 days which is 
maintained throughout treatment. Hypertrophy may be associated 
with a combined proliferation of the smooth endoplasmic 
reticulum and peroxisomes and in some instances, a 
contributory increase in mitochondrial number. The mitogenic 
effect of nafenopin and Wy-14,643 has been amply described 
(Bieri et al.,1984, Levine et al.,1977 and Reddy et al.,1979) 
and it is probably common to all peroxisome prolif erators 
causing hepatomegaly. It should be noted that the observed 
increase in DNA synthesis occurs in the absence of cyto­
toxicity/hepatocellular necrosis and therefore represents a 
replicative event and not reparative hyperplasia (Levine et 
al.,1977 and Reddy et al.,1979).
1.1.2 Proliferation of Smooth Endoplasmic Reticulum and
Induction of Cytochrome P-450.
No introductory section on cytochrome P-450 has been included 
as this area has been well documented. The physical and 
catalytic properties, induction and multiplicity of cytochrome 
P-450 have been reviewed (Lewis,1986, Guengerich,1987, Nebert 
et al.,1987) and the molecular biology and induction of 
cytochrome P-450 with respect to genetic variability and gene 
regulation has been described at length (Adesnik and 
Atchison,1986, Makowski et al.,1982, Nebert and Gonzalez,1987 
and Whitlock, 1986).
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Cytochrome P-450 Nomenclature.
Cytochromes P-450 are important in the oxidative metabolism of 
many endogenous substrates and innumerable drugs, chemical 
carcinogens and environmental pollutants. More than 300 
chemicals, which induce their own metabolism or metabolism of, 
compounds with chemically related structures, have been 
described (Conney,1967). Over the last two decades workers in 
the field have used a variety of different nomenclatures for 
an increasing number of cytochrome P-450 forms isolated in 
their laboratories. These trivial names may reflect the nature 
of the inducing agent, the substrate specificity, the reaction 
catalysed, the absorption maximum or may merely be 
alphabetical or numerical (Guengerich,1987).
Recently a standardised nomenclature for the cytochrome P-450 
gene superfamily was introduced (Nebert et al.,1987). This 
system is based on evolution and the recommendations include 
Roman numerals for distinct gene families, capital letters for 
subfamilies and Arabic numerals for individual genes. Using 
this nomenclature, the peroxisome-prolif erator inducible 
isoenzyme was assigned to the P450IV gene family containing 
one subfamily (Nebert et al.,1987). This form was designated 
cytochrome P450IVA1. In this thesis, the trivial terms 
cytochrome P-452 (Tamburini et al.,1984) and cytochrome P-450 
LAw (Hardwick et al.,1987) - are used interchangeably and are 
considered synonymous with P450IVA1.
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1.1.2.1 Smooth Endoplasmic Reticulum and Cytochrome P-450
Changes
Proliferation of smooth endoplasmic reticulum (S.E.R) in 
hepatocytes of rodents treated with peroxisome proliferators 
is associated with a concomitant increase in certain 
microsomal enzymes, in particular cytochrome P-450.
Proliferation of the S.E.R in rat liver is apparent as early 
as the third day of clofibrate treatment and is sustained 
after 14 and 30 days continuous administration with an 
associated increase in liver protein content accompanying 
hepatomegaly (Platt and Thorp,1966, Svoboda and 
Azarnoff ,1966). This was found to be readily reversible, 
rapidly regressing after treatment was discontinued for 14 
days (Hess et al., 19-65). Wy-14,643 and tibric acid induced a 
similar proliferation of the S.E.R (Reddy and Krishnakantha, 
1975). Fenofibrate and methyl clofenapate induce a 
dose-dependent increase in the liver to body weight ratio and 
cytochrome P-450 content, yet metabolism of model substrates 
was either inhibited or unaffected (Orton and Higgins, 1979). 
The induction of cytochrome P-450 by clofibrate has been 
attributed to the synthesis of specific haemoproteins based on 
the hepatic microsomal metabolism of model substrates (Odum 
and Orton,1980).
The involvement of cytochrome P-450 in the metabolism of fatty 
acids was implicated with the observed catalytic conversion of 
laurate (dodecanoic acid) to omega-hydroxylaurate using a
14
reconstituted system (Lu and Coon,1968). The omega-oxidation 
of fatty acids is defined as the oxidation of fatty acids at 
the omega-carbon atom (the terminal methylene carbon) whereas 
(omega-1)-oxidation is the oxidation of the penultimate 
methylene carbon. Extensive research has demonstrated the 
involvement of cytochrome P-450 in omega- and (omega-1)-
hydroxylation of saturated fatty acids such as laurate and 
unsaturated fatty acids such as oleic acid in the liver.
The first definitive report of a cytochrome P-450 species 
induced by a peroxisome proliferator with substrate 
specificity towards omega- and (omega-1)-hydroxy lation of 
fatty acids namely lauric acid, was reported by Gibson et
al.,(1982). Four cytochrome P-450 fractions were solubilised
from hepatic microsomes of animals pretreated with clofibrate.
Purified cytochrome P-450 fraction 1 had an absorbance maxima 
at 451.8nm and exhibited substrate specificity towards omega- 
and (omega-l)-hydroxylation with a ratio of 12- to 11-hydroxyl 
products of 4:1, yet was relatively inactive with respect to 
the metabolism of benzphetamine (Gibson et al.,1982). Chronic 
administration of clobuzarit and methyl clofenapate to male 
rats was found to induce liver microsomal cytochrome(s) P-450 
that hydroxy late lauric acid (Parker and Orton, 1980). 
Clofibrate administration was associated with a specific 
increase, approximately 28-fold, in the hepatic microsomal 
omega-hydroxylation of lauric acid (Orton and Parker, 1982).
Clofibrate at a concentration of 0.5mM in culture media 
maintains the cytochrome P-450 content of rat hepatocytes for
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up to 96 hours and this was associated with a marked induction 
of lauric acid hydroxylation (Lake et al.,1983). The induction 
of lauric acid hydroxylation in primary hepatocyte cultures by 
Wy-14,643, BR-931, tiadenol and nafenopin has also been
demonstrated (Lake et al.,1984a).
The clofibrate-induced cytochrome P-450 haemoprotein with an 
absorption maximum of 451.8nm has been identified on the basis 
of current criteria for homogeneity as a novel form, and 
designated cytochrome P-452 (Tamburini et al.,1984). Purified 
cytochrome P-452 isolated from the hepatic microsomes of rats 
pretreated with clofibrate was compared to the major 
phenobarbitone (PB)-induced form (cytochrome P-450b) and the 
major beta-napthoflavone (BNF)-induced isoenzyme (cytochrome 
P-450c). The spectral properties of cytochrome P-452 were 
determined and using SDS PAGE, the monomeric molecular weight 
was ascertained to be 51,530 daltons. Peptide mapping studies 
using limited proteolysis of the above 3 cytochromes showed 
that there was no similarity between the isoenzymes induced by 
the three compounds, indicating fundamental differences in the 
amino acid sequences of the three forms. Ouchterlony double 
immunodiffusion analyses were used to characterise the 
specificity of the antibodies raised to the three haemoprotein 
species. No immunological cross reactivity was observed 
between the different antibodies suggesting a structural 
dissimilarity between the three forms. Cytochrome P-452 was 
found to have a type 1 interaction (i.e cause a low to high 
spin transition of the haem iron) with lauric acid. The 
combined 11- and 12-hydroxylation of lauric acid by this
16
haemoprotein was the highest reported value for any cytochrome 
P-450 isoenzyme. Accordingly, lauric acid was considered to be 
a suitable substrate marker for cytochrome P-452 (Tamburini et 
al.,1984). It is possible that the increase in cytochrome 
P-450 observed with administration of peroxisome 
prolif erators, which in some cases has been shown to be 
associated with an overall increase in lauric acid 
hydroxylation, may represent the same haemoprotein species, 
namely cytochrome P-452.
The involvement of cytochrome P-450 monooxygenases in the 
oxidation of prostaglandins to hydroxy derivatives has also 
been shown (Kupfer and Navarro, 1976). Hepatic hydroxylation of 
prostaglandin alpha-1 and prostaglandin alpha-2, is primarily 
at the (omega-1)-position (95%) and to a lesser extent, 
omega-oxidation (5%) yielding (omega-1) (19-) and omega-(20-) 
hydroxy derivatives (Kupfer et al.,1978). Cytochrome P-450 
prostaglandin alpha-1 omega-hydroxylase activity was induced 
in rabbit liver by clofibrate and DEHP (Yamamoto et al.,1986). 
Complimentary DNA (cDNA) clones to cytochrome P-450 p-2
(prostaglandin omega-hydroxylase) were isolated from rabbit 
lung (Matsubara et al.,1987). This haemoprotein was found to 
share 74% amino acid similarity with rat hepatic cytochrome 
P-450 lauric acid omega-hydroxylase (LAw) (Hardwick et 
al.,1987), suggesting that cytochrome P-450 p-2 and cytochrome 
P-450 LAw are members of the same gene family (P-450 IV) 
(Nebert and Gonzalez,1987). Cytochrome P-452, purified and 
characterised by Tamburini et al. (1984), is considered to be 
identical to cytochrome P-450 LAw (Hardwick et al.,1987).
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The metabolism of arachidonic acid by rat hepatic microsomes 
in the presence of NADPH and oxygen was reported by Capdevila 
et al./(1981). Studies using various inhibitors indicated that 
metabolism of arachidonic acid to hydroxy derivatives was by a 
lipoxygenase-like function of the membrane bound cytochrome 
P-450. The involvement of cytochrome P-450 in the metabolism 
of arachidonic acid to a variety of products including 19- and 
20-hydroxy derivatives has been established (Oliw and 
Oates, 1981). Further investigation led to the identification 
of several new metabolites from hepatic microsomal metabolism 
of arachidonic acid including four novel epoxy acid 
derivatives (Chacos et al.,1982), hydroxyicosatetraenoic acids 
(HETES), (Capdevila et al.,1982), four epoxide intermediates 
(Oliw et al.,1982) and epoxyeicosatrienoic acids (Chacos et 
al. 1983a). It has been demonstrated that the hepatic 
metabolism of docosahexaenoic acid, presumably by cytochrome 
P-450 monooxygenases, results in the formation of 19,20-, 
16,17-, 13,14-, 10,11- and 7,8-dihydroxydocosapentaenoic
acids, 22-hydroxydocosahexaenoic acid and 21-hydroxy- 
docosahexaenoic acid (VanRollins et al.,1984).
Epoxyeicosatrienoic acids, the 8,9- and 14,15- isomers, have 
been detected in human urine (Toto et al.,1987) and purified 
from female rabbit kidneys (Falck et al.,1987). In addition 5- 
and 8-HETE metabolites of arachidonic acid have been isolated 
(Falck et al.,1984). The metabolism of leukotriene B4 by rat 
liver microsomes in the presence of oxygen and NADPH and in a 
reconstituted system with cytochrome P-450 LM2, has been 
reported (Bosterling and Trudell,1983).
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It has been demonstrated that pretreatment of rats with the 
fibric acid type hypolipidaemic drug, ciprofibrate results in 
a 7-fold stimulation of omega- and (omega-1)-hydroxylation of 
arachidonic acid (Capdevila et al.,1985). The omega- and 
(omega-1)-oxidation products predominated accounting for 70% 
of the total products whereas in PB-treated animals, omega- 
and (omega-l)-products accounted for 9%. The percentage of 
omega- and (omega-1)-products in ciprofibrate-treated rats was 
in the ratio of 80:20 in contrast to 30:70 in PB-treated 
animals. Further research in our laboratory has demonstrated 
that clofibrate, bezafibrate, Wy-14,643 and clobuzarit 
administration to the rat results in induction of lauric acid 
hydroxylation, accompanied by a concomitant induction of 
cytochrome P-452 (Bains et al.,1985). It has also been 
established that the profile of arachidonic acid metabolites 
from clofibrate treated rats is markedly different to that of 
control animals (Bains et al.,1985). The addition of lauric 
acid and arachidonic acid to hepatic microsomes from control, 
clofibric acid and DEHP treated animals results in the 
formation of typical type 1 spectra, indicative of a 
substrate-cytochrome P-450 interaction (Lake et al.,1984c).
The assumption is made that the cytochrome P-450 induced by 
ciprofibrate is identical to that induced by clofibrate 
treated animals (cytochrome P-452). As such, it is thought 
that the major physiological role of cytochrome P-452 is in 
the hepatic metabolism of endogenous substrates, namely fatty 
acids for example arachidonic acid. It is logical to propose 
that cytochrome P-452 represents a constitutive form and that
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its induction by peroxisome proliferators may be related to 
their hypolipidaemic effects. The former proposal has been 
substantiated in our laboratory where quantitation of 
cytochrome P-452 using a single radial immunodiffusion 
technique, has indicated that this enzyme is present in 
uninduced rat liver microsomes,.constituting 22% of the total 
cytochrome P-450 content. In induced rat liver microsomes the 
levels are proportionally higher (53.5-66.7%) (Bains et 
al.,1985). More recently, results from our laboratory (Sharma 
et al.,1988) using a more definitive ELISA technique for the 
immut*ioquantitation of hepatic cytochrome P-452, have revised 
the above figures. A more realistic estimation of cytochrome 
P-452 levels is lower than previously reported (Bains et 
al.,1985) in that constitutive levels are approximately 5% of 
the total cytochrome P-450 population and clofibrate 
pretreatment raises this level to approximately 45%. However, 
it is absolutely clear that peroxisome proliferators are 
functioning as inducers of a constitutive (endogenous) 
isoenzyme of cytochrome P-450. No other class of compounds has 
been found to induce this isoenzyme, a characteristic 
seemingly exclusive to the peroxisome proliferators.
The involvement of cytochrome P-452 in the omega- 
hydroxylation of saturated fatty acids has been established 
and it has been unequivocally demonstrated that the same 
isoenzyme actively hydroxylates arachidonic acid. It would 
seem plausible that the isoenzyme cytochrome P-452 with omega- 
hydroxylase activity is capable on the basis of broad 
substrate specificity to metabolise other endogenous
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substrates such as saturated and unsaturated medium to long 
chain fatty acids. The elucidation of the precise substrate 
specificity and catalytic properties of cytochrome P-452 will 
be of fundamental importance in clarifying the physiological 
role of this haemoprotein.
1.1.3 Peroxisome Proliferation and Associated Changes
in Enzyme Composition.
Peroxisomes are cytoplasmic organelles widely distributed in 
animal and plant cells (De Duve,1969). They are readily 
identified using the cytochemical procedure introduced by 
Novikoff and Goldfischer,( 1969), to localise catalase, a 
peroxisome enzyme marker (De Duve,1970). Hepatic peroxisomes 
are spherical or oval in shape (approximately 0.2-0.6um 
diameter) and are surrounded by a single limiting membrane, 
containing a finely ground matrix with a central inclusion 
(Cohen and Grasso,1981). This crystalloid core has been 
associated with the presence of urate oxidase (Angermuller and 
Fahimi,1986). The peroxisome membrane is permeable to small 
solutes including sucrose, inorganic ions and the cofactors 
for fatty acid oxidation, NAD+, CoA, ATP and carnitine (Van 
Veldhoven et al.,1987). The nonspecific permeability of the 
peroxisomal membrane to small solutes is based on the presence 
of a nonselective pore-forming protein in the membrane (Van 
Veldhoven et al.,1987).
It was originally belived that peroxisomes were formed by 
budding from the endoplasmic reticulum (De Duve and
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Baudhuin, 1966). However, the polypeptide composition of 
peroxisomal, mitochondrial and microsomal membranes are 
markedly dissimilar (Fujiki et al.,1982). Clofibrate 
administration causes a marked perturbation of the 
phospholipid composition of peroxisomal membranes (Crane and 
Masters,1986). The current model of peroxisome biogenesis 
suggests that peroxisomes form by fission from pre-existing 
organelles (Fujiki et al.,1984). Peroxisomal major 
polypeptides are synthesised on free polysomes and transported 
to the peroxisomal membrane without any apparent proteolytic 
processing (Suzuki et al.,1987). The apparent size of catalase 
does not alter when it enters peroxisomes (Robbi and
Lazarow, 1978), and both uncase and catalase are transported 
to the interior of peroxisomes by a post-translational 
mechanism (Goldman and Blobel,1978). Post-translation import 
into peroxisomes in vitro of two cell-free translation
products has been demonstrated (Fujiki and Lazarow,1985). 
Thiolase is synthesised as a large precursor implying 
post-translation import of thiolase into peroxisomes with 
proteolytic processing (Fujiki et al.,1985).
Peroxisomes participate in respiration, energy production and 
oxidative metabolism (De Duve and Baudhuin, 1966). Subsequent 
identification of additional peroxisomal enzymes led to 
further speculation on the metabolic roles of these organelles 
(Masters and Crane, 1984). The presence of a peroxisomal fatty 
acid beta-oxidation pathway and identification of three
enzymes involved has since been established (Lazarow and De 
Duve,1976, Lazarow,1978). The involvement of rat liver
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peroxisomes in cholesterol biosynthesis (Keller et al.,1985), 
in the shortening of acyl side chains of drugs by beta- 
oxidation (Yamada et al.,1984) and in the synthesis of
ether-linked glycerolipids (Balias et al.,1984) has been 
demonstrated. A comprehensive list of peroxisomal enzymes has 
been compiled by Tolbert, (1981). The oxidase enzymes reduce 
oxygen to hydrogen peroxide and catalase utilises hydrogen 
peroxide catalatically and ethanol, methanol and nitrite
peroxidatically. All the oxidases have a high affinity for 
oxygen with the exception of glycolate oxidase (Reddy and 
Lalwani,1983).
Peroxisomal and Mitochondrial Beta-Oxidation of Fatty Acids
The enzymes of peroxisomal beta-oxidation differ from 
mitochondrial enzymes with respect to catalytic and molecular 
properties. Peroxisomal beta-oxidation enzymes are KCN 
insensitive in vitro and do not require carnitine unlike the 
carnitine dependent KCN sensitive mitochondrial system
(Lazarow, 1982). The peroxisomal and mitochondrial beta- 
oxidation pathways are depicted in figures 1.1 and 1.2 with 
the enzymes listed. The oxidation of fatty acyl-CoA esters in
the peroxisome is catalysed by fatty acyl-CoA oxidase (a
purely peroxisomal enzyme) yielding hydrogen peroxide 
(Hashimoto, 1982). In peroxisomes the activities of enoyl-CoA
hydratase and 3-hydroxyacyl-CoA dehydrogenase have been shown 
to copurify on one single polypeptide whereas in mitochondria 
the enzyme activities reside on separate protein molecules
(Bremer and Osmundsen,1984). Peroxisomal thiolase is
Figure 1.1
The Fatty Acid Oxidation Cycle of the Peroxisome Matrix
R-CH CH CH -C
ATP
■Co ASH
AMP 
+ 2 (P)
R-CH CH CH -C
‘SCoA
Acyl-CoA Synthetase
Fatty Acyl-CoA Oxidase
RCH CH=CHCSCoA
RCH C-SCoA
RCH CHOHCH C-SCoA
NAD
NADH
CH C-SCoA
RCH CCH COSCoA
CoASH
[3] Enoyl-CoA hydratase
[4] 3-hydroxyacyl-CoA DH
[5] Thiolase
Figure 1.2
The Fatty Acid Oxidation Cycle of the Mitochondrial Matrix
ATP
AMP 
+ 2 (P
R-CH CH CH -C
2 2 2 'cf
CoASH
[1] Enzyme: Thiokinase
R-CH CH CH -C
2 2 2 SCoA
■FAD
-FADH
[21 Acyl DH
RCH C RCH CH=CHCOSCoA
SCoA
[3] Enoylhydratase
RCH CHOHCH COSCoA
NAD
B-OH acyl DH
NADH + H
CH C
SCoA
RCH COCH COSCoA
CoASH-
[5] B Ketothiolase
Each turn of the cycle shortens the fatty acid by 2 carbons
and generates one molecule of acetyl CoA and one molecule each
of NADH and FADH,.2.
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immunologically distinct from the mitochondrial and cytosolic 
forms (Lazarow, 1982, Bremer and Osmundsen, 1984). The 
existence of a peroxisomal system for beta-oxidation of 
dicarboxylic acids has been reported (Mortensen et al.,1982).
1.1.3.1 Peroxisome Proliferation and Induction of
Enzymes
The in vivo effects of peroxisome proliferators on peroxisome 
proliferation and enzyme induction are shown in tables 1.0 -
1.2. Induction of enzymes not included in the main tables and 
the in vitro changes following administration of these 
compounds are discussed as follows. The activity of
peroxisomal 2,4-dienoyl-CoA reductase is enhanced by 
clofibrate (Dommes et al.,1981) and the rate of C12-C19 
dicarboxylic acid beta- oxidation is stimulated (Mortensen et 
al.,1982). The existence of two beta-oxidation pathways for 
unsaturated fatty acids has been suggested (Mizugaki et 
al.,1982).
The use of rat hepatocyte primary cultures as a screening 
system to investigate the effects of peroxisome proliferators, 
has been a recent development. Culturing adult rat
hepatocytes with clofibrate revealed an increase in peroxisome 
number associated with a dose related stimulation of carnitine 
acetyltransferase activity (Gray et al.,1982). Within 12-24 
hours palmitoyl Co-A oxidation was markedly increased (Gray et 
al.,1983). Induction of carnitine acetyltransferase and 
palmitoyl-CoA oxidation has been observed in primary rat 
hepatocyte cultures with a concomitant increase in peroxisome
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number following the administration of nafenopin, BR-931,
tiadenol and acetylsalicylic acid (Gray et al.,1983).
In general it would appear that in vitro experimentation
provides a sensitive and rapid means of examining the hepatic 
responses to peroxisome proliferators.
1.1.4 Mitochondrial Changes
Treatment of rats with many structurally diverse peroxisome 
proliferators results in several observable mitochondrial
changes which may include proliferation, structural changes 
and induction of certain enzymes.
The administration of clofibrate to rats results in increased 
specific activity of cytochrome oxidase and glycerol-1-
phosphate dehydrogenase (Hess et al.,1965, Westerfeld et 
al.,1968). Structural changes in hepatic mitochondria of rats 
and mice have been observed (Svoboda and Azarnoff,1966) with 
marked organelle enlargement (Reddy et al.,1969). A 50-100% 
increase in the hepatic content of mitochondria has been 
reported (Kurup et al.,1970). The maximum increase was seen at 
2-4 days after administration (Gear et al.,1974); no change in 
particle size or specific content of DNA or RNA was observed 
and the organelle half-life was unaltered. A 30-40% decrease 
in the specific activity of monoamine oxidase, kyuramine 
hydroxylase and. rotenone-insensitive NADH-cytochrome c 
reductase was observed from 2-15 days. Neutral protease 
activity was inhibited (Gear et al.,1974). Chronic clofibrate
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treatment resulted in a 30% decrease in oxygen consumption and 
carbon dioxide production associated with the oxidation of 
fatty acids, indicative of impaired oxidation with a reduction 
in ketone bodies produced (Cederbaum et al.,1976).
A two to three-fold increase in hepatic total acyl-CoA 
synthetase activities was demonstrated and it is assumed that 
clofibrate treatment results in an induction of mitochondrial 
acyl-CoA synthetases (Krisans et al.,1980). Carnitine 
acetyltransferase is found primarily in the hepatic 
mitochondrial fractions and it constitutes 54% of the total 
enzyme activity whereas it is 2-3 times lower in peroxisomes 
(14%) (Markwell et al.,1973). This enzyme has been purified 
and characterised (Mittal and Kurup,1980). The substrate 
specificity pattern for peroxisomal carnitine acyltransferases 
is bi-modal with maxima at C4 and C12, however in mitochondria 
the specific activity appears to correspond to two different 
enzymes with maximal specificities for C4 and C12 fatty acids 
(Leighton et al.,1982). In ciprofibrate treated rats a 21- and 
7-fold increase was observed in mitochondrial C4 and C12 
transferase activities respectively (Leighton et al.,1982). A 
general 4 to 5-fold increase in peroxisomal acyltransferase 
activity was evident following ciprofibrate administration 
(Leighton et al.,1982). A variable increase in carnitine 
acyltransf erase activities, dependent on the chain length of 
the respective substrates, was also demonstrated in clofibrate 
treated animals (Solberg et al.,1972). Induction of carnitine 
acyltransferases exhibited an apparent dose-response increase
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which displayed a time lag during which the activity increased 
in microsomal and peroxisomal fractions (Mittal and 
Kurup,1981). The increase in the specific activity of the 
acyltransf erases was in the order of 5:3:2 for short-, medium- 
and long-chain transferases, respectively (Solberg et 
al.,1972). The activity of carnitine palmitoyltransferase, an 
enzyme exclusive to mitochondria, increased to 260% of the 
control activity following clofibrate treatment (Solberg et 
al.,1972).
The isolated hepatic mitochondrial fraction from clofibrate 
treated animals exhibited an increased capacity for the 
oxidation of short chain acyl carnitines (including acetyl- 
carnitine) whereas the oxidation of palmitoyl- and erucoyl- 
carnitine showed little change (Christiansen et al.,1978). The 
activity of 2,4-dienoyl-CoA reductase was increased (Dommes et 
al.,1981). The ratio of mitochondrial protein to cellular DNA 
was increased 2-fold with no alteration to the apparent rates 
of degradation of protein (Lipsky and Pedersen, 1982). The 
total activity of carnitine acetyltransferase was induced 
whereas sensitivity to malonyl-CoA was decreased; a similar 
pattern of increased activities was observed with 
palmitoyl-CoA and octanoyl-CoA as substrates (Lund and 
Bremer,1983). SaH-42,348 and nafenopin treatment resulted in a 
large increase in mitochondrial protein and phospholipid in 
accordance with the observed increase in organelle size and 
number (Dalton et al.,1974, Kurup et al.,1970). Tibric acid 
and fenofibrate administration resulted in a dose dependent 
increase in alpha-glycerophosphate dehydrogenase activity
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(Holloway and Thorp,1979), reflecting increased thyroxine
activity in the liver (Holloway and Orton, 1980). Gemfibrozil 
increased the activity of this enzyme in addition to carnitine 
acyltransf erase (Kahonen and Ylikahri, 1979). Bezafibrate, 
ciprofibrate, fenofibrate and tiadenol also increased the 
activity of hepatic carnitine palmitoyltransferase in rats 
(Halvorsen,1983). Fenofibrate administration significantly 
increased glutamate dehydrogenase, carnitine palmitoyl­
transferase, carnitine acetyltransferase activities and 
mitochondrial beta-oxidation (Van Veldhoven et al.,1984).
Methyl clofenapate induced alpha-glycerophosphate
dehydrogenase activity (Krishnakantha and Kurup,1974).
The induction of mitochondrial enzymes involved in beta-
oxidation of fatty acids would suggest, in conjunction with 
other known cellular responses, that a common mechanism is 
involved in the hypolipidaemic effect of peroxisome 
proliferators.
1.1.5 Changes in Cytosolic Enzyme Levels
The influence of peroxisomal proliferators on cytosolic
enzymes has not been studied extensively. However, the major
changes appear to be at the level of cellular defence, namely 
glutathione peroxidase, superoxide dismutas.e and epoxide hydrolasej
!enzyme a c t iv i t ie s . / /L—■ -—  v
Glutathione peroxidase is a selenium containing tetrameric 
protein located in mammalian cell cytosol and mitochondria.
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The enzyme consists of four identical sub-units each of 
molecular weight of 21,000 daltons. It is present at the 
highest levels in the cytosol of liver, kidney and erythroid 
cells (Wendel,1980). This enzyme converts glutathione to 
glutathione disulphide during hydroperoxide metabolism and 
utilises hydrogen peroxide, lipid and steroid peroxides as 
substrates (Wendel,1980, Halliwell and Gutteridge,1985). A 
decrease in hepatic glutathione peroxidase and superoxide 
dismutase activities has been observed in the rat following 
administration of clofibrate and fenofibrate for 30 days 
(Ciriolo et al.,1982 and 1984). Superoxide dismutase catalyses 
the conversion of superoxide radicals into oxygen and hydrogen 
peroxide. The superoxide radical is a highly reactive species 
of oxygen which is likely to cause irreversible damage at the 
site of origin unless it is removed. The hydrogen peroxide 
formed is less reactive than the radical and may undergo 
further metabolism by glutathione peroxidase and catalase 
(Lehninger,1975).
It has been reported that following a 14 day clofibrate 
treatment, glutathione peroxidase levels remain unchanged 
(Hietanen et al.,1985). Glutathione peroxidase activity was 
decreased 40-60% in rats and mice pretreated with nafenopin 
and DEHP (Tomaszewski et al.,1986). Nafenopin also decreased 
glutathione transferase activity (Furukawa et a l . , 1 9 8 5 ) .  E p o x id e  
hy dro las e  is induced in microsomal  and c y toso l ic  f rac t io n s  by c lo f ib ra te
i(Crane and M a s t e r s , 1 9 8 6 ) .
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1.1.6 Hepatocarcinoqenesis Induced by Peroxisome
P rolif erator s
The extrapolation from rodent carcinogenesis studies to other 
species is rarely satisfactory as qualitative and quantitative 
differences exist between the respective responses. It should 
be noted that predictions are based on a direct interspecies 
comparison and it is assumed that the mechanism of action in 
the model is both identical and reproducible in man. Rodent 
studies completed on several structurally diverse peroxisome 
proliferators have established that long term treatment 
results in hepatocarcinogenesis (Reddy,J.K. et al.,1980). It 
is now believed that that these compounds in rodents, are as a 
class, non-genotoxic carcinogens.
1.1.6.1 Short Term Carcinogenicity Tests
The potential of clofibrate, nafenopin, SaH-42,348, tibric 
acid, Wy-14,643 and BR-931 to produce DNA damage has been 
tested using the lymphocyte thymidine incorporation and 
Salmonella/microsomal assays (Warren et al.,1980). In the 
absence and presence of liver 9,000g supernatant, all of the 
above compounds were negative in 5 Salmonella typhimurium 
strains and in both assays (Warren et al.,1980). Using the 
same strains (TA 98, TA 100, TA 1535, TA 1537 and TA 1538), 
gemfibrozil and 5 urinary metabolites failed to induce a 
significant increase in revertant bacterial colonies 
(Fitzgerald et al.,1981). Similarly, other peroxisome 
proliferators such as methyl clofenapate and bezafibrate were
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negative in Ames tests (Reddy and Lalwani, 1983, Reddy,J.K. et 
al.,1982). Wy-14,643 induced unscheduled DNA synthesis in rat
hepatocytes, whereas ciprofibrate and nafenopin exhibited no 
apparent effect (Glauert et al.,1984). BR-931 mediated
unscheduled DNA synthesis was observed only at the maximum 
non-toxic dose. It should be noted that all 4 compounds were 
negative in the Ames/Salmonella assay using the newly 
developed strains TA 102 and TA 104 which are more sensitive 
to a variety of agents including oxidative mutagens (Glauert 
et al.,1984). The induction of sister chromatid exchanges by 
2,4-D, MCPA and clofibrate, in vivo and in vitro has been 
studied (Linnainmaa,1984). No significantly increased 
induction occurred and there was no apparent dose-related 
effects.
1.1.6.2. Long Term Carcinogenicity Studies
Clofibrate administered in the diet at a concentration of 
0.5% (w/w) to male F344 rats resulted in the development of 
hepatocellular carcinomas in 91% of the treated animals 
sacrificed between 24 and 28 months (Reddy and Qureshi, 1979). 
The long term administration of nafenopin to acatalasemic mice 
produced a 100% incidence of hepatocellular carcinomas between 
18 and 20 months in male and female animals (Reddy et 
al.,1976a). Between 18 and 25 months, hepatocellular
carcinomas developed in 7 3% of nafenopin treated male F-344 
rats (Reddy and Rao, 1977a). Dietary administration of
Wy-14,643 to male acatalasemic CSb mice and F-344 rats
resulted in a 100% incidence of liver tumours in animals
surviving chronic administration at 14.5 and 16 months, 
respectively (Reddy et al.,1979). Using a semi-purified diet 
to avoid possible xenobiotic contamination, Wy-14,643 was 
administered to male F-344 rats for 65 weeks (Lalwani et 
al.,1981a). Fourteen out of fourteen treated animals developed 
liver tumours between 40 and 65 weeks. A significant increase 
in the incidence of liver tumours in female CSb mice and F-344 
rats has been observed with long term treatment with BR-931 
(Reddy,J.K. et al.,1980). A 97% incidence of liver tumours in 
male F-344 rats treated for a period of 16.5 months with 
tibric acid has also been reported (Reddy, J.K. et al.,1980). 
Gemfibrozil was administered in the diet to groups of non 
inbred CD/1 mice and non inbred CD rats for 78 and 104 weeks 
respectively (Fitzgerald et al.,1981). In mice there was no 
significant increase in the frequency of mean latency period 
of tumours. Statistically significant increases in the 
incidence of liver tumours were observed in rats and these 
appeared to be dose related.
The administration of bezafibrate at concentrations effective 
in decreasing serum triglycerides did not cause an increased 
incidence of liver tumours in rats (Fahimi et al.,1982). At 
substantially higher dose levels, an enhanced rate of 
hepatocellular carcinoma development was observed (Hartig et 
al.,1982). Dietary administration of 0.1%(w/w) (equivalent to 
lOmg/kg) ciprofibrate for a period of 60 weeks to male F-344 
rats resulted on the basis of histological criteria, in a 100% 
incidence of developing liver tumours (Rao et al.,1984). 
Methyl clofenapate administration to male F-344 rats caused
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the development of hepatocellular carcinomas between 65 and 75 
weeks in fourteen out of fourteen animals (Reddy,J.K. et 
al.,1982). A slight increase in carcinoma incidence was seen 
in fenofibrate treated animals (Reddy and Lalwani, 1983).
In conclusion, it should be stated that all the peroxisome 
proliferators tested, produce hepatic tumours in rodents.
1.1.6.3 Possible Mechanisms of Hepatocarcinoqenesis
In general in carcinogenesis, both initiation and promotion 
are important phases (Berenblum,1974). Chemically induced 
initiation involves a direct interaction of the chemical or 
electophilic metabolite with cellular DNA with a subsequent 
alteration to the genome, whereas promotion is a stimulation 
of the transformed cell with ultimate tumour production 
(Taussig, 1984). Epigenetic or non-genotoxic carcinogens are 
defined as compounds which do not damage DNA but act by 
indirect mechanisms (Williams,1981). All the peroxisome 
proliferators tested produce hepatic tumours in rodents 
following prolonged administration at high dose levels and yet 
exhibit no apparent capacity to induce genetic damage using 
the range of mutagenicity tests currently available. This 
would infer that this group of compounds are epigenetic 
carcinogens, consistent with reports that these compounds 
enhance the carcinogenic effect of previously administered 
genotoxic carcinogens. For example, administration of 
Wy-14,643 to male F-344 rats following a prior "initiating" 
period of 2 weeks with diethyl-nitrosamine (DEN) resulted in
the development of a significantly higher number of liver 
tumours in comparison to the DEN group (Reddy and Rao,1978).
That hepatocellular carcinomas develop in animals treated with 
peroxisome proliferators alone indicates that these compounds 
possess both promoting and initiating ability. It is possible 
that peroxisome proliferators can produce liver tumours, if 
they promote tumour development from spontaneously arising 
pre-neoplastic foci, susceptible to endogenous and exogenous 
growth stimuli (Schulte-Hermann et al.,1983).
The development of gamma-glutamyltransf erase (gamma-GT) 
negative altered foci, neoplastic nodules and hepatocellular 
carcinomas between 21 and 70 weeks has been demonstrated with 
Wy-14,643 (Rao et al.,1982). This indicated that gamma-GT 
cannot be considered as a general phenotypic marker of all 
pre-neoplastic cells. This would suggest that the precursor 
lesions of induced hepatocellular carcinomas may differ from 
the gamma-GT enzyme positive altered hepatocyte foci induced 
by genotoxic agents. It would appear that this group of 
compounds induce neoplasia by initial non-genotoxic processes. 
However, it is possible that initial genotoxic events occur 
and that the tests currently used are not sufficiently 
sensitive to detect the changes. It is apparent that prior to 
the established promoting activity of these compounds, 
initiation must occur, whether by non-mutational events or by 
the indirect action of the chemical.
It has been suggested that the peroxisome proliferators may
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interact with a non DNA target producing active oxygen species 
with subsequent DNA attack (Reddy and Lalwani, 1983). In such 
an event, the normal cellular protective mechanisms utilising 
glutathione would operate with the probable removal of the 
short lived oxygen radicals. Reddy has proposed that the 
marked peroxisome proliferation produced by the administration 
of these compounds acts as the endogenous initiator of 
neoplastic change (Reddy,J.K. et al.,1980). Administration to 
rodents results in peroxisome proliferation with increased 
activity of fatty acyl-CoA oxidase and a marked induction of 
fatty acid beta-oxidation pathway enzymes, resulting in a 2 to 
22-fold stimulation of peroxisomal beta-oxidation (Cohen and 
Grasso,1981, Inestrosa et al.,1979, Lalwani et al.,1981a).This 
is thought to result in the excessive production of hydrogen 
peroxide, which on the basis of a 2.5-fold induction of 
catalase, cannot be adequately removed (Reddy and 
Lalwani, 1983). This surfeit of hydrogen peroxide could lead to 
the formation of reactive oxygen species leading to lipid 
peroxidation. Persistent lipid peroxidation may ultimately 
lead to DNA attack and damage providing the initiating 
mutational event.
However, the beta-oxidation step which generates hydrogen 
peroxide in peroxisomes appears to be rate-limiting as the 
specific activity of fatty acyl-CoA oxidase is lower than that 
of the other beta-oxidation enzymes (Hashimoto, 1982). Under 
normal physiological conditions the hydrogen peroxide produced 
in peroxisomes is largely disposed of by catalase whereas 
hydrogen peroxide arising from mitochondria, the endoplasmic
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reticulum or cytosolic enzymes such as superoxide dismutase is 
acted upon by glutathione peroxidase (Halliwell and 
Gutteridge,1985). Catalase has a relatively minor role in 
hydrogen peroxide catabolism at low rates of hydrogen peroxide 
generation. Xn the endoplasmic reticulum however the catalase 
function increases as the rate of hydrogen peroxide production 
is enhanced (Jones et al.,1981). It should be noted that the 
specific activity of catalase remains constant throughout 
treatment with peroxisome proliferators (Goldenberg et
al.,1976), which combined with its extremely high turnover 
number for hydrogen peroxide may be capable of removing the 
excess hydrogen peroxide produced during peroxisome 
proliferation. One molecule of bovine liver catalase
metabolises 2.5 million molecules of hydrogen peroxide per 
minute under optimal conditions (Lehninger, 1975).
Consistent with the lipid peroxidation proposal of neoplastic 
transformation is the observed accumulation of lipofuscin in 
the livers of treated animals (Reddy, J.K. et al.,1982). In a 
recent study it has been reported that the antioxidants, 
ethoxyquin and BHA, which have free radical scavenging 
properties exert an inhibitory influence on ciprofibrate 
induced hepatic tumourigenesis (Rao et al.,1984). This
indicates that hydrogen peroxide and/or free radicals may be 
involved in the hepatocarcinogenesis induced by this compound. 
However, it has been estimated that the extent of radical 
production in the livers of rats exposed to peroxisome 
proliferators is insufficient to result in a biologically 
significant degree of DNA damage (Elliot and Elcombe,1987).
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It is apparent that peroxisome proliferators possess both 
initiating and promoting abilities and it is possible that the 
initiating effect may result from a combination of non- 
mutagenic events or as yet, a not clearly defined mutagenic 
effect, mediated by the indirect action of these chemicals.
1.2 RENAL RESPONSES TO ADMINISTRATION OF PEROXISOME
PROLIFERATORS
Unlike the liver, no kidney enlargement and renal 
proliferation of the endoplasmic reticulum has been observed 
in animals treated with peroxisome proliferators. The major 
cellular response of the kidney to treatment is peroxisome 
proliferation with a corresponding increase in peroxisomal 
beta-oxidation enzymes and induction of the polypeptide PPA
80,000 (peroxisomal-proliferation-associated 80,000 mol.wt. 
polypeptide, immunoc hemic ally identical to the bifunctional 
protein).
The distribution of the peroxisomes in the kidney of untreated 
rats is primarily in the P-3 segment, i.e the cells of the par 
descendens of the proximal convolution located in the outer 
medulla and medullary rays (Le Hir and Dubach,1982). In the 
cells of the pars convoluta in the cortex (P-l and P-2 
segments), peroxisomes are smaller and less reactive. In the 
P-3 cell, mitochondrial activity is less than that in P-2 and 
P-l, suggesting that P-3 cells possess an extra mitochondrial 
means of oxidation in which peroxisomal oxidases play an 
important role. Fatty acyl-CoA oxidase activity is localised
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in the matrix of renal peroxisomes (Yokota and Fahimi, 1982).
In mice fed . BR— 931, Wy-14,643, fenofibrate and methyl 
clofenapate, a marked peroxisome proliferation was induced in 
the proximal convoluted tubular epithelium of the kidney 
(Lalwani et al.,1981). This peroxisome proliferation was
associated with an enhanced activity of the peroxisomal 
palmitoyl-CoA oxidase system in the renal cortical 
homogenates. The activity of peroxisomal heat labile enoyl-CoA 
hydratase in the kidney cortex increased 3 to 5-fold on 
treatment with peroxisome proliferators. Enoyl-CoA hydratase 
and PPA-80 which were also substantially induced upon 
treatment, were found to have an identical distribution, 
limited exclusively to the cytoplasm of the proximal
convoluted tubular epithelium (Lalwani et al.,1981). A rapid
increase in renal palmitoyl-CoA oxidase and palmitoyl-CoA
oxidation was seen with clofibrate with a minimal elevation in 
the activity of catalase (Small et al.,1982). Administration 
of SaH-42,348 increased the activity of catalase in male 
wild-type mice and caused a mild to moderate increase in 
peroxisomal number in the proximal convoluted tubular 
epithelium (Reddy et al.,1975).
Peroxisomal fatty acid acyl-CoA oxidase activity is restricted 
to the proximal tubule indicating that this is the location of 
the renal peroxisomal beta-oxidation system (Le Hir and 
Dubach, 1982). After 48 hours of starvation the peroxisomal 
enzyme activity increased in glomeruli, proximal convoluted 
tubules and collecting ducts. 3-Hydroxy-acyl-CoA,
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dehydrogenase, representing the mitochondrial pathway, is 
distributed in all cortical proximal and distal segments. It's 
activity is much lower in glomeruli and collecting ducts and 
is unaffected by starvation. It would appear that the proximal 
tubule possesses a peroxisomal pathway for beta-oxidation with 
a capacity of the same order of magnitude as in hepatocytes 
(Le Hir and Dubach,1982). The induction of polypeptide PPA-80, 
heat labile enoyl-CoA hydratase has been shown to parallel the 
increase in peroxisome number in the proximal convoluted 
tubular epithelium (Lalwani et al.,1981). The induction of 
mitochondrial carnitine acetyltransferase in the kidney as the 
result of clofibrate treatment has been reported (Mittal and 
Kurup,1981).
The existence of at least one haemoprotein species exhibiting 
a carbon monoxide adduct absorption maxima of 452-454nm with 
omega-hydroxylase activity, has been reported in rat kidney 
cortex microsomes (Jakobsson et al.,1970). A cytochrome P-450 
species, designated P-450 K-5, with a monomeric molecular
weight of 52,000 and a CO-reduced absorption maximum at 452nm, 
was purified from untreated rat kidney microsomes. This 
haemoprotein catalysed the omega- and (omega-l)-hydroxylation 
of lauric acid (Imaoka and Funae,1986). Cytochrome b5 plays a 
role in both NADPH- and NADH-dependent hydroxylation of fatty 
acids in kidney microsomes (Sasame et al.,1974). The 
involvement of renal cytochrome P-450 in the omega- and 
(omega-l)-hydroxylation of prostaglandins has also been 
established (Okita et al.,1981). Two renal cytochrome P-450 
forms, P-450 K-l and P-450 K-2 were purified (Yoshimoto et
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al.,1986). The monomeric molecular weights were 51,500 and
52,000 respectively, with absorption maxima of 450.5 and 
451nm. Both forms catalysed the omega- and (omega-1)- 
hydroxylation of fatty acids; P-450 K-l exhibited a higher
specific activity with all fatty acids and catalysed the 
omega-hydroxylation of PGA-1 and PGA-2. It is generally
accepted that renal cytochrome P-450 monooxygenase enzyme 
activity is directed towards the omega- and (omega-1)- 
oxidation of fatty acids and that there may be one or several 
haemoprotein species involved. It appears that one cytochrome 
P-450 is involved in both omega- and (omega-l)-hydroxylation 
of saturated fatty acids and that omega-hydroxylation 
predominates. The ratio between omega- and (omega-1)- 
hydroxylation depends on chain length, the ratio decreasing 
with increasing chain length (Ellin et al.,1973).
The metabolism of arachidonate primarily to 20-(omega) and 
19-(omega-1)-hydroxy arachidonate and additionally 19-keto 
arachidonate and a dicarboxylic acid has been demonstrated 
(Morrison and Pascoe,1981). The stimulatory effect of the 
hypolipidaemic agent clobuzarit on kidney cortex microsomal 
cytochrome P-450 (2 to 3-fold induction) has been reported.
The induction of renal cytochrome P-450 was associated with a 
similar fold increase in total lauric acid omega- and
(omega-l)-hydroxylation; PB and saline had no effect on fatty
acid hydroxylation (Parker and Orton, 1980) .The relationship 
(if any) between hepatic cytochrome P-452 and peroxisome 
proliferator induced kidney cytochrome P-450-dependent fatty 
acid hydroxylase is not clear at present.
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1.3 MECHANISMS OF THE HYPOLIPIDAEMIC ACTION OF
PEROXISOME PROLIFERATORS
The hepatic subcellular, biochemical and ultrastructural 
responses observed in rodents following treatment with 
peroxisome proliferators has been clearly established. 
However, the relationship between these changes and the 
observed hypolipidaemic activity has yet to be clarified.
As discussed previously, the proliferation of S.E.R. and the 
concomitant induction of cytochrome P-452 displaying 
specificity towards omega- and (omega-1)-hydroxylation of 
lauric acid, has been demonstrated (Tamburini et al.,1984). An 
increase in cytochrome P-452 omega-hydroxylation of fatty 
acids would reflect the overall enhanced lipid catabolism 
resulting from clofibrate treatment although omega-oxidation 
has been calculated to account for only 5-10% of the total 
oxidation of fatty acids in starved rats (i.e. in the non 
drug-induced state) (Bjorkhem,1978). However in
normolipidaemic and hyperlipidaemic fats, the antilipidaemic 
action of clofibrate does not depend critically on the 
enhanced omega-hydroxylation of fatty acids (Reich and Ortiz 
de Montellano, 1986). In starved rats, competition exists 
between the acyl-CoA synthetases involved in the biosynthesis 
of glycerides and the microsomal hydroxylase(s) involved in 
omega-oxidation of fatty acids (Bjorkhem,1976). It is possible 
that elevated omega-oxidation in treated animals may be 
inhibitory to triglyceride synthesis, competing with this 
pathway for fatty acid substrates. This is substantiated by
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the observed inhibitory effect of clofibrate on fatty acid 
synthesis (Landriscina et al.,1975). The physiological
significance of omega-oxidation may be to produce succinyl-CoA 
from fatty acids in mitochondria stimulating oxidation of 
accumulated acetyl-CoA thereby conserving carbohydrate stores 
(Wada et al.,1971). The hypocholesterolaemic action of DEHP 
arises largely from its ability in vivo to stimulate the 
degradative removal of the sterol as bile acids (Nair and 
Kurup,1986).
Mitochondrial changes have been observed in rodents on 
treatment with peroxisome proliferators and these include 
proliferation and alterations to the inner membrane. The major 
biochemical feature is the induction of beta-oxidation enzymes 
which is possibly the major contribution to the hypolipidaemic 
action exhibited by these compounds. The flux of palmitate 
through mitochondrial and peroxisomal beta-oxidation pathways 
was studied in isolated untreated rat hepatocytes (Kondrup and 
Lazarow,1985). It was estimated that approximately 32% of 
palmitate oxidation began in peroxisomes. The effect of 
peroxisome proliferators on the flux of fatty acids through 
the two systems would be of obvious interest.
It has been postulated that the reduction in serum 
triglycerides seen with peroxisome proliferators is due to the 
displacement of thyroxine from its serum-binding proteins by 
these compounds, resulting in a hyperthyroid effect in the 
liver (indicated by increased mitochondrial alpha-glycero- 
phosphate dehydrogenase activity) and a hypothyroid effect in
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other organs (based on the lack of change in metabolic rate 
and thyroid function) (Ruegamer et al.,1969). In the 
hyperthyroid state, fatty acid oxidation and ketogenesis are 
stimulated simultaneously and esterification of fatty acids to 
triglycerides reduced as is the secretion of very low
density lipoproteins (Heimberg et al.,1985). The hepatic 
mitochondria of rats fed dessicated thyroid oxidise 
alpha-glycerophosphate 5 times more rapidly than mitochondria 
from untreated animals (Lee et al.,1959). A 2 to 5-fold 
increase in peroxisomal palmitoyl-CoA oxidation has been found 
following treatment of male rats with daily doses of 
L-thyroxine (Just and Hartl,1983).
Hepatic peroxisomes adapt in a structural and proliferative 
manner to 3,3,5 triiodothyronine i.e. hyperthyroidism (Fringes 
Reith,1982). Thyroid hormones may regulate the rate of fatty 
acid oxidation in the liver by changing the activity of the 
outer membrane carnitine palmitoyltransferase (Stakkestad and 
Bremer,1983) The hypotriglyceridaemic effect of clofibrate and 
thyroxine may be via the activation of carnitine-mediated 
transport of fatty acids in hepatic mitochondria (Pande and 
Parvin,1980). Thyroidectomy abolishes the hypolipidaemic 
effect of clofibrate in male rats yet peroxisome proliferation 
and increased catalase activity persists (Svoboda et al,1969). 
The hypocholesterolaemic action of DEHP is unaffected by 
thyroidectomy yet elevated alpha-glycerophosphate
dehydrogenase activity is largely abolished (Nair and 
Kurup, 1986a). The role of thyroxine in peroxisome 
proliferation and the observed hypolipidaemic action has yet
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to be clarified. One of the physiological roles attributed to 
peroxisomes is beta-oxidation whereby the accumulation of 
fatty acids poorly metabolised by other metabolic pathways is 
prevented. These include polyunsaturated fatty acids and very 
long chain fatty acids (Karki et al.,1987, Singh et al.,1987) 
Additionally, trans-fatty acids are readily degraded enhanced 
by a channelling mechanism on the peroxisomal bifunctional 
enzyme polypeptide (Yang et al.,1986). The hypolipidaemic 
action of clofibrate appears to be dissociated from the 
induction of peroxisomal beta-oxidation in normolipidaemic 
animals (Harrison,1984).
In bezafibrate, gemfibrozil and nafenopin normolipidaemic 
treated rats, the serum hypolipidaemic effect is not 
dose-dependent and does not correlate with an increased 
peroxisome volume and associated increased enzymes, implying a 
minor role of peroxisomes in the mode of action of 
hypolipidaemic drugs (Stegmeier et al.,1982). Whether this is 
true in the hyperlip id aemic animal has yet to be ascertained. 
It has been estimated that the contribution of peroxisomal 
fatty acid oxidation is less than 10% in control and 
clofibrate treated animals (Mannaerts et al.,1979). This would 
suggest that peroxisome proliferation in rodents is a toxic 
side-effect of these compounds with a minimal contribution to 
their pharmacological action. However, a decrease in serum 
lipids by various plasticisers occurs only with peroxisomal 
proliferation (Moody and Reddy,1982). The relationship between 
peroxisome proliferation and the observed hypolipidaemic 
effect was examined by treating animals bearing non-peroxisome
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prolif erator-induced tumours with tibric acid or W y - 14,64 3. 
Peroxisomal enzyme induction was found to be dissociated from 
the decrease in serum cholesterol while an inverse biological 
association existed between liver catalase and serum 
cholesterol (Moody et al.,1984). It was suggested that 
carnitine acetyltransferase was associated with serum 
triglycerides during the perturbation state only.
The rate of incorporation of oleate into perfusate 
triglycerides is reduced by clofibrate (Ide and Sugano,1983), 
and methyl clofenapate causes an increased palmitate 
utilisation through oxidation and esterification (Ghis et 
al.,1984). This suggests that the hypolipidaemic effect 
results from both increased catabolism and decreased anabolism 
of triglycerides. In control animals, microsomal 
omega-oxidation and peroxisomal beta-oxidation contribute 
between 5 and 10% to the total oxidation of fatty acids 
respectively (Bjorkhem,1978, Mannaerts et al.,1979). The major 
intracellular location of increased triglyceride catabolism is 
probably the mitochondria, reflecting the induction of beta- 
oxidation enzymes following treatment. The mechanisms 
accounting for the hypolipidaemic action have yet to be 
clearly defined.
1.4 MECHANISMS OF PEROXISOMAL PROLIFERATION AND INDUCTION
OF CYTOCHROME P-452
It is clear that administration of peroxisome proliferators to 
rodents results in an increased activity of certain
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peroxisomal enzymes and cytochrome P-450 with respect to 
lauric acid hydroxylation. In general, these changes reflect a 
dual proliferation of peroxisomes and S.E.R.. Immunological 
quantitation of cytochrome P-452 (Bains et al.,1985) and 
PPA-80/enoyl CoA hydratase in treated animals indicate that as 
with catalase, increased activity is due to an overall 
enhanced synthesis of the proteins as opposed to alterations 
to catalytic activity and/or protein degradation (Reddy and 
Lalwani, 1983). With respect to peroxisomal enzymes it has been 
established that Wy-14,643 administration resulted in 
peroxisome proliferation and a marked increase in CoA-thiolase 
and enoyl-CoA hydratase, as determined using immuno-
precipitation studies (Chatterjee et al.,1983).
It is possible that peroxisome proliferators and/or their 
metabolites act as substrates for the peroxisomal beta-
oxidation pathway thereby initiating enzyme induction as a 
result of substrate overload (Reddy and Lalwani, 1983). It has 
long been established that the activities of drug metabolising 
enzymes in liver microsomes are markedly increased when 
animals are treated with a variety of xenobiotics, of which 
many stimulate their own metabolism (Conney,1967). This
enhanced activity is termed enzyme induction and represents 
new enzyme synthesis. It is possible that peroxisome 
proliferators containing an omega-carbon group may serve as 
substrates for cytochrome P-452 hydroxylase activity and act 
as inducers in a similar manner to the peroxisomal system. The 
limited formation of hydroxybezafibrate by a cytochrome P-450 
mediated process has been demonstrated in an in vitro system
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(Facino et al.,1981). This is consistent with a substrate 
linked induction mechanism. The in vitro metabolism of ME HP to 
omega-, (omega-1)- and (omega-2)- hydroxylation products has 
been demonstrated and it is believed to be mediated by the 
cytochrome P-450 isoenzymes associated with omega- and 
(omega-1)- and (omega-2)-hydroxylation of fatty acids (Albro 
et al.,1984).
It has been suggested that an influx of fatty acids into the 
liver, as a result of drug treatment leads to a lipid excess, 
thereby triggering peroxisomal beta-oxidation. Fatty acids 
serve as substrates for the microsomal cytochrome P-450 
hydroxylase system and for peroxisomal beta-oxidation, and 
both activities undergo substantial induction in peroxisome 
proliferator treated animals. A similar mechanism may account 
for the increased enzyme activity in both organelles. This 
concept has been, in part substantiated by induction of 
peroxisomal enzymes and peroxisomal beta-oxidation by high fat 
diets (Neat et al.,1980). Peroxisomal proliferation was less 
apparent, yet peroxisomal beta-oxidation more marked in diets 
containing a high amount of fatty acids which are poorly 
oxidised by mitochondria (Osmundsen, 1982). The presence of a 
haemoprotein with a CO-adduct absorption maximum at 454 nm, 
designated cytochrome P-454 has been identified in rat kidney 
cortex microsomes (Jakobsson et al.,1970). This cytochrome 
catalysed the omega-oxidation of fatty acids whereas 
metabolism of model substrates was minimal. A diet 
supplemented with 10% lauric acid resulted in a marked 
increase in cytochrome P-454 concentration, a type 1 spectral
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change and a moderate enhancement of total omega-oxidation of 
laurate (Jakobsson et al.,1970). It would appear that the 
concentration of endogenous substrates such as fatty acids may 
have a regulatory effect on the levels of the cytochrome P-454 
omega-hydroxylase system in the kidney cortex. The influence 
of a lauric acid supplemented diet on the hepatic microsomal 
system was not studied, but it is tempting to speculate that a 
similar response may exist.
It has been demonstrated that rats maintained on a high fat 
diet exhibit a significantly increased hepatic microsomal 
membrane phospholipid to cholesterol ratio (Narbonne et 
al.,1984). This effect tends to increase the microsomal 
membrane fluidity and is associated with an increased ability 
of cytochrome P-450 to hydroxylate aniline. The increased 
cytochrome P-450 hydroxylase activity observed in the kidney 
and liver following the administration of peroxisome 
proliferators and high fat diets may in part be attributed to 
the decreased viscosity and increased mobility of the 
microsomal membrane which may either:
1. facilitate the interaction of cytochrome P-450 and the 
NADPH-cytochrome P-450 reductase (Jakobsson et al.,1970), 
or,
2. favourably affect the accessibility of the respective 
components to the substrate.
Induction may result from an interaction of these compounds 
and/or their metabolites with a receptor in the cytoplasm of 
hepatocytes (and renal proximal tubular epithelium) (Reddy and 
Lalwani, 1983). Recently, tritiated nafenopin was shown to bind
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to a specific saturable pool of binding sites in cytosols from 
rat liver and kidney cortex (Lalwani et al.,1983). Tissue 
levels of this protein correlated with the ability of 
nafenopin to induce peroxisomal enzymes in these organs. 
Ciprofibrate and clofibrate competitively blocked the specific 
binding of nafenopin. This peroxisome-prolif erator binding 
protein has been purified using nafenopin, clofibric acid and 
ciprofibrate as affinity ligands and eluting agents (Lalwani 
et al.,1987). It was suggested that this protein probably 
plays an important role in the regulation of the induced 
pleiotropic response. In this context it should be noted that 
a cytosolic receptor has been identified and implicated in the 
induction process of certain cytochrome P-450 species, namely 
the murine Ah locus with polycyclic aromatic compounds 
(Whitlock,1986). The molecular events involve the passive 
transfer of the inducer across the cell membrane with specific 
binding to the cytosolic Ah receptor, the major regulatory 
gene product. The pleiotropic response, including the 
activation of numerous structural genes follows the apparent 
translocation of the inducer-receptor complex into the 
nucleus. The induction of several drug metabolising enzymes, 
the structural gene products, is the final outcome 
(Whitlock, 1986).
It is both plausible and tempting to speculate that a 
cytosolic receptor binding protein is responsible for the 
induction of microsomal and/or peroxisomal parameters; binding 
occurring via a functional group or structural orientation 
common to all the agents producing peroxisome and S.E.R
proliferation. This would by its presence or absence readily 
explain tissue, sex and species differences in the
responsiveness to these agents. The existence of the
peroxisome-proliferator binding receptor has not been 
universally accepted with the original receptor binding 
studies having yet to be verified in other laboratories. Our 
laboratory has been unable to verify the presence of this
putative receptor and found no evidence of specific binding of 
peroxisome proliferators to hepatic cytosolic proteins or 
receptor material (Milton et al.,1988). Further research is 
necessary to identify and characterise this postulated binding 
protein and receptor inhibitor studies will clarify the 
relationship between the induction of both systems and this
"cytosolic receptor".
1.5 RESPONSE OF DIFFERENT SPECIES TO THE ADMINISTRATION
OF PEROXISOME PROLIFERATORS
The hepatic changes induced by the administration of 
peroxisome proliferators to rats and mice has been reviewed in 
depth herein. It is important to determine whether the changes 
induced in rodents represents a rodent specific phenomenon or 
a species common response. Clofibrate induced hepatomegaly has 
been studied in the dog and Rhesus monkey following various 
dose regimens (Platt and Thorp, 1966). An increased liver 
weight was observed in dogs and monkeys following 3 months of 
treatment. No increase was demonstrated in the latter group as 
a result of administration for a 2 year period (Platt and 
Thorp,1966). Hamsters, guinea pigs and rabbits were fed 0.25%
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(w/w) clofibrate in the diet for 14 days (Svoboda et 
al.,1967). An increased peroxisome number was observed in 
hamsters only, the peroxisomes exhibiting marked structural 
variation. No peroxisome changes were detected in chickens fed
0.25% (w/w) clofibrate in the diet for 3 weeks. The number of 
peroxisomes increased in the dog following a daily dose of 
25mg/kg clofibrate for 26 days. No changes were detected in 
the squirrel monkey treated with clofibrate (75mg/kg/day for 
22 days) (Svoboda et al.,1967).
The administration of BR-931, fenofibrate and methyl 
clofenapate to male Syrian golden hamsters resulted in a 
marked peroxisome proliferation with a concomitant induction 
of enoyl-CoA hydratase and PPA-80 and elevation of peroxisomal 
beta-oxidation (Reddy,M.K. et al.,1982). The effect of 
clofibrate was less marked. The influence of gemfibrozil on 
peroxisomes in Rhesus monkeys, dogs and hamsters of both sexes 
has been studied (Gray and De La lglesia,1984). In hamsters 
(400mg/kg/day for 2 weeks), peroxisome proliferation with a 
correspondingly decreased mean volume of individual 
peroxisomes was observed. In dogs, the number of peroxisomes 
per hepatocyte was increased and the volume fraction was 
significantly increased in females only. Peroxisome numbers 
were unchanged in young monkeys (3-4 years old) with sex 
dependent alterations in organelle volume. Treatment of aged 
monkeys (6-13 years old) resulted in an increase in peroxisome 
number and volume in both sexes. Both groups were administered 
gemfibrozil at 300mg/kg/day for 3 months (Gray and De La 
Iglesia,1984). It would appear that a species dependent
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organelle response occurs with gemfibrozil treatment, the 
order of susceptibility being dog < monkey < hamster < rat.
The oral administration of DEHP at 25-lOOOmg/kg/day for 14 
days to male Syrian golden hamsters has also been studied
(Lake et al.,1984). Liver enlargement and peroxisome 
proliferation was observed in response to this compound,
however the magnitude of response was considerably less than 
that of rats at the same dose levels. A similar response was 
demonstrated with the administration of ME HP and clofibrate, 
indicating that a marked species difference exists (Lake et
al.,1984). Acute toxicity studies with DEHP in the rat and
marmoset (oral administration, 2000mg DE HP/kg body weight for 
14 days) demonstrated that none of the hepatic changes found 
in the rat were observed in the marmoset (Jackh et al.,1984). 
However, bioavailability of DEHP is much lower in the marmoset 
than in the rat and the marmoset has also been shown to have a 
different physiological and pharmacological response to DEHP 
and its metabolites (Jackh et al.,1984).
The effect of clobuzarit, a structural analogue of clofibrate,
has been examined in various species following a 14 or 15 day 
treatment period (Orton et al.,1984). A limited peroxisome
proliferation was detected in hamsters with an increase in 
endoplasmic reticulum fatty acid oxidase. No proliferative 
effects were observed in the liver of the dog or marmoset at 
dose levels of 15 and 45mg/kg. In a recent study, the
administration of ciprofibrate resulted in hepatic peroxisome 
proliferation in cats, pigeons, chickens, Rhesus monkeys and
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Cynomolgus monkeys (Reddy et al.,1984). The dose levels were 
as follows;
1) Cats; morphology (50mg/kg x 1 week, lOOmg/kg x 2 weeks),
biochemistry (lOmg/kg x 1 week, 20mg/kg x 2 weeks, 
40mg/kg x 1 week),
2) Pigeons; morphology (300mg/kg x 3 weeks),
biochemistry (300mg/kg x 2 weeks),
3) Chickens; morphology (lOOmg/kg x 6 weeks),
biochemistry (50mg/kg x 4 weeks),
4) Rhesus monkeys; morphology (50mg/kg x 1 week, lOOmg/kg x 3
weeks, 200 mg/kg x 3 weeks), 
biochemistry (50mg/kg x 1 week, lOOmg/kg x 
3 weeks, 200 mg/kg x 3 weeks),
5) Cynomolgus monkeys; morphology (400mg/kg x 3 weeks),
biochemistry (400mg/kg x 2 weeks).
A marked but variable increase in the activities of 
peroxisomal catalase, carnitine acetyltransf erase, heat labile 
enoyl-CoA hydratase and the fatty acid beta-oxidation system 
was observed, indicating that peroxisome proliferation is a 
dose-dependent phenomenon. A significant increase in 
mitochondrial volume density was observed in the cat and 
chicken.
The effect of long term clofibrate therapy on human liver has 
been studied by Hanefeld et al.,(1980). With the short term 
use of clofibrate, an increase in E.R especially in the 
agranular membranes of hepatocytes of all patients was 
observed. Selective alterations in peroxisomes were not seen 
but an increase in liver cell mitochondrial inner membranes
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was detected. With long term treatment the above changes were 
more marked; structural alterations in mitochondria were 
observed and a further increase in agranular and granular E.R 
and peroxisomes was demonstrated. These ultrastructural 
alterations observed in hepatocytes (proliferation of E.R and 
peroxisome populations) persisted for several months after 
cessation of treatment (Hanefeld et al.,1980).
The morphological effects of clofibrate in man were 
investigated more thoroughly in a later study (Hanefeld et 
al.,1983). Clofibrate treatment resulted in a significant 
increase in the numerical density of mitochondria and 
peroxisomes (38% and 50%) respectively. The volume density 
similarly increased by 34% and 23% for mitochondria and 
peroxisomes. A marked proliferation of both organelles 
occurred during the first months after which no further 
significant increases were observed. There was a significant 
reverse correlation between the increase in volume density of 
mitochondria and the decrease in triglyceride levels, whereas 
no relation between the proliferation of peroxisomes and 
hypolipidaemic action appeared to exist. The increase in 
peroxisomes was less pronounced in man in contrast to the 
marked proliferation observed in rodents and this was 
proportional to the increase in mitochondria (Hanefeld et 
al.,1983).
Fenofibrate treatment of patients for a 2 year period revealed 
no increase in peroxisomes nor were any other peroxisomal 
morphological alterations observed (Blumcke et al.,1983).
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Mitochondria containing paracrystalline inclusions were more 
common in treated subjects and dilated S.E.R associated with 
reduced amounts of R.E.R appeared to be more evident in 
patients receiving fenofibrate. Light and electron microscopy 
of liver biopsies from fenofibrate treated and untreated 
patients showed no morphological differences in peroxisome 
numbers or volume densities (Gariot et al.,1983 and 1984). 
Biopsies from subjects on long term gemfibrozil therapy (17-27 
months) revealed peroxisome populations varying from 656 to 
1452 per hepatocyte with a mean of 830 per group (De La 
lglesia et al.,1981). Considerable variation in peroxisome 
volume was detected with some peroxisomes containing marginal 
plates and spurious densities. No peroxisome proliferation was 
noted. Gemfibrozil treatment was found to cause no observable 
alterations in nuclei and mitochondria whereas S.E.R membranes 
appeared proliferated when EM sections were examined 
subjectively (De La lglesia et al.,1982). No induction of 
peroxisomes occurred although similar ultrastructural changes 
were observed.
1.6 MOLECULAR APPROACH TO STUDY THE HEPATIC RESPONSES
INDUCED BY PEROXISOME PROLIFERATORS
The hepatic responses induced in rats by peroxisome 
proliferators have been studied extensively at the biochemical 
and ultrastructural levels. However, the use of recombinant 
DNA technology to examine gene expression in treated animals 
has been limited, although this approach offers the 
opportunity to gain a fundamental insight into the process of
induction.
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Recombinant DNA technology has provided a novel approach to 
investigating the regulation of gene expression. Any region of 
a cell's DNA can be excised with restriction nucleases, 
replicated by DNA cloning and sequenced. Similarly 
complimentary DNA (cDNA) copies of any messenger RNA can be 
isolated. Using nucleic acid hybridisation methods, mRNA 
molecules corresponding to the cloned DNA molecules can be 
detected, quantitated and characterised. It is also possible 
to use the specific antisera to pure proteins to isolate the 
gene encoding for them. Alternatively, specific DNA probes 
(oligonucleotide probes) corresponding to a short length of 
amino acid sequence from the protein, can be synthesised which 
will hybridise with the mRNA and DNA encoding the protein 
(Alberts et al.,1983).
Much of the current research on the molecular biology of the 
cytochrome P-450 system is concerned with the elucidation of 
the genetic, molecular and evolutionary mechanisms responsible, 
for the existence of a multiplicity of forms of cytochrome 
P-450 and also for the induction of distinct forms by specific 
inducing agents (Adesnik and Atchison, 1986). Using an antibody 
to cytochrome P-450 LAw, thought to be identical to cytochrome 
P-452 purified by Tamburini et al.(1984), the haemoprotein was 
immunochemically detected in non-induced rat liver and kidney. 
The level of this isoenzyme was markedly elevated after 
clofibrate treatment due to an activation of cytochrome P-450 
LAw mRNA synthesis, as determined using the corresponding cDNA
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probe (Hardwick et al.,1987). This rapid transcriptional 
increase is similar to the transcriptional activation of fatty 
acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxy acyl CoA 
dehydrogenase induced by clofibrate in rat liver (Reddy et 
al.,1986). It appears that cytochrome P-450 LAw is regulated 
by the same mechanism that regulates these peroxisomal 
enzymes. A lKbp (kilo base pair) cDNA probe to cytochrome 
P-452 was recently isolated in our laboratory from a 
clofibrate-induced rat liver cDNA library in the bacteriophage 
expression vector lambda gtll using anti-cytochrome P-452 sera 
and a biotin-streptavidin linked immunoassay (Earnshaw et 
al.f1988). This cDNA probe is being used in our laboratory to 
examine the corresponding mRNA levels in untreated and treated 
animals utilising hybridisation methodology.
It has been reported that clofibrate and fenofibrate treatment 
decrease glutathione peroxidase (GPX) enzyme activity (Ciriolo 
et al.,1982 and 1984). The mouse GPX-1 gene has been isolated 
using recombinant DNA technology (Goldfarb et al.,1983, 
Chambers et al.,1986). A genomic DNA probe (p2D6) derived from 
the 3' end of the gene, has very strong homology with 
sequences in human and rat DNA and mRNA. This probe can 
therefore be used to study GPX gene expression in a variety of 
species. The tissue distribution of glutathione peroxidase 
varies between species, and in the mouse there is good 
evidence that tissue specificity of gene expression is 
controlled at the transcriptional level (Goldfarb et al.,1985, 
Affara et al.,1985, Chambers et al.,1986).
The techniques of molecular biology, namely the use of 
hybridisation probes, were applied in this study to 
rationalise the ciprofibrate-dependent modulation of the 
cytochrome P-452 and GPX-1 gene expression. Use of the cloned 
DNA probes combined with immunochemical and catalytic analyses 
should clarify the level at which the regulation of enzyme 
changes occurs. The inter-relationships between enzyme levels 
and gene expression will be delineated in susceptible and non- 
susceptible species. It is hoped that this will define the 
hepatic response in rodents as species common or species 
specific.
1.7 AIMS OF THE PRESENT INVESTIGATION
The aim of the present study was twofold;
1. to endeavour to clarify the rodent hepatic response to 
peroxisome proliferators as species specific or species 
common, and;
2. to assess the validity of extrapolating animal toxicity 
data to predict human risk.
The effect of xenobiotic pretreatment was investigated at a 
biochemical and molecular level. Enzyme levels were determined 
in the cytosolic, mitochondrial, microsomal and peroxisomal 
fractions. The influence of pharmacokinetic differences in 
metabolism on the relative potency of peroxisome proliferators 
was examined in the rat (Chapter 3). The hepatic and renal
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response was studied in five rat strains and six species
following the short term administration of ciprofibrate
(Chapter 4 and 6). The effect of long term ciprofibrate
treatment in the marmoset and Fischer rat was also undertaken
(Chapter 5).
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Chapter 2
METHODOLOGY RELATING TO PREPARATION AND CHARACTERISATION
OF ENZYME CONTENT AND ACTIVITY IN SUBCELLULAR FRACTIONS
2.1 MATERIALS
Acetylacetone, ammonium acetate, citric acid, copper sulphate, 
EDTA, Folin-Ciocalteau phenol reagent, gelatin, glycine, 
hydrogen peroxide, magnesium chloride, mercaptoethanol, 
potassium cyanide, potassium phosphate, sodium carbonate, 
sodium chloride, sodium dithionite, sodium potassium tartrate, 
sucrose and Triton-X-100 were purchased from British Drug 
Houses Ltd. (Poole, Dorset). Emulgen 911 was obtained from 
K.A.O Atlas Co. (Tokyo, Japan).
Analytical grade acetyl-CoA, bovine serum albumin, carnitine, 
coenzyme A, 5, 5'-dithiobis (2-nitro-ben zoic acid), dithio- 
threitol, flavin adenine dinucleotide, 4-hydroxyquinoline, 
kynuramine, lauric acid, NAD + , NADH, NADPH, nicotinamide, 
palmitoyl-CoA, sodium cholate, sodium alpha-glycerophosphate, 
sodium malonate, sodium succinate, Tris (Trizma base), Tween 
20 and uric acid were purchased from the Sigma Chemical Co. 
Ltd. (Poole, Dorset). Benzphetamine was obtained from the 
Upjohn Co. (Kalamazoo, Michigan, USA), ciprofibrate, 
bezafibrate, clofibric acid and gum tragacanth from Sterling 
Winthrop Research Centre (Alnwick,Northumberland),
ethoxyresorufin and resorufin from Molecular Probes Inc. 
(Junction City, Oregon, USA) and 14-C-lauric acid from the 
Radiochemical Centre (Amersham, Bucks.). Glycerol was obtained
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from the Fisons Scientific Equipment Co. (Loughborough 
Leics.).
Nitrocellulose filters (0.45um) were purchased from Anderman
and Co. Ltd. (Kingston Upon Thames, Surrey). Control donkey
.....
anti-sheep IgG enzyme l a b e l  and orthophenylenediamine were kindly 
supplied from the Guildhay unit (University of Surrey.)
horseradish perox idase.
All other chemicals were obtained as Analar grade wherever 
possible.
2.2. ANIMALS
Male Wistar albino rats were obtained from the University of
Surrey breeders and male Gunn rats from the University of
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Dundee breeders. Male Sprague Dawley, Fischer|and Long Evans 
rats, mice (CD-I) and marmosets were purchased from Charles 
River UK (Margate, Kent). The rats, approximate body weight of 
140-160g, were housed at the University of Surrey in cages 
with sawdust bedding, being allowed food (Spratts Animal Diet 
No.l) and water ad libitum. A 12 hr light-dark cycle was in 
operation (0700-1900 light) at 22 degrees centigrade and 50% 
humidity.
Male albino (Duncan Hartley) guinea pigs were obtained from 
the Porcellus Animal Breeding Ltd. (Heathfield, Sussex), male 
half-lop rabbits from Froxfield Research Suppliers of 
Laboratory Animal Breeders (Froxfield, Hants) and male 
golden Syrian hamsters from the National Institute of
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Medical Research (Mill Hill, London) as young adults (post­
juvenile) .The bodyweight at the start of the experiments were 
as follows ; mice (25-35g), hamsters (85-130g), guinea pigs 
(450-550g) and rabbits (2750-3200g). Marmosets, mice, 
hamsters, guinea pigs and rabbits were housed in the barrier 
maintained animal unit at Sterling Winthrop Research Centre 
(Alnwick, Northumberland) with a 12 hr light/dark cycle 
(0700-1900 light) at 21 (+/-1) degrees centigrade, 50 (+/-5) % 
humidity with 30 air changes per hour during the day, 15 
changes per hour at night.
2.2.1 Treatment of Animals
Ciprofibrate was administered as a suspension in 0.25%(w/v) 
gum tragacanth,.the vehicle. Rats, hamsters, mice, guinea pigs 
and rabbits received 2 mg/kg or 20 mg/kg per day ciprofibrate 
for a duration of 14 days and were sacrificed 24 hours 
following the final dose. Marmosets were dosed with 20 mg/kg, 
80 mg/kg or 100 mg/kg for a period of 2 weeks or 6 months. An 
additional group of rats received varying doses of 
ciprofibrate, bezafibrate, or clofibrate for a treatment 
period of 6 months. Bezafibrate and clofibrate were also 
administered as a suspension in 0.25% (w/v) gum tragacanth. In 
each case the drugs and vehicle were administered by oral 
gavage in a volume of 5ml/kg. The concentration and 
homogeneity of drug suspensions used in studies at Sterling 
Winthrop Research Centre were assessed prior to use by Quality 
Control Laboratories.
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2.3 Autopsy Procedure
The animals were weighed prior to sacrifice and the body
weights recorded. Marmosets were anaesthetised with an i.p.
5kinjection of sagatal (intravenous anaesthetic) and were bled
from the posterior vena cava, death resulting from
exsanguination. With other species a single lethal dose of
sagatal was used and no blood samples were collected. The
livers and kidneys were removed and weighed as rapidly as
possible and as required, sections for light and electron
microscopy were taken. Frozen sections were also taken from
marmoset livers for enzyme histochemistry. The remaining
tissue was maintained on ice in 0.9% (w/v) sodium chloride.
5k Pentobarbi tone
2.3.1 Isolation of Hepatic and Renal Microsomes
Microsomes were prepared by ultracentrifugation using a 
modification of the method of Omura and Sato, (1964). The 
livers were removed and perfused with 0.9% (w/v) aqueous
sodium chloride to remove contaminating haemoglobin, blotted 
dry and placed in ice cold 0.25M sucrose. All subsequent steps 
were carried out at 4 degrees centigrade. The kidneys from 
animals of the same group were pooled and decapsulated. 
Likewise livers were pooled from hamsters and mice. The livers 
and kidneys were scissor minced and homogenised in 0.25M 
sucrose using a Potter Elvehjem glass teflon homogeniser (3 
return strokes). The liver homogenate was adjusted to 25-33% 
(w/v) and kidney homogenate to 15% (w/v) by the addition of
0.25M sucrose. Aliquots of homogenate were taken, with 1ml of
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the liver samples being retained on ice for catalase and 
monoamine oxidase assays. The remaining aliquots were frozen at 
-80 degrees centigrade.
The homogenates were spun at 10,000rpm for 30 minutes using a 14 
x 50 ml rotor in a Beckman J2-21 centrifuge at 4 degrees 
centigrade, or a 12 x 30ml rotor in a Sorvall ultracentrifuge at 
4 degrees centigrade. The supernatant was decanted and
centrifuged at 40,000rpm for 1 hr using a 8 x 25ml rotor in a
Beckman LK65 refrigerated ultracentrifuge at 4 degrees
centigrade or a 12 x 30ml rotor in a Sorvall ultracentrifuge at 4 
degrees centigrade. Aliquots of the supernatant, designated the 
cytosol, were frozen at -80 degrees centigrade. The microsomal
pellet was suspended in ice-cold 50mM potassium phosphate 
buffer, pH 7.25, containing 20% (v/v) glycerol using a motor
driven Potter Elvehjem glass teflon homogeniser. A final volume 
of 8-10ml per liver sample (equivalent to a protein
concentration of 10-15 mg/ml) and 6-8ml per kidney sample
(corresponding to a protein concentration of 3-8 mg/ml) was 
achieved.
The microsomal suspension was stored as 1ml aliquots at -80 
degrees centigrade and under these conditions was shown to be 
stable for a period of several months.
2.3.2 Preparation of Tissue for Electron Microscopy
The methodology employed was one routinely used in the
Toxicology Department at Sterling Winthrop Research Centre
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(Alnwick, Northumberland). All chemicals were purchased as EM 
grade from Taab Laboratories (Reading, Berks.).
After removal of the livers and kidneys, sections were cut 
from the median lobe of the liver and the cortex of the 
kidney. These sections were then sliced into 1mm cubes and 
fixed at room temperature for 2-4 hrs in Karnowskyl fixative 
(0.1M sodium phosphate bufffer, pH 7.4, containing 2.5% (v/v)
glutaraldehyde, 2% (w/v) paraformaldehyde and 0.01% (w/v)
magnesium chloride). After fixation, this solution was 
decanted and replaced with 0.1M sodium phosphate buffer, pH
7.4, and the samples stored at 4 degrees centigrade prior to 
processing.
The tissue blocks were counterstained in 1% (w/v) osmium
tetroxide in 0.1M sodium phosphate buffer, pH 7.4 for 1 hr, 
rinsed in distilled water and stained for 30 minutes with 2% 
(w/v) uranyl acetate in distilled water. The tissue blocks 
were rinsed in distilled water and dehydrated by means of a 
70% (v/v) ethanol wash, two 95% (v/v) ethanol washes, and
three absolute alcohol washes. Each wash allowed for a minimum 
tissue contact time of 10 minutes. The tissue blocks were 
subsequently rinsed in propylene oxide and immersed in a 1:1 
solution of propylene oxide and Epon 812 resin for 30 minutes. 
The blocks were left overnight in resin, prior to embedding in 
Epon 812 resin-filled truncated capsules. The capsules were 
incubated at 58 degrees centigrade for 48 hrs to allow the 
resin to polymerise.
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Silver-grey sections were cut on a Reichardt Ultramicrotome 
(Reichardt-Jung, Austria), counterstained with uranyl acetate 
and lead citrate (Lewis and Knight, 1977) and examined on a 
JEOL 100B electron microscope (JEOL, Japanese Optical Co, 
Japan);(courtesy  of the M icrostructura l  Studies Unit, Univers ity of Surrey ) .
2.4 GENERAL ANALYTICAL PROCEDURES
2.4.1 Protein Determination
Protein concentrations of liver and kidney homogenates, 
cytosolic and microsomal samples were routinely determined by 
a modified method of Lowry et al., (1951) using bovine serum 
albumin as the standard.
REAGENTS
2% (w/v) sodium carbonate in 0.1M sodium hydroxide.
1% (w/v) hydrated copper sulphate.
2% (w/v) sodium potassium tartrate.
A stock solution of bovine serum albumin (20 mg/ml) was
diluted in distilled water to give 0, 8, 16, 24, 32 and 40 ug/
tube in duplicate. Protein samples were diluted as necessary
and a range of 2-4 dilutions were used in duplicate assays.
With microsomal samples (which routinely contained glycerol) 
com pensatory
appropriate ) additions of glycerol were made to the standard 
curve. Copper sulphate, sodium potassium tartrate and sodium 
carbonate/hydroxide solution were mixed sequentially to give 
the ratio (1:1:100 by volume) immediately before use. The
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protein standards, samples and blanks (0.5ml) were mixed with 
2.5ml of the above reagent and allowed to stand for 10 minutes 
at room temperature. Folin-Ciocalteu phenol reagent, diluted 
1:1 with distilled water, was added (0.25ml) and the solutions 
were immediately vortexed. After a thirty minute incubation 
period at room temperature the absorbance was recorded at 
750nm using a Cecil 292 Ultraviolet spectrophotometer. The 
extent of colour development is a partial function of the 
amino acid composition, due to the reaction of tyrosine 
residues with the Lowry reagent.
2.5. ASSESSMENT OF ENZYME LEVELS AND ACTIVITIES IN THE
MICROSOMAL FRACTIONS
2.5.1 Determination of Cytochrome P-450 Content
A). LIVER MICROSOMES
Cytochrome P-450 was routinely measured as the reduced carbon 
monoxide adduct (Omura and Sato, 1964). Microsomal samples were 
diluted to give a protein concentration of 1-2 mg/ml with 50mM 
potassium phosphate buffer (pH 7.25), 20% (v/v) glycerol.
Reduction of the ferric to the ferrous form of the 
haemoprotein was achieved by the addition of sodium 
dithionite. The reduced sample was divided between two 
cuvettes and the baseline recorded between 400nm and 500nm 
using a Kontron-Uvikon 860 spectrophotometer or Varian 2200 
split beam spectrophotometer. Carbon monoxide (40 bubbles at 
approximately 1 bubble per second) was gassed through the 
sample cuvette only. The spectrum was repetitively scanned
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until there was no further absorbance development at 450nm. 
The concentration of cytochrome P-450 was calculated using the 
difference millimolar extinction coefficient (450nm minus 
490nm) of 91.
B). KIDNEY MICROSOMES
Because of the presence of mitochondrial contamination a 
different method was utilised to determine the cytochrome 
P-450 content in kidney microsomes. In this instance, sodium 
succinate was added to the assay solution to reduce
mitochondrial electron transport enzymes and NADH to reduce 
any cytochrome b5 present.
To 0.6ml of kidney microsomal suspension, 0.6ml sodium
succinate (lOOmM) and 4.8ml potassium phosphate buffer (50mM, 
pH 7.25, containing 20% (v/v) glycerol) were added. The sample 
was divided between two cuvettes and the baseline (4 00nm to 
500nm) recorded. NADH (25 ul, 2% (w/v) solution) and a few
grains of sodium dithionite were added to each cuvette. Carbon 
monoxide was bubbled through the sample cuvette for 40
seconds, the spectrum was rescanned and concentration 
measurements calculated as for liver microsomes.
2.5.2 Determination of Laurie Acid Hydroxylation
The metabolism of 14-C lauric acid to 12- and 11- hydroxylated 
products was evaluated using HPLC, utilising the method
described by Parker and Orton, (1980).
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The 2ml incubation volume contained 14-C lauric acid (0.1 uCi 
in 10 ul methanol) and a final concentration of O.lmM 12-C 
lauric acid (200mM stock solution in methanol diluted to ImM 
in 0.5M Tris-HCl buffer, pH 7.4). One mg of protein from
control and kidney samples was used per assay or 0.5 mg 
protein from induced microsomes. The tubes were incubated for 
5 minutes at 37 degrees centigrade prior to the addition of 40 
ul of 40mM NADPH to initiate the reaction. NADPH blanks 
were completed using distilled water in place of NADPH. 
Samples from untreated animals were incubated for 10 minutes 
and samples from treated animals for 5 minutes. The reaction 
was terminated by the addition of 0.2ml 3M HC1. Incubations
were carried out in polypropylene stoppered tubes.
Extraction and Analysis of 11- and 12- Hydroxylauric Acid
A total of 10 ml of diethyl ether was added to the incubation 
mixtures and the tubes were subsequently rotated end over end 
for 15 minutes. The tubes were allowed to stand for 10 minutes 
to clarify the phases and the upper (ether) layer
(approximately 9ml) was transferred to a test tube and
evaporated to dryness under a stream of nitrogen. The test 
tubes were sealed and stored at -20 degrees centigrade until 
used.
High Performance Liquid Chromatography (HPLC) Procedure
for the Quantitation of 11- and 12- Hydroxylauric Acid
The dried ether extracts were reconstituted in 150 ul of
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eluting solvent (water: methanol: glacial acetic acid,
45:55:0.05 by volume). A 100 ul aliquot was then injected into 
a HPLC column of the following specifications (column : 
ultrasphere ODS 15 x 0. 46cm). The HPLC column was calibrated 
with the NADPH blanks to check that the metabolism of 
lauric acid was NADPH-dependent.
Elution of the products was achieved by using a gradient of 
0.1% (v/v) glacial acetic acid in distilled water : methanol
(45:55 by volume) to 35% (v/v) 0.1% (v/v) glacial acid in
water and 65% (v/v) methanol over a 30 minute period. The
percentage of methanol was increased to 100% over 5 minutes 
and maintained to the end of the programme, the duration of 
which was 40 minutes. A constant flow rate of 1ml/min was 
used. The 11- and 12- hydroxylauric acids were successively 
eluted followed by the unmetabolised lauric acid. The elution 
profile of the radioactive products was monitored using a
Berthold LB 503 HPLC radioactivity monitor interfaced (Rexagan 
interface,ICI) with a PET 4032 microcomputer linked to a chart 
recorder for data analysis. Results were expressed as nmoles 
hydroxyproduct formed/minute/mg protein or nmoles
hydroxyproduct formed/ minute/nmol cytochrome P-450.
2.5.3 Determination of Ethoxyresorufin-O-Deethylation
The O-deethylation of ethoxyresorufin was routinely determined 
by the method of Burke et al., (1977), using the difference in 
fluorescent properties of ethoxyresorufin (excitation 
wavelength = 456nm, emission wavelength = 560nm) and the
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product resorufin (excitation wavelength = 510nm, emission
wavelength = 586nm).
A standard assay system contained 2ml of 0.1M Tris-HCl buffer, 
pH 7.8, a final concentration of 50uM ethoxyresorufin (stock 
solution in methanol) and an appropriate volume of microsomes; 
25-50 ul (equivalent to 0.5-1 mg protein) of liver microsomes 
or 100-150 ul (equivalent to 1-2 mg protein) of kidney sample. 
The complete system was transferred to a fluorimeter cuvette 
and placed in a thermostatically controlled cuvette housing of 
a Perkin-Elmer MPF-3 fluorimeter, set at an excitation 
wavelength of 510nm and an emission wavelength of 586nm. After 
preincubation at 37 degrees centigrade for 2 minutes, a steady 
baseline with time was established. The reaction was initiated 
with 10 ul of 50mM NADPH and the production of resorufin with 
time monitored as the increase in fluorescence at 586nm. The 
fluorimeter was calibrated with multiples of 2 ul of resorufin 
standard (lOuM in methanol).
2.5.4 Determination of Benzphetamine Demethvlase Activity
The hydroxylation of the benzphetamine-N-methyl group results 
in the formation of an unstable amino-carb in ol intermediate 
which breaks down to release formaldehyde which can 
subsequently be determined by the method of Nash (1953).
The 1ml incubation volume contained 0.1ml microsomal 
suspension (equivalent to approximately 2 mg protein) and a 
final concentration of 1.5mM benzphetamine, 15mM magnesium
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chloride and 50mM potassium phosphate buffer (pH 7.25). The 
tubes were preincubated at 37 degrees centigrade for 5minutes 
prior to the addition of 40ul of 50mM NADPH to initiate the 
reaction. After 10 minutes the reaction was terminated by the 
addition of 0.5ml of ice cold 12.5% (w/v) trichloroacetic
acid. Samples were mixed and allowed to stand on ice for 5 
minutes following which they were centrifuged at 3500 rpm for 
15 minutes in a Beckman J6B centrifuge. The supernatant (1ml) 
was then removed for the determination of formaldehyde using 
the Nash assay.
Nash Assay
REAGENT
Ammonium acetate (150g) was dissolved in 900ml of distilled 
water. Acetylacetone (2ml) was added and completely dissolved. 
The pH was adjusted to pH 6 with glacial acetic acid and the 
volume adjusted to 1L. The reagent was stored at 4 degrees
centigrade.
METHOD
The supernatant from the trichloroacetic acid precipitation 
(lml) was added to Nash reagent( lml), mixed and heated in a 
water bath at 58 degrees centigrade for 10 minutes in the 
dark. After cooling for 5 minutes, the absorbance at 412nm was 
recorded using a Cecil 292 Ultraviolet spectrophotometer. A
standard curve was constructed using lml volumes containing 0, 
10, 20, 40, 60, 100 and 140 nmol formaldehyde treated in an
77
Identical manner to the test samples.
2.5.5 Enzyme-Linked Immunosorbent Assay (ELISA)
The technique of ELISA (enzyme linked immunoabsorbent assay) 
as described by Voller et al., (1978) and modified for the 
quantitation of cytochrome P-452 by Sharma et al., (1988) was 
utilised to quantitate antigen within specific tissues.
Microsomes were solubilised by the addition of 1 mg cholate 
and 0.2 mg Emulgen 911 per mg of protein with stirring for 20 
minutes on ice. The antigen was diluted as appropriate 
(0.01-0.05 pmoles cytochrome P-450) with 0.1M sodium 
carbonate/ bicarbonate buffer (pH 9.6) and coated onto ELISA 
plates (200 ul/well) which were left overnight at 4 degrees 
centigrade in a humid environment. The plates were washed with 
phosphate buffered saline, pH 7.4, containing 0.1% (w/v)
gelatin and 0.05% (v/v) Tween 20 (PBS-GT). The antisera
(cytochrome P-452 antibody) and pre-immune sera were diluted 
as required using PBS-GT buffer and applied to the plates in 
200 ul volumes.
The plates were incubated at 37 degrees centigrade for 2 hrs
and rewashed with PBS-GT buffer. A second 2 hour incubation at
37 degrees centigrade was completed using a donkey anti-sheep 
*
enzyme label (200 ul per well) with a subsequent PBS-GT wash. 
The substrate (lOOmls of 0.025M citric acid, 0.05M sodium 
hydrogen phosphate buffer, pH 5.6, containing 40 mg 
orthophenylenediamirie and 40 ul hydrogen peroxide) was added (150 
*  horseradish perox idase
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ul per well) and the plates incubated for 30 minutes at 37 
degrees centigrade. The colour reaction was stopped by the 
addition of 2.5M sulphuric acid (50 ul per well). The plates 
were read at 490nm using a Dynatech plate reader. The wells 
initially incubated with the pre-immune sera act as blanks. A 
standard curve was constructed using purified cytochrome P-452 
as the antigen.
2.6 ASSESSMENT OF ENZYME ACTIVITY IN THE MITOCHONDRIAL
FRACTION
2.6.1 Determination of Monoamine Oxidase Activity
Monoamine oxidase is localised mainly within the mitochondrial 
fraction and it is termed an outer mitochondrial membrane 
enzyme. Its major role is in the degradation of intracellular 
biogenic amines. The modified fluorimetric method of Krajl, 
(1965) was used with kynuramine as the substrate which 
undergoes cyclisation to 4-hydroxyquinoline, the reaction 
product. The assay was carried out using fresh whole 
homogenate.
The 3ml incubation volume contained 0.5ml of the suitably 
diluted sample (100-200 dilution) and lOOug kynuramine in 50mM 
potassium phosphate buffer, pH 7.4. The tubes were incubated 
for 30 minutes at 37 degrees centigrade in a shaking water 
bath and the reaction was stopped by the addition of 2ml 6% 
(v/v) perchloric acid. The samples were spun at 3,500 rpm for 
15 minutes in a Beckman J6B centrifuge. In fluorimeter
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cuvettes, 2ml 1M sodium hydroxide was mixed with lml of 
supernatant and the fluorescence was read in a Perkin-Elmer 
MPF-3 fluorimeter, set at an excitation wavelength of 315nm 
and emission wavelength of 380nm.
A standard curve using 4-hydroxyquinoline (1-5 ug total) was 
carried out in a similar manner.
2.6.2 DETERMINATION OF SUCCINATE DEHYDROGENASE ACTIVITY
Succinate dehydrogenase is an inner mitochondrial membrane 
enzyme catalysing an intermediate step in the citric acid 
cycle. A modification of the method of Prospero, (1974) was 
used in which 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenol 
tetrazolium chloride (INT) acts as the synthetic electron 
acceptor. On reduction, INT yields a red, water insoluble 
formazan which can be extracted with ethyl acetate and the 
absorbance measured at 490nm.
An aliquot of whole liver homogenate was diluted with 0.2M 
phosphate buffer (pH 7.4) to give approximately 1-2 mg 
protein/ml and 0.5ml of this was added to 0.25ml of the above 
buffer containing 1.25 mg/ml INT. The reaction was initiated 
with 0.25ml 0.3M sodium succinate in 0.2M phosphate buffer (pH 
7.4) and incubated at 37 degrees centigrade for 10 minutes. 
The reaction was linear over a period of 20 minutes with a 
protein concentration of 3-5 mg and to an absorbance at 490nm 
of 2. The tissue blanks were prepared in a similar manner 
except 0.25ml of 0.3M sodium malonate replaced 0.3M sodium
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succinate.
Enzyme activity was stopped by the addition of 4ml reagent (a 
mixture of 96% (v/v) ethanol, ethyl acetate and 15% (w/v)
trichloroacetic acid, 13:20:2 by volume). Following mixing, 
the tubes were centrifuged at 3500 rpm for 15 minutes in a J6B 
Beckman centrifuge to remove the denatured protein and the 
extinction was read at 490nm in a Cecil 292 Ultraviolet 
spectrophotometer. The activity was calculated as nmoles INT 
reduced/minute/mg protein using the molar extinction 
coefficient of 20,000.
2.6.3 Determination of alpha-Glycerophosphate Dehydrogenase
Activity
This enzyme is located in the inner mitochondrial membrane and 
it functions as one of the intracellular shuttle systems for 
reducing equivalents which pass into the mitochondrial matrix. 
The analytical method of Lee and Lardy, (1965) was used, based 
on the principle that diaphorases catalyse the reoxidation of 
NADH produced by alpha-glycerophosphate when the cytochrome 
chain is blocked by cyanide.
An aliquot of whole liver homogenate (10-50 ul) was mixed with 
50 ul of 0.125M phosphate buffer, pH 7.5, containing 5mM 
potassium cyanide and 0.15M sodium alpha-glycerophosphate. 
Sodium alpha-glycerophosphate was omitted in the blanks. The 
tubes were incubated for 10 minutes at 37 degrees centigrade. 
To each sample, 90 ul of distilled water and 100 ul of a
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freshly prepared solution of INT (4 mg/ml) and phenazine 
methosulphate (2.5 mg/ml) in 50mM potassium phosphate buffer, 
(pH 7.5) was added with a further incubation period of 15 
minutes. The reaction was stopped with 50 ul of 10% (w/v)
trichloroacetic acid and 2.5ml of 96% (v/v) ethanol. After
centrifugation at 3,500 rpm for 15 minutes in a J6B Beckman 
centrifuge to remove precipitated protein, the extinction was 
measured at 500nm in a Cecil 292 Ultraviolet 
spectrophotometer. Results were expressed as change in optical 
density/min/mg protein.
2.6.4 Determination of Carnitine Transferase Activity
Carnitine transferases for short-, medium- and long-chain acyl 
groups, occur in mitochondria and are involved in shuttling 
acyl groups across the membrane. The assays for carnitine 
transferases are based on the measurement of free CoA formed 
during the acyl transfer from acyl-CoA to added carnitine; the 
free CoA is determined using the sulphydryl reagent 
5,5'-dithiobis (2-nitrobenzoic acid) [DNB] according to the 
methodology of Bieber et al.,(1972) and Bock et al.,(1980). 
The liberated coloured anion from this reagent is measured 
spectrophotometrically at 412nm with acyl-CoA as the 
substrate. Total carnitine acetyltransferase activity from the 
peroxisomal and mitochondrial fraction was measured. Carnitine 
palmitoyltransferase is located exclusively in the 
mitochondria and is assayed using long chain palmitoyl-CoA as 
the acyl group.
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The 2ml incubation volume contained 0.2ml of diluted whole 
homogenate (1:5 - 1:10 dilution) and a final concentration of
O.lmM substrate (acetyl-CoA or palmitoyl-CoA) and 99mM 
Tris-HCl buffer, pH 8, containing 0.25mM DNB, 2.13mM EDTA and 
0.2% (v/v) Triton-X-100. The solution was mixed and
centrifuged at l,000rpm in a Beckman J6B centrifuge for 4 
minutes and transferred to cuvettes and the reaction started 
with 10 ul 1M carnitine. The change in absorbance was recorded 
for 5 minutes at 412nm, 25 degrees centigrade in a Beckman DU7 
spectrophotometer. A blank without carnitine was run for each 
sample. Values were calculated using the molar extinction 
coefficient of the reaction product at 412nm of 13,600. 
Results were expressed as nmol CoA formed/min/mg protein.
2.7 ASSESSMENT OF ENZYME ACTIVITY IN THE PEROXISOMAL FRACTION
2.7.1 Determination of Catalase Activity
Catalase is a marker enzyme for peroxisomes and catalyses the 
breakdown of hydrogen peroxide to oxygen. Catalase activity 
was measured in fresh liver homogenates using the method 
described by Bock et al., (1980) and Chance and Maehley, 
(1955).
The test incubation contained 0.1ml of diluted sample (diluted 
1:4 0 in the diluent 2% (w/v) sodium chloride containing 1%
(w/v) Triton-X-100 and 0.33% (w/v) bovine serum albumin) and
1.9ml of 33mM sodium phosphate buffer, pH 7, containing 0.33% 
(w/v) bovine serum albumin. The reaction was initiated with
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lml of the substrate (30mM hydrogen peroxide in 50mM sodium 
phosphate buffer, pH 7). All assays were carried out at 25 
degrees centigrade at 240nm in quartz cuvettes in a Cary 219 
split beam spectrophotometer. The reaction was followed for 1 
minute and the change in extinction measured over the first 30 
seconds of reaction.
Results were calculated as follows:
k = 2.3 / change in time X log [Al / A2]
where;
k = first-order rate constant^
Change in time = 30 seconds (that is 0.5 minutes).
Al = absorbance of reactants at time zero, and 
A2 = absorbance of reactants at time 30 seconds.
Values were expressed as k (min. r 1 . ) /  rng proteins
2.7.2 Determination of Uricase Activity
The conversion of uric acid to allantoin is catalysed by 
uricase. Uric acid has an absorption peak at 292.5nm and the 
rate of reaction was determined by following the change in 
absorbance at this wavelength. The method of Beaufay et al., 
(1959) was used.
The substrate (30mM sodium phosphate buffer, pH 7.4, 
containing 7.6mg uric acid/lOOml and 0.3% (w/v) Triton-X-100)
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and diluent (30mM sodium phosphate buffer pH 7.4, 0.3% (w/v)
Triton-X-100) were equilibrated at 37 degrees centigrade. To 
test tubes containing lml of 5mM sodium phosphate buffer, pH 
7.4, lml of the diluted whole homogenate sample was added. 
After equilibration at 37 degrees centigrade the solutions 
were transferred to cuvettes and lml of the substrate solution 
was added to the test cuvette and lml of the diluent to the 
blank. The change in absorbance was recorded for 4 minutes at 
292.5nm at 37 degrees centigrade in a Cary 219 
spectrophotometer. The activity was calculated using the molar 
extinction coefficient of 12.2 and results were expressed as 
nmoles uric acid metabolised per minute per mg protein.
2.7.3 Estimation of Cyanide Insensitive Palmitoyl-CoA
Beta-Oxidation
The method of Bronfman et al.,(1979) was adopted. The 
oxidation of palmitoyl-CoA results in the reduction of FAD and 
NAD + . In mitochondria, the latter is' reoxidised by the 
cytochrome chain which can be blocked by cyanide. In 
peroxisomes, FADH is reoxidised by molecular oxygen but the 
NADH accumulates and as added NAD + penetrates peroxisomes, an 
assay of NADH production in the presence of cyanide serves as 
a measure of the peroxisomal fatty acid oxidase system.
A reaction mixture containing CoA (75uM), FAD (180uM), NAD + 
(555uM), nicotinamide (141mM), DTT (4.2uM), KCN (3uM) and BSA 
(0.255mg/ml) in 60mM Tris-HCl buffer (pH 8.3) was freshly 
prepared and stored on ice. A 2ml aliquot of the reaction
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cocktail and 0.96ml of 60mM of Tris-HCl buffer, (pH 8.3), were 
equilibrated at 37 degrees centigrade for 5 minutes. The whole 
homogenate was diluted 1:1 with 60mM Tris-HCl buffer (pH 8.3) 
containing 1% (w/v) Triton-X-100 and equilibrated at 37
degrees centigrade for 2 minutes and 40 ul of sample was then 
added to the cocktail buffer mix. This was centrifuged at 
lOOOrpm for 3 minutes in a J6B Beckman centrifuge and 
transferred to a cuvette and placed in a Beckman DU7 
spectrophotometer. The reaction was initiated with 20 ul of 75 
uM palmitoyl-CoA and the change in absorbance at 340nm was 
recorded for 10 minutes at 37 degrees centigrade. A time lag 
was occasionally observed before the reaction commenced. 
Results were expressed as nmol NAD+ reduced/minute/mg protein 
assuming the molar absorbance coefficient of NADH at 340nm is 
6220.
2.7.4 Determination of Carnitine Acetyltransferase Activity
The activity of carnitine acetyltransf erase was determined in 
peroxisomes and mitochondria using whole homogenate with 
acetyl-CoA as the substrate. (See section 2.6.4 for details of 
the methodology). This gives a total measurement of carnitine 
acetyltransf erase activity from both subcellular fractions.
2.8 ASSESSMENT OF ENZYME ACTIVITY IN THE CYTOSOLIC FRACTION
2.8.1 Determination of Glutathione Peroxidase Activity
Selenium dependent glutathione peroxidase acts as an enzymatic
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defence against oxidative damage by catalysing the metabolism 
of hydrogen peroxide and lipid peroxides, utilising 
glutathione as the reducing agent. Glutathione peroxidase 
activity was measured in the presence of sodium azide to 
inhibit peroxisomal catalase, using the method described by 
Awasthi et al (1975) and Lawrence and Burk,(1976).
The incubation volume of lml contained potassium phosphate 
buffer (0.1M, pH 7), NADPH (0.2mM), glutathione reductase (1 
international unit), glutathione (4mM), EDTA (4mM), sodium 
azide (4mM) and an appropriate amount of enzyme (cytosolic 
fraction). The reaction mixture was incubated at 37 degrees 
centigrade for 10 minutes after which 10 ul t-butylhydro- 
peroxide was added to the test cuvette but not the blank, to 
initiate the reaction. The rate of reaction was measured at 37 
degrees centigrade by following the decrease in absorbance at 
340nm using a Cary 219 spectrophotometer. The enzyme solution 
was diluted using 0.1M potassium phosphate buffer, pH 7. 
Results were expressed as umol NADPH oxidised / minute / mg of 
protein assuming the molar absorbance coefficient of NADPH at 
340nm is 6220.
Hydrogen peroxide (0.25mM) may be substituted for 
t-butylhydroperoxide as the substrate as both give similar 
results.
2.8.2 Determination of Glutathione-S-Transferase Activity
Glutathione-S-transferase may be referred to as the selenium
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independent glutathione peroxidase and this enzyme metabolises 
cumene hydroperoxide, but not hydrogen peroxide, using 
glutathione as the reducing agent. The selenium dependent 
glutathione peroxidase catalyses the reduction of both the 
above substrates using glutathione. Using the methodology as 
described in section 2.8.1, glutathione S-transf erase activity 
was determined as the difference between the total activity 
using cumene hydroperoxide and the activity with hydrogen 
peroxide.
2.9 METHODOLOGY RELATING TO THE MOLECULAR BIOLOGY OF 
CYTOCHROME P-452 AND GLUTATHIONE PEROXIDASE
Genetic information in eukaryotes is stored as linear 
sequences of nucleotides in deoxyribonucleic acid (DNA) which 
replicates itself and ultimately directs the synthesis of all 
proteins. DNA acts as the template for the synthesis of a 
corresponding RNA molecule by a process known as DNA 
transcription. The RNA molecules undergo subsequent 
modification to give messenger RNA which is complimentary to 
the base sequence of DNA. This directs the synthesis of 
proteins in the cytoplasm, mediated by transfer RNA and 
ribosomes.
To study the expression of cytochrome P-452 and glutathione 
peroxidase at the molecular level, total RNA was isolated from 
untreated and ciprofibrate treated animals. Subsequent 
hybridisation- of these RNA samples to the cytochrome P-452 
cDNA (complimentary DNA) probe and glutathione peroxidase
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genomic DNA probe was carried out in order to determine the 
influence of ciprofibrate on levels of mRNA coding for these 
proteins.
2.9.1 Materials
Ultrapure enzyme grade agarose, caesium chloride, guanidine 
hydrochloride, guanidinium isothiocyanate, NACS Prepac columns 
and nick translation kits were obtained from Bethesda Research 
Laboratories (Maryland, USA). Antifoam A emulsion, dextran 
sulphate, MOPS (3[N-morpholino]propanesulphonic acid ), salmon 
sperm DNA (Sigma type 111, sodium salt), and ethidium bromide 
were purchased from Sigma Chemical Company (Poole, Dorset). 
Ficoll (400,000) was obtained from Pharmacia Fine Chemicals AB 
(Upsalla, Sweden). Sodium N-lauroyl sarcosine (Sarkosyl), 
Amberlite MB1 resin and diethylpyrocarbonate were purchased 
from British Drug Houses Ltd. (Poole, Dorset). (Alpha 32-P) 
deoxycytidine triphosphate (specific activity 3000 Ci/mmol) 
was obtained from Amersham International (Amersham, 
Buckinghamshire).
All other chemicals were obtained as Analar grade wherever 
possible.
2.9.2 Isolation of DNA Probes to Cytochrome P-452 and
Glutathione Peroxidase.
1) Cytochrome P-452
A cDNA library from clofibrate-induced rat liver poly (A) +
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mRNA was constructed in the bacteriophage expression vector 
lambda gtll (Earnshaw et al.,1988). Recombinant phage were 
screened for cytochrome P-452 protein expression using a 
polyclonal P-452 specific antiserum and a biotin-streptavidin- 
horseradish peroxidase linked immunoassay. Positive clones 
were shown to contain cDNA inserts ranging from 0.9-2.2 Kbp 
(kilo base pair) in length. The DNA sequence of these inserts 
has been determined and the longest showed an open reading 
frame coding for a 58 kd (kilo dalton) protein (Earnshaw et 
al.,1988), corresponding almost exactly to the amino acid 
sequence of cytochrome P-450 LAw (Hardwick et al.,1987).
A 3' cDNA insert of 1 Kbp was subsequently subcloned into 
plasmid M13mpll, propagated and the insert fragment isolated 
using restriction enzyme digestion, agarose gel 
electrophoresis and phenol extraction. This cDNA probe was 
used in hybridisation assays to study the expression of 
cytochrome P-452 mRNA in treated and untreated animals from 
several species.
2) Glutathione Peroxidase
Recombinants were isolated from a library of Balb-c mouse 
genomic DNA fragments cloned in lambda-Ch4A by screening with 
cDNA derived from 13 day foetal liver cells or adult 
reticulocyte poly A+ RNA (Goldfarb et al.,1983). One genomic 
DNA recombinant, lambda R68A, was subsequently identified as 
encoding the entire mouse GPX gene (Chambers et al.,1986). The 
main coding region of the GPX-1 gene was located in a 0.7 kb 
EcoRl fragment and an adjacent Xbal-EcoRl fragment (Goldfarb
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et al.,1985). The 0.7 kb EcoRl fragment (termed 2D6) was 
subcloned into plasmid pAT153 using EcoRl sites. The plasmid 
was propagated in E.coli MCW61, cut with EcoRl and the insert 
fragment isolated using agarose gel electrophoresis and phenol 
extraction.
This mouse genomic DNA probe (containing the 3' end of the 
gene) was subsequently used in hybridisation assays to study 
the expression of GPX-1 mRNA in treated and untreated animals 
from several species. It has >85% homology with sequences from 
the rat, cat, dog and human (Goldfarb, personal communication) 
and appears to be highly conserved in other species (see 
chapter 4).
2.9.3 Treatment of Animals 
As described in section 2.2.
2.9.4 Extraction of Total Cellular RNA
The major technical problems in experiments involving the 
isolation of RNA is one of preventing RNA hydrolysis and 
degradation by ribonucleases. Stringent precautions were 
followed to minimise ribonuclease activity and to prevent any 
subsequent contamination.
INHIBITION OF RIBONUCLEASE ACTIVITY
The primary objective was to denature ribonucleases contained 
within the biological material used and to avoid contamination
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by exogenous ribonuclease sources. Diethylpyrocarbonate (DEP) 
is an effective inhibitor of ribonuclease, reacting with the 
imidazole nitrogens of histidine residues and the free amino 
groups, causing subsequent loss of enzyme activity. Where 
possible, solutions were treated with 0.1% (w/v)
diethylpyrocarbonate for at least 12 hours. Subsequent 
autoclaving converts the DEP to ethanol and carbon dioxide. 
All glassware was thoroughly washed, rinsed with deionised 
water and autoclaved. Alternatively, it was baked at a 
temperature of 250 degrees centigrade for a period of at least 
5 hours. All solutions were prepared using sterile water and 
baked spatulas. Latex gloves were worn at all times in order 
to avoid contact between fingers (a source of exogenous RNAase 
contamination) and glassware and solutions. The strong 
chaotropic agent guanidinium isothiocyanate was also used in 
the extraction procedure to further prevent degradation by 
RNAases.
ISOLATION OF TOTAL CELLULAR RNA
The method used was a modification of the procedures of 
Chirgwin et al.,(1979).
One gram of liver, fresh or frozen, was homogenised in 16ml of 
4M guanidinium isothiocyanate solution, pH 7, containing 0.5% 
sodium N-lauroyl sarcosine, 25mM sodium acetate, 0.1M 
2-mercaptoethanol and 0.1% antifoam A. When using frozen 
homogenate (25-30%) a ratio of 2ml to 14ml tissue to 
guanidinium isothiocyanate solution was employed. The tissue 
was solubilised in this medium using an u l t ra tu r ra x ;  for 30-60 sec
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at maximum speed. The homogenate was subsequently centrifuged 
for 10 minutes at 9000 rpm at 10 degrees centigrade using a 14 
x 15ml rotor in a Beckman J-21 centrifuge. A total of 3.5ml 
5.7M caesium chloride solution, pH 7.4, containing lOmM EDTA, 
was added to quickseal polyallomer centrifuge tubes. The 
homogenate was gently layered onto the caesium chloride 
cushion. The tubes were sealed and centrifuged overnight using 
a 65Ti rotor (8 x 13ml) in a Beckman ultracentrifuge at 36,000 
rpm at 20 degrees centigrade.
After centrifugation the liquid was removed leaving a pellet 
at the base of the tube. Using sterile cotton wool swabs the 
sides of the tubes were cleaned to remove traces of 
supernatent. The pellet was resuspended in a total volume of 
5ml of 7.5M guanidine hydrochloride solution, pH 4.5, 
containing 20mM potassium acetate, lOmM dithiothreitol and 
transferred to a sterile 10ml Falcon tube. Dissolution of the 
RNA pellets was facilitated by vigorous mixing with brief 
heating in a 68 degree centigrade water bath. To this 0.25ml 
of 0.5M EDTA, 0.25ml of 2M potassium acetate (pH 5) and 2.5ml 
of ice-cold ethanol (stored at -20 degrees centigrade) were 
added and the samples were left overnight at -20 degrees 
centigrade to allow precipitation of the RNA. The tubes were 
subsequently spun at 9,000 rpm, 10 degrees centigrade for 10 
minutes. The liquid was removed and the tubes dried with 
sterile swabs. The RNA pellets were dissolved in 2ml sterile 
water and centrifuged at 9,000 rpm at 10 degrees centigrade 
for 10 minutes. The aqueous phase was transferred to a sterile 
Falcon tube and the pellet resuspended in 2ml sterile water
93
prior to spinning at 9,000 rpm, 10 degrees centigrade for 10 
minutes. The aqueous phases were combined and 0.4ml 3M sodium 
acetate (pH 4.8) and 8ml ice cold ethanol (-20 degrees 
centigrade) were added. The samples were left overnight at -20 
degrees centigrade and were then centrifuged at 10,000 rpm, 10 
degrees centigrade for 20 minutes. The liquid was removed and 
all traces of ethanol wiped from the tubes. The pellets were 
dissolved in 0.5ml sterile water and stored at -20 degrees 
centigrade.
2.9.5 Determination of RNA Purity and Concentration
RNA aliquots were diluted 1:100 with sterile water and 
transferred to 1ml quartz cuvettes. The samples were scanned 
between 200 and 320nm. RNA absorbs at 260nm and protein at 
280nm. A 260:280 ratio of 2.0 is indicative of pure RNA, and a 
ratio of less than 2.0 assumes protein contamination. The 
concentration of RNA can be determined using the absorbance at 
260nm where 1 O.D unit is equal to 40ug/ml (Maniatis et 
al.,1982).
2.9.6 RNA Agarose Gel Electrophoresis
A Biorad horizontal mini-gel system was used with a gel former 
giving gel dimensions of 10cm x 7cm. The electrophoresis tank 
and perspex gel former were cleaned with absolute alcohol and 
tape was used to seal the gel former ends. The method of 
Lehrach et al.,(1977) was adapted and used.
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A total of 1.05g agarose was dissolved in a total of 50.4ml 
sterile water, mixed with 12.6ml 37% (v/v) formaldehyde and
7ml lOx running buffer (60ml 2M MOPS, pH 7, 2.46g sodium
acetate and 1.2ml 0.5M EDTA). The mini-gel was poured and an 8 
track comb inserted. When the agarose had set, the comb and 
tape were removed and the gel slab placed in the
electrophoresis tank filled with lx running buffer. The gel
was immersed to a depth of approximately 1cm and the
electrophoresis tank was then placed on ice.
The RNA samples were prepared as follows: 20 ug RNA was mixed 
with 2 ul lOx running buffer, 3.5 ul formaldehyde and 10 ul 
deionized formamide (2g Amberlite MB1 resin was mixed with 
50ml formamide for 1 hr at 4 degrees centigrade and the resin 
was subsequently removed by filtration). The samples were 
vortexed and briefly centrifuged prior to incubation at 65 
degrees centigrade for 15 minutes. The samples were cooled on 
ice and mixed with 2 ul of loading buffer (50% glycerol, ImM 
EDTA, 0.4% bromophenol blue and 0.4% xylene cyanol) and 
centrifuged. Using a Gilson pipette, 20 ul of sample was 
loaded per well. The gel was run at 150mA (constant current) 
until the bromophenol blue had run three quarters the length 
of the gel. The gel pattern was visualised by staining with 
ethidium bromide (50 ul of 20 mg/ml stock solution in 150ml of 
sterile water) for 1 hr before viewing under ultra violet 
illumination. Gels were subsequently photographed.
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2.9.7 Dot Blots with Nitrocellulose
Dot blotting was carried out routinely using an adaptation to 
the method of White and Bancroft,(1982). Total RNA was 
prepared in sterile water to give stock solutions of 0.01 
ug/ul and 0.2 ug/ul. The samples were diluted to give 0.01, 
0.1, 1, 10, and 20 ug/lOOul water and then 150 ul of 6.15M 
formaldehyde and 20x SSC (3M sodium chloride and 0.3M sodium 
citrate, pH 8) were added. The samples were incubated at 65 
degrees centigrade for 15 minutes.
The nitrocellulose filter was soaked twice in lOx SSC, sterile 
water for 5 minutes and finally in lOx SSC for 5 minutes. The 
dot blot apparatus (BRL) was cleaned with acetone and ethanol 
and assembled with the filter according to the manufacturers 
instructions. The RNA samples were applied to the wells, 
loading being completed under a slow vacuum. The wells were 
subsequently washed with 400 ul lOx SSC, and when completed 
the filter was removed and dried between Whatman 3MM paper 
prior to baking at 80 degrees centigrade for 2-3 hr. The baked 
filters were stored at room temperature between sheets of 
Whatman 3MM paper, covered in foil prior to hybridisation.
2.9.8 Nick Translation
The process of "nick translation" utilises DNAase 1 to create 
single strand nicks in double stranded DNA. The 5' to 3' 
exonuclease and 5' to 3' polymerase properties of E.Coli 
DNAase polymerase 1 are used to remove stretches of single
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stranded DNA starting at the nicks and to replace them with 
new strands made with the incorporation of labelled 
deoxyribonucleotides (Rigby et al.,1977). As a result, each 
nick moves along the DNA strand being repaired in a 5' to 3' 
direction (nick translation) (Kelly et al.,1970).
The nick translation kit was obtained from BRL and the 
accompanying instructions followed: -
600 ng rat cytochrome P-452 DNA, or,
400 ng mouse glutathione peroxidase DNA,
5 ul dATP, dGTP, dTTP,
100 uCi 32P dCTP;
and sterile water to give a total volume of 40 ul.
This was vortexed briefly and DNAase polymerase 1 (5 ul) was 
added. The solution was mixed and centrifuged rapidly prior to 
incubating for 2 hr at 15 degrees centigrade. The reaction was 
terminated by the addition of 0.3M EDTA (5 ul) to the solution 
which was stored on ice. A further 200 ul of TNE buffer (lOmM 
Tris, lOOmM sodium chloride and ImM EDTA, pH 8) and 5 ul of 
salmon sperm DNA (2 mg/ml) were added.
2.9.9 Removal of Unincorporated Alpha 32-P dCTP
NACS Prepac cartridges (1cm x 0.5cm) contain NACS 52, a 
derivative of hydroxylapatite and these were used to remove 
unincorporated alpha-32-P nucleotides (Maniatis et al.,1982). 
Under low salt concentrations DNA is bound to the column by 
the phosphates whereas nucleotides do not bind. In conditions 
of high salt concentration, DNA is eluted.
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The column was attached to a 2ml syringe and hydrated with 5 x 
lml volumes of 2M NaCl in TE buffer (lOmM Tris, ImM EDTA, pH 
8) and equilibrated with 10 x lml washes of 0.5M NaCl in TE 
buffer. The column was secured in a retort stand and the nick 
translation volume adjusted to lml with 0.5M NaCl/TE and 
loaded onto the column via the syringe barrel. The column was 
washed with 15 x lml volumes of 0.5M NaC'1/TE buffer collected 
into eppindorfs and eluted with 6 x 0.1ml aliquots of 2M NaCl 
in TE buffer.
2.9.10 Filter Hybridisation with Radioactive Probes
The application of nucleic acid hybridisation has been studied 
extensively (Hames and Higgins,1985) allowing for modification 
to optimise conditions. The baked filters were soaked in 5 x 
SSC before being transferred to 250ml prehybridisation buffer, 
warmed to 42 degrees centigrade in a plastic container. 
Prehybridisation was carried out at 42 degrees centigrade in a 
shaking water bath for 7 hours. The buffer was removed and 
replaced with hybridisation buffer containing the radioactive 
probe which had previously been boiled for 5 minutes to 
denature the double stranded DNA. The filters were hybridised 
for a minimum of 15 hours at 42 degrees centigrade in a 
shaking water bath.
Prehvbridisation buffer
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Deionised formamide 250ml
50 x Denhardts solution 50ml
(2% w/v Ficoll, 2% w/v BSA and 2% w/v polyvinyl-pyrrolidine) 
20 x SSC 125ml
Boiled salmon sperm DNA (10 mg/ml) 12.5ml
Sterile water 62.5ml
Poly A (20 mg/ml stock soln.) 0.25ml
Poly C (20 mg/ml stock soln.) 0.25ml
Hybridisation buffer:-
Deionised formamide 
50 x Denhardts solution 
20 x SSC
50% Dextran sulphate 
Boiled salmon sperm DNA (10 mg/ml)
Poly A (20 mg/ml stock soln.)
Poly C (20 mg/ml stock soln.)
2.9.11 Washing of Filters Following Hybridisation
250ml 
10ml 
125ml 
100ml 
5ml 
0.2 5ml 
0.25ml
Filters were washed after hybridisation to remove 
non-specifically bound probe (Hames and Higgins,1985, Maniatis 
et al.,1982). The hybridisation buffer was removed and 
replaced with 2 x SSC, 0.1%(w/v) SDS for 3 consecutive washes 
at room temperature for 30 minutes. There were 2 successive 
washes in 0.5 x SSC, 0.1% (w/v) SDS for 45 minutes at 55
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degrees centigrade. The final wash was completed at room 
temperature in 5 x SSC for 30 minutes. The filters were dried 
between sheets of Whatman 3MM paper at 37 degrees centigrade 
for 30 minutes and then placed in an X-ray cassette with an 
intensifying screen with fast X-ray film (Kodak GBX2) for 4 
days at -70 degrees centigrade. The X-ray films were developed 
and qualitative assessment of the RNA dot blots made by visual 
inspection.
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Chapter 3
HEPATIC INDUCTION POTENCY OF THREE HYPOLIPIDAEMIC DRUGS
3.1 INTRODUCTION
In this chapter the relative potencies of 3 hypolipidaemic 
drugs (ciprofibrate, bezafibrate and clofibric acid) were 
examined with reference to changes in hepatic enzyme 
activities.
Clofibrate was first marketed in 1962 and has been accepted 
worldwide as an effective lip id-lowering drug. The long term 
use and knowledge of the therapeutic efficacy of clofibrate 
coupled with an increasing understanding of lipoprotein 
metabolism has made this drug a reference compound for 
comparison with other antihyperlipidaemic agents (Cayen, 
1985). Gemfibrozil, a derivative of clofibrate, causes a 
marked increase in high density lipoprotein (HDL) cholesterol 
and persistent reductions in serum levels of total, low 
density lipoprotein and non-HDL cholesterol and triglycerides 
(Frick et al.,1987). Modification of lipoprotein levels with 
gemfibrozil reduces the incidence of coronary heart disease in 
men with dyslipidaemia (Frick et al.,1987). Ciprofibrate,
2-[-4-(2,2-dichlorocyclopropyl)phenoxyl]-2-methyl-propanoic 
acid, is a newly developed potent hypolipidaemic congener of 
clofibrate which is currently undergoing evaluation in 
clinical trials (Arnold et al.,1979, Edelson et al.,1979). 
Bezafibrate is a structural analogue of clofibrate and was 
introduced to the German market in 1978 following extensive
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preclinical and clinical evaluation (Cayen, 1985). At present 
bezafibrate sales dominate the fibrate market in Germany, 
Italy, Spain and the United Kingdom. Clofibrate is second in 
the United Kingdom, United States and Spain. As yet, 
ciprofibrate is marketed in France only where it holds second 
place to fenofibrate (Sterling Winthrop, personal 
commu nication).
An adequate risk/benefit assessment for ciprofibrate must 
include the development of an appropriate perspective on the 
toxicity profile of this compound in relation to other 
phenoxyisobutyrate derivatives. The manifestation of toxicity 
of peroxisome proliferators is dependent upon their intrinsic 
biological activity (i.e. lipid lowering potency) and is 
modified by pharmacokinetic characteristics and the 
sensitivity of the species/strain to the effect. These are 
major influencing factors and must be considered in terms of 
study design and data interpretation.
Of the three peroxisome prolif erators investigated, 
ciprofibrate is the most potent with respect to hypolipidaemic 
action and it exhibits a prolonged duration of effect in the 
rat. This is a reflection of the plasma half life which is 3-4 
days, as compared to 6-16 and 5-8 hours for bezafibrate and 
clofibrate/clofibric acid respectively (Cayen et al.,197 7, 
Davison et al.,1975, Schmidt et al.,1980, Sterling Winthrop, 
personal communication and Thorp, 1972). The ultimate 
consequence of this slow elimination of ciprofibrate is 
prolonged biological activity and therefore sustained
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biochemical effects in the liver. This clearly indicates that 
ciprofibrate has an enhanced toxicity as compared to other 
peroxisome prolif erators. To provide an insight into the 
relative potencies (with reference to toxicity) of different 
compounds it is necessary to conduct studies where 
dose-regimes have been modified to compensate for the marked 
differences in the pharmacokinetic characteristics of these 
peroxisome prolif erators.
Two studies were designed to investigate the hepatic effects 
in the rat resulting from chronic administration. In clinical 
practice the recommended frequency of dosing varies for these 
agents [ciprofibrate is required once daily whereas 
bezafibrate and clofibrate are recommended two to three times 
daily] (Cayen,1985, Olsson and Lang,1978 and Rouffy et 
al.,1985). In study 1, the dose levels chosen were based on 
comparative lipid lowering potency, derived from published 
data (Sterling Winthrop, personal communication).
Administration was once daily for a duration of 6 months.
In the second study, the dosing regimens for each agent were 
adjusted to compensate for their different pharmacokinetic 
profiles in the rat i.e ciprofibrate once every 2 days, 
bezafibrate and clofibric acid twice a day. The treatment 
period was 6 months and twice daily administration was 
separated by 8 to 12 hours. In the second study, the dose 
levels for bezafibrate and clofibric acid were increased as a 
result of the widely differing potencies of these compounds 
exhibited when administered once daily (i.e as in study 1).
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The objectives of these two studies, completed consecutively, 
were to compare the chronic effects of three hypolipidaemic 
drugs on hepatic mitochondrial, peroxisomal and cytosolic 
enzyme parameters. In addition, the importance of using a 
pharmacokinetic basis to choose dose regimens - with respect 
to relative potencies of compounds - was examined.
3.2 Hepatomegaly
Hepatomegaly is expressed as an increased liver/body weight 
ratio and appears to be an adaptive response to the 
administration of peroxisome prolif erators. In general, the 
increased liver weight is due to hyperplasia and hypertrophy. 
There was a significant increase in the liver/body weight 
ratio in treated animals (table 3.1). With once daily dosing, 
a maximal 2-fold induction was seen with ciprofibrate with a 
minimal increase in 'the clofibric acid treated group. In the 
second study (differential dosing frequencies) the extent of 
hepatomegaly with all 3 compounds was very similar. In the 
ciprofibrate treated animals the increase in liver/body weight 
ratio was unchanged by reduced dosing frequency whereas liver 
enlargement in the bezafibrate and clofibric acid treatment 
groups was greater with twice daily administration and 
increased dose levels.
It has been shown with a 3-day treatment period that 
hepatomegaly in the Wistar rat was greater in bezafibrate 
treated animals than with clofibric acid even with dose levels 
of 200 and 250 mg/kg/day for bezafibrate and clofibric acid,
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Table 3.1.
Comparison of Hypolipidaemic Drugs under Varying Dosing
Regimens on Liver Size in the Fischer Rat following Chronic
. . #Administration.
Study Dose Level Liver/Body weight
Number Ratio(%)
1[a] Control 3.10 +/- 0.24[b] (100)[c]
Ciprofibrate 7.19 +/- 0.31[e] (232)
(20 mg/kg)
Clofibric acid 3.84 +/- 0.13[d] (124)
(50 mg/kg)
Bezafibrate 5.06 +/- 0.26[e] (163)
(100 mg/kg)
2[f] Control 3.27 +/- 0.18 (100)
Ciprofibrate 7.08 +/- 0.33[e] (216)
(20 mg/kg)
2[g ] Control 2.87 +/- 0.19 (100)
Clofibric acid 5.42 +/- 0.52[e] (189)
(75 mg/kg)
Bezafibrate 6.27 +/- 0.42[e] (218)
(150 mg/kg)
Jfc 2 6  w e e k  a dm in is t ra t io n
[a] Dosing once daily.
[b] Values are means +/- S.D.
[c] Figures in brackets are values expressed as percentage
of Corresponding control.
P values for results significantly different (Students T-test) 
from control data are [d] p<0.01 and [e] p<0.001.
[f] Dosing once every 48 hours.
[g] Dosing twice daily.
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respectively (Sharma et al.,1988). With the dietary
administration of these two compounds at a concentration of 
0.4% (w/w) clofibrate and 0.2% (w/w) bezafibrate, a similar 
observation has been reported (Bains et al.,1985). The short 
term administration of ciprofibrate resulted in a 2 to
2.3-fold increase in liver weight as reported by Lalwani et 
al.,( 1983a,b). Following clofibrate and fenofibrate treatment 
for 26 weeks, a 1.5 to 2-fold increase in liver weight was 
observed (Price et al.,1986). With DEHP administration for a
period of 3 days to 9 months, hepatomegaly was minimal but
j
sustained (Mitchell et al.,1985). It would appear that
hepatomegaly is a response characteristic of peroxisome 
prolif erators, associated with both acute and chronic
administration.
3.3 THE MICROSOMAL DRUG METABOLISING ENZYME SYSTEM
Hepatic microsomes were prepared from animals pretreated with 
ciprofibrate, bezafibrate and clofibric acid (once daily 
administration) and enzymes of the microsomal drug 
metabolising system were assayed (results presented in chapter 
5). In the second study, tissue samples were frozen at -20 
degrees centigrade for 12 weeks prior to homogenisation and 
preparation of the microsomal and cytosolic fractions. 
Mitochondrial, peroxisomal and cytosolic enzymes displayed 
stable activities as evidenced by comparison of activities of 
the control groups between the two studies. In the microsomes, 
considerable degradation of cytochrome P-450 to cytochrome 
P-420 had occurred and the specific content of the
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haemoprotein could not be determined accurately. No further 
microsomal enzyme assays were completed.
3.4 MITOCHONDRIAL ENZYME ACTIVITIES
Administration of peroxisome prolif erators to rats results in 
several observable mitochondrial changes which may include 
proliferation, structural changes and induction of certain 
enzymes. In this investigation the effect of ciprofibrate, 
bezafibrate and clofibric acid on the mitochondrial marker 
enzymes succinate dehydrogenase and alpha-glycerophosphate 
dehydrogenase (both inner membrane enzymes) has been studied.
3.4.1 Succinate Dehydrogenase Activity
With once daily administration succinate dehydrogenase 
activity was significantly elevated in the ciprofibrate 
treated animals (table 3.2). When the dosing regimen was 
altered with respect to pharmacokinetic profiles, enzyme 
activity was decreased in the ciprofibrate and clofibric acid 
treatment groups. The cause of this differential effect of 
ciprofibrate on succinate dehydrogenase activity is unclear at 
present. In both studies Fischer rats were used, however the 
starting weight was different - 250 and 150 grammes - prior to 
a 7 day acclimatisation period for studies 1 and 2 
respectively.
It has been reported that the short term administration (14 to 
21 days) of MEHP and DEHP to rats results in a significantly
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decreased succinate dehydrogenase activity (Lake et al., 1975, 
Lake at al.,1984). A non significant decrease in enzyme
activity has also been observed in DEHP treated animals (Mann 
et al.,1985). The observed decrease in succinate dehydrogenase 
activity in ciprofibrate and clofibric acid treated animals 
(study 2) would appear to be an effect associated with chronic 
administration. Following a 14 day treatment with ciprofibrate 
in 5 rat strains, the specific activity of this enzyme was 
unchanged (chapter 4).
3.4.2 Alpha-Glycerophosphate Dehydrogenase Activity
Alpha-glycerophosphate dehydrogenase activity was induced 2 to
3-fold in rats treated once daily with all three 
hypolipidaemic agents (table 3.2). There were no clear
differences between the compounds with respect to enzyme 
activity. A similar response was seen with different dosing 
frequencies, although the increase was in the order of 4 to 
5-fold. This induction in the bezafibrate and clofibric acid 
treated animals would appear to be the result of increased
dose levels and frequency of dosing. The cause of the unequal 
increases observed in the ciprofibrate treated groups is 
unclear.
It has been reported that alpha-glycerophosphate dehydrogenase 
activity was elevated 3 to 4-fold following a 14 day 
administration period with clofibrate and tibric acid
(Holloway and Orton,1979). With DEHP treatment for 3,10 and 21 
days increased enzyme activity was observed at each time point
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(Mann et al.,1985). Induction of alpha-glycerophosphate 
dehydrogenase activity in DEHP treated animals was dose 
dependent and increased with the duration of administration 
[3, 7 14 and 28 days and 9 months] (Mitchell et al.,1985).
Induction of this enzyme would appear to be a common response 
in rats exposed to a variety of peroxisome proliferators and 
it is sustained throughout acute and chronic treatment.
3.5 MITOCHONDRIAL AND PEROXISOMAL CARNITINE ACETYLTRANS FERASE
ACTIVITY
Mitochondria and peroxisomes possess carnitine transferase 
activity directed towards short-chain acyl substrates. A 
measurement of total carnitine acetyltransf erase activity was 
determined, that is a combined activity from both subcellular 
fractions.
In the chronically treated rat there was a marked induction of 
carnitine acetyltransferase activity which was significant 
with each hypolipidaemic drug in both studies (table 3.3). 
With once daily dosing, the increase in activity in 
ciprofibrate and bezafibrate treated animals was similar (60 
to 65-fold). In the clofibric acid treatment group, the extent 
of induction was approximately 16-fold. In study 2, where 
dosing frequencies were altered, the increase in enzyme 
activity with ciprofibrate and bezafibrate was similar, as in 
the first study, however the induction was less marked 
(13-fold). The clofibric acid treated animals exhibited higher
Table 3.3.
Comparison of Hypolipidaemic Drugs under Varying Dosing 
Regimens on Mitochondrial and Peroxisomal Carnitine 
Acetyltransf erase Activity in the Rat following Chronic
Administration.
Study
Number
Dose Level Carnitine Acetyltransferase 
Activity (nmol/min/mg protein)
l[a] Control 1.53 +/- 0.55[bJ (100) [c]
C ip r of ib r at e 
(20 mg/kg)
98.11 +/- 8.49[e] (6412)
Clofibric acid 
(50 mg/kg)
24.40 +/- 6.23[d] (1595)
Bezafibrate 
(100 mg/kg)
100.73 +/-12.56[e] (6584)
2[f ] Control 2.14 +/- 0.35 (100)
Ciprofibrate 
(20 mg/kg)
28.84 + /-11.77[d] (1348)
2[gJ Control 2.15 +/- 0.24 (100)
Clofibric acid 
(75 mg/kg)
52.06 +/- 9.35[e] (2421)
Bezafibrate 
(150 mg/kg)
29.16 +/- 7.17[e] (1356)
#
[a]
26 week administration 
Dosing once daily.
[b] Values are means +/-S .D.
[c] Figures in brackets are values expressed as % of
corresponding control.
P values for results significantly different (Students T-test' 
from control data are [d] p<0.01 and [e] p<0.001.
[f] Dosing once every 48 hours.
[g] Dosing twice daily.
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activity (24-fold) in the second study as opposed to the first 
study, reflecting the increase in dose level and dosing 
frequency.
It would appear that both ciprofibrate and bezafibrate have 
equivalent inductive effects on carnitine acetyltransferase 
activity at the dose levels and with the dosing regimens used 
in these two studies. In the first study with once daily 
dosing, the difference in enzyme induction between clofibric 
acid and bezafibrate was marked. However by altering the 
dosing frequency in study 2, the effects were similar. This 
increased enzyme induction with clofibric acid in study 2 
indicates that this biochemical end point is closely related 
to the duration of pharmacological activity reflecting the 
clearance characteristics of clofibric acid in the rat. The 
cause of the difference in the level of induction between the 
2 studies with bezafibrate and ciprofibrate is not known. The 
lower induction of carnitine acetyltransferase with 
ciprofibrate in the second study may reflect less frequent 
dosing.
It has previously been reported that carnitine acetyl­
transferase activity was increased 58-fold in Fischer rats 
following the dietary administration of ciprofibrate (Lalwani 
et al.,1983b). This is comparable to the increase in enzyme 
activity observed with once daily administration of 
ciprofibrate in the current study. With clofibrate and 
bezafibrate administration (250 and 200 mg/kg respectively) to 
Wistar rats for 3 days, the increase in enzyme activity was 20
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to 25-fold (Sharma et al.,1988) as opposed to 13 to 24-fold at 
150 and 75 mg/kg twice daily for bezafibrate and clofibric 
acid respectively. Clofibrate (500 mg/kg/day) and DEHP 
administration for 14 days to rats resulted in a reported 35- 
and 26-fold induction in carnitine acetyltransferase activity 
(Lake et al.,1984b). At the same dose level - 500 mg/kg
clofibrate per day - the increase in enzyme activity was found 
to be in the order of 18-fold (Lake et al.,1984). Induction of 
carnitine acetyltransferase activity is characteristic in rats 
exposed to a wide range of peroxisome prolif erators and is 
apparent following short and long term treatment. The increase 
in enzyme activity is marked but variable.
3.6 PEROXISOMAL ENZYME ACTIVITIES
The administration of peroxisome prolif erators to rats results 
in the characteristic proliferation of peroxisomes with the 
concomitant induction of enzymes associated with peroxisomal 
beta-oxidation. Catalase, the peroxisomal marker enzyme, 
metabolises hydrogen peroxide catalatically or peroxidatically 
preventing the accumulation of this potentially toxic oxygen 
species. Uricase, an oxidative enzyme exclusive to 
peroxisomes, catalyses the conversion of uric acid to 
allantoin with the formation of hydrogen peroxide. Peroxisomal 
beta-oxidation is cyanide-insensitive in vitro and the 
reduction of fatty acyl-CoA by fatty acyl-CoA oxidase is rate 
limiting and generates hydrogen peroxide. The subsequent 3 
steps are the same as mitochondrial bet a-oxidation.
3.6.1 Cat alas e
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The catalase assay was completed on homogenised fresh tissue 
as freezing causes dissociation of the enzymes sub-units 
leading to inaccurate measurement of enzyme activity. Catalase 
activities were determined for animals in study 1 and these
are, in part presented in chapter 5. In the second study, 
tissue was frozen at -20 degrees centigrade prior to 
homogenisation and therefore no catalase assays were 
completed.
3.6.2. Peroxisomal Beta-Qxidation
In the chronically treated rat there was a marked, significant 
increase in peroxisomal beta-oxidation (figure 3.1). With once
daily dosing, induction was 34-, 10- and 5-fold for
ciprofibrate, bezafibrate and clofibric acid, respectively. By 
altering dosing frequency and dose levels for bezafibrate and 
clofibric acid, the increase in beta-oxidation for the three 
compounds was by comparison, similar. The increase in 
peroxisomal beta-oxidation was 28-, 30- and 29-fold for
ciprofibrate, bezafibrate and clofibric acid. The induction 
with ciprofibrate in the second study was less marked than
with once daily dosing indicating that the dosing frequency of 
this compound influences the induction of peroxisomal beta- 
oxidation. It is clear that altering the frequency of dosing 
of these compounds with respect to clearance characteristics, 
fundamentally influences the induction of peroxisomal 
beta-oxidation.
114
Figure 3.1.
Comparison of Hypolipidaemic Drugs under Varying Dosing 
Regimens on Peroxisomal Beta-Qxidation in the Fischer Rat 
Following Chronic Administration ^
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It has been reported that palmitoyl-CoA oxidation was elevated
2.5 to 3.5-fold with fenofibrate and clofibrate after one 
day's administration (Price et al.,1986). This was sustained 
for 18 months following continuous treatment with clofibrate 
and fenofibrate (Mann et al.,1985, Mitchell et al.,1985). With 
dietary administration of clofibrate and tibric acid, the 
increase in peroxisomal beta-oxidation was in the order of 15- 
and 4-fold respectively (Holloway and Orton,1980). The 
induction was 14- and 18-fold for orally administered MEHP and 
clofibrate (Lake et al.,1984). The increase in the peroxisomal 
beta-oxidation system occurs rapidly after the administration 
of peroxisome prolif erators and is dependent on the relative
potency of the compound, dose level and dosing frequency.
3.6.3. Uricase Activity
With once daily dosing, the specific activity of uricase was 
unchanged (table 3.4). When the dosing frequency was altered, 
uricase activity was significantly decreased in the 
ciprofibrate treated group. Activity with bezafibrate and 
clofibric acid was unaffected by administration. The cause of 
this difference in uricase activity in the 2 ciprofibrate 
groups is unclear at present. It is possible that with dosing 
once every 48 hours, proliferation of "coreless" (i.e. uricase
deficient) peroxisomes occurs. Increasing the dosing frequency 
to once daily may allow for sufficiently high levels of
ciprofibrate to maintain uricase positive peroxisomes. 
Similarly, with DEHP administration for 3, 7, 14 and 28 days,
a reduction in uricase activity was observed (Mitchell et
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Table 3.4.
Comparison of Hypolipidaemic Drugs under Varying Dosing 
Regimens on Peroxisomal Uricase Activity in the Fischer Rat 
Following Chronic Administration,
Study Dose Uricase Activity
Number Level (nmol/min/mg)
1[a] Control 20.04 +/- 3.15[b] (100)[c]
Ciprofibrate 23.43 +/- 2.11 (117)
(20 mg/kg)
Clofibric acid 18.66 +/- 0.83 (93)
(50 mg/kg)
Bezafibrate 20.55 +/- 2.47 (103)
(75 mg/kg)
2[e] Control 19.29 +/- 2.34 (100)
Ciprofibrate 15.31 +/- 0.67[d] (70)
(20 mg/kg)
2[f] Control 18.74 +/- 3.27 (100)
Clofibric acid 15.80 +/- 1.37 (84)
(75 mg/kg)
Bezafibrate 19.02 +/- 1.05 (101)
(150 mg/kg)
i f  2 6  w e e k  adm in is t ra t io n
[a] Dosing once daily.
[b] Values are means +/- S.D.
[c] Figures in brackets are values expressed as % of
corresponding control.
P values for results significantly different (Student's 
T-test) from control data are d p<0.05
[e] Dosing once every 48 hours.
[f] Dosing twice daily.
al.,1985). This was significant at the high dose level at 28 
days.
In general, the specific activity of uricase remained 
unchanged or was decreased with peroxisome proliferator 
administration. This would indicate that either uricase 
synthesis is increased in line with proliferation or that 
uricase deficient peroxisomes develop.
3.7. CYTOSOLIC GLUTATHIONE PEROXIDASE ACTIVITY
Glutathione peroxidase (GPX) contains covalently bound seleno- 
cysteine in the active site and metabolises both hydrogen 
peroxide and organic peroxides as substrates. The selenium 
independent glutathione peroxidase enzymes are termed 
glutathione-S-transferases (GST) and these enzymes metabolise 
only the organic hydroperoxides. The difference in enzyme 
activity observed on treatment, when expressed as percentage 
of control using hydrogen peroxide as the substrate (utilised 
by GPX only) and t-butylhydroperoxide (utilised by GPX and 
GST) is minimal (results described in chapter 4). In the two 
current studies GPX activity was determined using 
t-butylhydroperoxide as the substrate.
With once daily dosing, GPX activity in ciprofibrate and 
bezafibrate treated animals was significantly decreased 
(figure 3.2). Activity in the clofibric acid treated group was 
unchanged. When the dosing frequencies were altered, enzyme 
activity was decreased significantly with all three
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Figure 3.2.
Comparison of Hypolipidaemic Drugs under Varying Dosing
Regimens on Cytosolic Glutathione Peroxidase Activity fal in
to
the Fischer Rat Following Chronic Administration.
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hypolipidaemic drugs. In both studies, the decrease in enzyme 
activity was greater in ciprofibrate treated animals.
3.8. DISCUSSION
The selection of compounds to be tested for hypolipidaemic 
activity in man is generally based upon an assessment of their 
effects on circulating lipids in laboratory animals (Cayen, 
1985). The rat is the most frequently used species for the 
detection and evaluation of agents affecting lipid metabolism, 
although there are differences in the distribution of lipids 
between the rat and human serum lipoproteins. The decision to 
test such a compound in man is therefore usually based on 
results obtained mainly in the rat.
The primary aim of this chapter was to examine the effects of 
ciprofibrate, clofibric acid and bezafibrate, administered 
under varying dosing regimens, on selected hepatic enzyme 
parameters in the Fischer rat. In the first study the dose 
levels chosen were based on comparative lipid lowering potency 
derived from published data (Sterling-Winthrop, personal 
communication). The hypolipidaemic agents were administered 
once daily and the dose levels used were 20, 50 and 75 mg/kg 
for ciprofibrate, |clofibric acid and bezafibrate respectively.
With reference to the observed hepatomegaly and hepatic enzyme 
changes it is apparent that the inductive potency of these 
compounds varied considerably.
It has been estimated that the ED-33 (the dose effective in
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suppressing serum lipids by 33% from control values) of 
ciprofibrate for cholesterol and triglycerides in 
hyperlip id aemic animals is 1.5 mg/kg/day and «  1.5 mg/kg/day, 
respectively (Edelson et al.,1979). In normolip id aemic rats, 
ciprofibrate at a dose level of 1 mg/kg caused a 52% decrease 
in serum triglycerides (Dvornik and Cayen, 1980). At 2 mg/kg, 
total serum cholesterol and phospholipids were lowered and 
increasing the dose to 5 and 25 mg/kg produced no further 
decrease. This would infer that the hypolipidaemic properties 
of ciprofibrate are similar at dose levels of 2 mg/kg/day and 
20 mg/kg/day. The inductive potency of ciprofibrate at these 
latter two dose levels with respect to enzyme activities, is 
studied in the following chapter. Clofibrate at a dose level 
of 48 mg/kg/day, decreased serum triglycerides and LDL 
phospholipids (Dvornik and Cayen,1980). Higher doses (121 and 
242 mg/kg/day) caused a reduction in serum cholesterol. 
Bezafibrate decreased serum triglycerides, HDL cholesterol and 
HDL phospholipids at dose levels of 11 and 36 mg/kg/day 
(Dvornik and Cayen, 1980). To effectively use the rat as a 
model to predict hypolipidaemic activity requires assessment 
of rodent data with relevant clinical data from studies in 
man. When the minimal effective doses are compared with 
clinically effective doses for the rat and man respectively, a 
parallelism in dose requirements was observed (Dvornik and 
Cayen,1980). With clofibrate, bezafibrate and ciprofibrate, 
dose levels of 48, 11 and 1 mg/kg in the rat corresponds to 
25, 7.5 and 1.7-3.3 mg/kg in man, respectively (Dvornik and
Cayen, 1980).
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The dose levels chosen for these studies could have been more 
accurately selected with reference to hypolipidaemic activity. 
However, the primary objective was to compare the effects of 
these hypolipidaemic drugs on hepatic enzyme activities under 
similar and different dosing regimens and not to study 
hypolipidaemic activity per se.
With once daily dosing, the order of magnitude of response for 
liver enlargement, induction of peroxisomal beta-oxidation and 
decreased GPX activity was ciprofibrate > bezafibrate > 
clofibric acid. By altering the frequency of dosing, the 
differences in response with these compounds became 
negligible. The liver enlargement observed in rats treated 
with peroxisome proliferators appears to be an adaptive 
response and does not represent gross hepatocellular damage. 
The hepatomegaly was accompanied by a short-lasting burst of 
mitosis, centrilobular loss of glycogen and a fall in 
glucose-6-phosphatase activity (Mitchell et al.,1985). A 
midzonal to periportal accumulation of fat occurs (Mann et 
al.,1985).
The peroxisomal beta-oxidation system oxidises saturated 
acyl-CoAs with chain lengths from 7 to 22 or more carbons 
(Lazarow,1982). It also actively oxidises long chain 
unsaturated acyl-CoAs. The enzymatic capacity of the uninduced 
system is approximately 1 umole of acetyl-CoA formed/min/g 
liver (Lazarow,1982). The marked induction of the peroxisomal 
beta-oxidation system in rats exposed to peroxisome 
proliferators is probably an adaptive change associated with
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altered lipid metabolism (Mitchell et al.,1985). The decrease 
in GPX activity was associated with an unchanged or slightly 
elevated cytosolic protein content and may reflect decreased 
enzyme synthesis, impaired enzyme stability or in vivo 
inhibition of GPX by the peroxisome proliferator and/or 
metabolite. It has been established that ciprofibrate 
irreversibly binds to glutathione-S-transferase in vitro 
(Aswathi et al.,1984).
Succinate dehydrogenase is a marker enzyme for mitochondria 
and its specific content remained unchanged with clofibric 
acid and bezafibrate treatment. With ciprofibrate, enzyme 
activity was increased in study 1 and decreased in the second 
study. The results suggest that there may be no change in 
mitochondrial number and structure or that proliferation 
occurs with an associated proportional synthesis of succinate 
dehydrogenase. Mitochondrial alpha-glycerophosphate
dehydrogenase acts as a specific marker for the metabolic 
activity of thyroxine in the liver (Lee et al.,1959). The 
activity of this enzyme was increased in a similar manner by 
the three hypolipidaemic agents. The induction in study 1 was 
2 to 3-fold and in study 2, 4 to 5-fold. This enhanced
alpha-glycerophosphate dehydrogenase activity appears to 
involve the synthesis of new protein (Lee et al.,1959). It has 
been estimated that the relative amount of circulating 
thyroxine (T-4) present as "free T-4" is increased by 40% on 
clofibrate administration (Ruegamer et al.,1965). The 
displaced T-4 was concentrated in the liver which consequently 
became hyperthyroid as evidenced by elevated alpha-
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glycerophosphate dehydrogenase activity. A single dose of 
clofibrate to the rat caused radiolabelled thyroxine to move 
from the plasma to liver (Harland and Orr, 1975). Acute 
administration resulted in an increased flow of thyroxine to 
liver whilst serum levels of the hormone were maintained. With 
DEHP treatment, serum triiodothyroxine (T-3) levels remain 
unchanged and T-4 levels in plasma were reduced by half while 
morphological characteristics of the thyroid indicated 
hyperactivity at 7 and 14 days and 9 months (Hinton et 
al.,1986). Alpha-glycerophosphate dehydrogenase activity was 
elevated in animals exposed to DEHP. This marked increase in 
enzyme activity appears to be due to synthesis of new protein 
as a selective response to peroxisome proliferators mediated 
by an, as yet unclarified treatment-induced effect on the 
thyroid.
Carnitine acetyltransf erase is an enzyme catalysing the 
reversible transfer of an acetyl group from acetyl-CoA to 
carnitine (Kahonen and Ylikahri, 1974). The mitochondrial fatty 
acid beta-oxidation system is dependent on this enzyme as an 
intermediate carrier of acyl-substrates into the mitochondrial 
matrix. Mitochondria possess short-, medium- and long-chain 
carnitine acyltransf erase activities whereas only short- and 
medium-chain length carnitine acyltransf erase activities are 
observed in peroxisomes (Markwell et al.,1973). Carnitine is 
not involved in the entry of fatty acids into peroxisomes but 
may play a role in the removal of end products which could be 
shuttled to the mitochondria for further oxidation or 
conversion into ketone bodies (Lazarow, 1982). Carnitine
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acetyltransferase activity was increased to a similar extent 
by ciprofibrate and bezafibrate in both studies although the 
induction was considerably lower in the second study. 
Clofibric acid treatment resulted in increased enzyme activity 
and this was higher when the compound was administered twice 
daily. It should be remembered that total carnitine 
acetyltransferase activity was measured (i.e. mitochondrial 
and peroxisomal enzyme activity). It has been reported that 
clofibrate administration elevated carnitine acetyltransferase 
activity in both subcellular fractions (Goldenberg et 
al.,1976) and a similar response may be assumed in these two 
current studies.
It has previously been demonstrated that in clofibrate treated 
animals, the specific activity of uricase was appreciably 
decreased (Goldenberg et al.,1976). This decrease in enzyme 
activity was associated with a marked proliferation of 
peroxisomes indicating that the synthesis of uricase did not 
parallel the increase in organelle number. The specific 
activity of uricase was unchanged in bezafibrate and clofibric 
acid treated groups, however a decrease in activity was 
observed with ciprofibrate administration. The results would 
suggest, that in the event of peroxisome proliferation, 
synthesis of uricase occurs either in parallel to or not in 
proportion to the numerical increase in organelles (Goldenberg 
et al.,1976). In a similar manner the reduced activity of 
uricase in DEHP treated animals accompanied proliferation of 
hepatic peroxisomes lacking the uricase-rich core (Mann et 
al.,1985, Mitchell et al.,1985).
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The plasma half-lives of ciprofibrate, bezafibrate and 
clofibrate/clofibric acid in the rat are 3-4 days, 6^ -16 hours 
and 5-8 hours respectively (Baldwin et al.,1980, Cayen et 
al.,1977, Edelson et al.,1979, Thorp et al.,1972, Schmidt et 
al.,1980 and Sterling-Winthrop,personal communication). In my 
second study, ciprofibrate was administered once every 48 hrs 
and bezafibrate and clofibric acid twice daily in an attempt 
to compensate for the markedly different pharmacokinetic 
profiles in the rat and to mimic the recommended dosing 
frequency of these hypolipidaemic drugs in clinical practice. 
It is apparent that at the dose levels used, with daily
administration, considerable differences exist in the 
inductive potencies of these compounds with respect to hepatic 
enzymes. In contrast, altering the dosing frequency (as in my 
second study) rendered all three compounds equipotent with 
respect to hepatic induction.
The level of exposure (measured as area under the curve [AUC]) 
of ciprofibrate in the rat is clearly greater than in
bezafibrate and clofibric acid treated animals. Steady state
levels of the three drugs were achieved within 7 days 
following study commencement (Sterling-Winthrop, personal 
communication). With ciprofibrate administration, once every 
48 hrs, the steady state concentrations were reached at 7 days 
although drug levels were lower than with daily 
administration. As expected with clofibric acid and
bezafibrate, steady state levels increased with increasing 
dosing frequency. It has been estimated that the AUC of 
ciprofibrate (10 mg/kg once every 48 hrs) is approximately
126
equal to a bezafibrate dose level of 125 mg/kg, twice daily 
(Sterling-Winthrop,personal communication). In this study, 
dose levels of 20 and 150 mg/kg ciprofibrate and bezafibrate 
respectively, were used.
It is apparent that when making comparisons of biological 
activity between different members of a class of compounds, 
that both dose levels utilised and the frequency of dosing 
should be a fundamental consideration. Clofibric acid and 
bezafibrate are rapidly eliminated in the rat whereas 
ciprofibrate elimination is slow. Ciprofibrate treatment 
predisposes the animal to inductive processes as a direct 
result of its pharmacokinetic characteristics of accumulation 
and elimination.
A more scientifically enlightened outlook, as seen with the 
completion of these studies at Sterling Winthrop Research 
Centre, is required in regulatory and research toxicology to 
optimise knowledge of pharmacokinetics to rationalise the 
selection of dose levels when using different members of the 
same class of compounds.
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Chapter 4
SPECIES AND STRAIN DIFFERENCES IN THE HEPATIC RESPONSES TO
SHORT TERM ADMINISTRATION OF CIPROFIBRATE
4.1 INTRODUCTION
In the preceding chapter the influence of pharmacokinetic 
differences in the metabolism of ciprofibrate , bezafibrate 
and clofibrate were examined. Using a chronic multiple dose 
regimen, the relative potencies of these compounds, with 
respect to hepatic enzyme parameters, were studied and the 
metabolism and pharmacokinetic profiles discussed. It is 
apparent that this approach to optimise drug administration, 
compensates for the characteristic accumulation of 
ciprofibrate in the rat and that the potency of these 
compounds becomes qualitatively similar.
Ciprofibrate is a recently developed phenoxyisobutyrate
derivative and it is considered one of the most potent 
peroxisome prolif erators currently available. It effectively 
decreases serum cholesterol and triglyceride levels in normal 
laboratory animals and in animals rendered hyperlipid aemic by 
dietary perturbations (Arnold et al.,1979). The peroxisome
proliferation induced by ciprofibrate has been studied in the 
Fischer rat and in several non-rodent species (cats, chickens, 
pigeons, Rhesus and Cynomolgus monkeys) (Lalwani et al.,1983a 
and b, Reddy et al.,1984). The aim of the following
investigation was to clarify the species and rat strain
hepatic responses to the 14-day administration of ciprofibrate
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at a biochemical and molecular level.
Determination of enzyme levels in the cytosolic, microsomal, 
mitochondrial and peroxisomal subcellular fractions was 
undertaken. The number of animals per dose group is shown in 
table 4.0 (experimental design). Hybridisation probes to 
cytochrome P-452 and glutathione peroxidase were used to study 
the expression of mRNA in livers from untreated and treated 
animals. The results obtained will be discussed at length to 
elucidate the mechanism of induction as species specific or 
species common following the short term administration of 
ciprofibrate.
4.2 HEPATOMEGALY
With ciprofibrate, there was a significant dose-dependent 
increase in liver/body weight ratio with a maximal 2-fold 
induction at comparable dose levels in the Sprague Dawley, 
Fischer, Wistar and Long Evans rat; a similar increase was 
observed in the mouse (tables 4.1 and 4.2). However, 
hepatomegaly was less marked in the treated Gunn rat. A 
significantly increased liver/body weight ratio was seen in 
the hamster at the high dose level yet in the guinea pig, 
rabbit and marmoset there was no significant change in liver 
weight (table 4.2). It should be remembered that the animals 
were aged matched as appropriately as possible across rat 
strains and species. In the untreated animal the liver/body 
weight ratio in all 5 rat strains, the mouse, guinea pig and 
marmoset were very similar (5-6%). The lowest basal value was
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Table 4.0
EXPERIMENTAL DESIGN
SPECIES/STRAIN NUMBER OF ANIMALS PER 
DOSE LEVEL
Mouse a 1 pool of 6 animals
Hamster a 2 pools of 3 animals
Gunn rat Control: 4 animals
2 and 20 mg/kg: 3 animals
Sprague Dawley rat Control: 5 animals
2 and 20 mg/kg: 4 animals
Fischer rat Control:
2 mg/kg: 
20 mg/kg:
5 animals
4 animals
5 animals
Wistar rat Control: 5 animals
2 and 20 mg/kg: 4 animals
Long Evans rat Control: 5 animals
2 and 20 mg/kg: 4 animals
Guinea pig Control: 4 animals
2 and 20 mg/kg: 5 animals
Rabbit Control: 4 animals
2 and 20 mg/kg: 4 animals
Marmoset Control:
20 mg/kg: 
100 mg/kg:
4 animals 
4 animals 
4 animals
[a] no statistical analysis completed except with liver/ 
body weight ratio, expressed as mean of 6 animals 
+/- S.D.
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seen in the rabbit and hamster- (3-4%).
The response of the Fischer rat to ciprofibrate was consistent 
with the published data (Lalwani et al.,1983b). With DEHP, 
ME HP and clofibric acid administration, liver enlargement was 
observed in the rat and Syrian hamster, the magnitude being 
greater in the rat in each case (Lake et al.,1984, Lake et 
al.,1986). However with MEHP administration, hepatomegaly was 
more marked in Chinese hamsters as opposed to Syrian hamsters 
(Lake et al.,1986a). With fenofibrate treatment a non­
significant increase in liver/body weight ratio in the hamster 
was observed (Pourbaix et al.,1984). The extent of 
hepatomegaly is probably a product of the relative potency of 
the peroxisome proliferator in use. Hepatomegaly has also been 
observed in the ferret following DEHP treatment (Lake et 
al.,1976). There is no published data with respect to the 
measurement of liver/body weight ratios in the guinea pig or 
rabbit. No liver enlargement was observed in the marmoset 
following a 14 day treatment period with clofibrate, 
clobuzarit and DEHP (Jackh et al.,1984, Orton et al.,1982, 
Orton et al.,1984). It would appear that the guinea pig, 
rabbit and marmoset are refractory in response to ciprofibrate 
treatment with reference to hepatomegaly, bearing in mind that 
ciprofibrate is a very potent compound. In general terms, the 
greatest induction of hepatomegaly in peroxisome proliferator 
treated rats is 2-fold, irrespective of increased dose levels 
(Cohen and Grasso,1981). This would suggest saturation of a 
metabolic process producing a maximal response.
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4.3 THE MICROSOMAL DRUG METABOLISING ENZYME SYSTEM
The administration of peroxisome prolif erators to rodents 
results in the proliferation of the S.E.R. and the 
characteristic induction of a cytochrome P-450 species 
involved in lipid metabolism. This haemoprotein has been 
purified, characterised and described as a novel form, 
cytochrome P-452, which actively catalyses the 12 
hydroxylation of lauric acid ( Tamburini et al., 1984 ). 
Cytochrome P-452 is an unusual isoenzyme in that it exhibits 
specificity for endogenous substrates as opposed to model drug 
substrates unlike the cytochromes P-450 induced by the classic 
compounds phenobarbitone and 3-methylcholanthrene. In this 
investigation the ability of ciprofibrate to induce cytochrome 
P-452, as assessed catalytically and immunochemically, has 
been examined. In addition, the metabolism of benzphetamine 
and ethoxyresorufin, model drug substrates, has been studied.
4.3.1 Cytochrome P-450 Content
Variable changes in the specific content of cytochrome P-450 
were observed in the treated animals. In the Sprague Dawley, 
Fischer and Wistar rat there was an increase at both dose 
levels (table 4.1). However this was not dose-dependent and 
the specific content was higher at the 2 mg/kg than at 20 
mg/kg dose levels. The increases were significant at the low 
dose level and only at the high dose level in the Fischer rat. 
There was a significant dose-dependent increase (p<0.05) in 
the Long Evans rat with no significant changes detected in the
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cytochrome P-450 content of the Gunn rat. In the rat, the 
greatest induction in cytochrome P-450 levels was displayed in 
the low dose group in the Sprague Dawley and Fischer rat (1.5 
to 2-fold).
As with hepatomegaly a pattern of induction similar to the 
Fischer rat was demonstrated in the mouse (table 4.2). In the 
hamster an increased specific content was apparent at the high 
dose level with a non-significant dose-dependent elevation in 
cytochrome P-450 levels in the guinea pig (table 4.2). A 
significant 1.5-fold induction (p<0.05) at 20 mg/kg was seen 
in the rabbit. A dose-dependent increase in the cytochrome 
P-450 content is observed in the marmoset, significant at the 
high dose level(p<0.001). The marmoset was the most responsive 
species to the inductive influence of ciprofibrate on 
cytochrome P-450 content and displayed a 3-fold induction at 
the high dose level. The high dose level in the marmoset was 
100 mg/kg whereas the high dose level in the other species was 
20 mg/kg. The basal level of cytochrome P-450 in the untreated 
animal was widely variable between species and rat strain. The 
lowest cytochrome P-450 specific content was exhibited by the 
marmoset which was 4 to 8-fold lower than the rabbit, mouse, 
Fischer, Wistar and Long Evans rat. In close ascending order 
was the Sprague Dawley rat and hamster with the Gunn rat and 
guinea pig specific content being 8 to 9-fold greater than the 
marmoset.
By comparison with the above data, administration of 
clobuzarit resulted in a significant dose-dependent increase
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in cytochrome P-450 content in the rat and mouse, a minimal 
non-significant increase in the hamster and unchanged levels 
in the marmoset (Orton et al.,1984). With DEHP, MEHP and 
clofibric acid, a maximal 1.5-fold induction of cytochrome 
P-450 was observed in the hamster (Lake et al.,1984). 
Induction of cytochrome P-450 by peroxisome prolif erators 
appears to be a characteristic response in the rat, mouse and 
hamster. Cytochrome P-450 levels in the ferret remained 
unchanged following the administration of DEHP (Lake et 
al.,1976). The increase observed in the marmoset by 
ciprofibrate has not been demonstrated with clobuzarit and may 
reflect both the relative potencies and pharmacokinetic 
characteristics of these two compounds.
4.3.2 Benzphetamine-N-Demethylase Activity
In the rat there was a dose-dependent decrease in 
benzphetamine-N-demethylase activity which was significant in 
all strains with the exception of the Gunn rat (table 4.3). In
the Fischer and Long Evans rat, the activity at the high dose
level was 15-30% of the control value whereas in the remaining 
strains it was approximately 50%. In the mouse, enzyme
activity was halved at both 2 and 20 mg /kg ciprofibrate (table 
4.4). There was an increased benzphetamine turnover at the low 
dose level in the hamster, at the high dose level values were 
similar to control. In the guinea pig, activity remained
unchanged however there was a significantly decreased activity 
at the high dose in the rabbit. An apparent dose-dependent
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decrease in benzphetamine-N-demethylase activity was exhibited 
by the marmoset but this was not significant due to a marked 
inter-animal variation within each dose group (table 4.4). The 
basal levels in the mouse, guinea pig, Sprague Dawley and Gunn 
rats were very similar whereas the marmoset, rabbit, Wistar, 
Long Evans and Fischer rat exhibited an activity approximately 
2-fold higher. The turnover of benzphetamine was lowest in the 
untreated hamster.
Benzphetamine is used as a marker substrate for the major
phenobarbitone-inducible form of cytochrome P-450 in the rat
liver (designated P-450b) (Ryan et al.,1979). A wide range of
peroxisome proliferators including clobuzarit decreased
benzphetamine-N-demethylase activity in a manner similar to
that seen with ciprofibrate in the present study, in the
Wistar rat (Sharma et al.,1988). Aminopyrine may also be used
as a substrate for cytochrome P-450b. With clobuzarit
metabolism
treatment a significant increase in aminopyrine|was observed 
in the rat and mouse (Orton et al.,1984). However activity was 
decreased with clobuzarit treatment in the hamster and 
marmoset but this was not significant. The influence of 
peroxisome prolif erators on microsomal mediated benzphetamine 
metabolism has not been studied in the rabbit and guinea pig.
4.3.3 Ethoxyresorufin-O-Deethylase Activity
Ethoxyresorufin-O-deethylase activity was decreased in a 
dose-dependent manner in the rat (table 4.3). This was 
significant in all strains except the Gunn rat. In the
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Fischer, Wistar, Sprague Dawley and Long Evans rat, activity 
was decreased to 20-30% of the control value whereas in the 
Gunn rat this value was 40%. A similar pattern was observed in 
the mouse with a maximal decrease of 30% at the high dose 
level (table 4.4). A dose-dependent decrease was seen in the 
rabbit and marmoset but this was not significant due to the 
large response variation within each group. The activity of 
ethoxyresorufin-O-deethylase in untreated animals was highest 
in the rabbit and marmoset. Activity in the guinea pig 
remained unaffected by ciprofibrate treatment. The changes in 
ethoxyresorufin-O-deethylase activity in the hamster were 
similar to that with benzphetamine demethylation; there was 
increased activity at the low dose but values were similar to 
control at the high dose level. The activity in the untreated 
Gunn rat was approximately 2-fold higher than in the remaining 
rat strains,mouse, hamster and guinea pig.
Cytochrome P-450c is the major 3-methylcholanthrene-inducible 
form in rat liver and preferentially catalyses the metabolism 
of 7-ethoxyresorufin to resorufin. Administration of the 
phthalate ester plasticisers (DEHP and MEHP), clofibrate, 
bezafibrate and clobuzarit decreased ethoxyresorufin-O- 
deethylase activity (Sharma et al.,1988). This was comparable 
to ciprofibrate in the present study. In an earlier study with 
a clobuzarit dose level of 10 mg/kg as compared to 50 mg/kg, 
no change in activity (nmol/min/mg protein), was seen in the 
rat (Orton et al.,1984). Ethoxyresorufin-O-deethylase levels 
were unchanged in the clobuzarit treated mouse, hamster and 
marmoset. The activity in the untreated marmoset (expressed
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as n mol/min/nmol P-450), was quantitatively similar with 
ciprofibrate in the present study and with clobuzarit in the 
published data.
4.3.4 Induction of Cytochrome P-452
The induction of cytochrome P-452 was assessed:
1) catalytically using the marker substrate lauric acid. The 
11- and 12- hydroxy metabolites were separated by reverse 
phase HPLC, and
2) immunochemically using an enzyme linked immunosorbent assay 
(ELISA) technique utilising a polyclonal non-cross reacting 
antibody raised to the pure protein.
In the rat there was a dose-dependent increase in the 
11-hydroxylation of lauric acid which was significant at the 
low dose level in the Sprague Dawley, Fischer and Wistar rat 
and at the high dose level in every strain (table 4.5). The 
induction of lauric acid (omega-1)-hydroxylase varied between
1.5 to 2-fold in the Long Evans rat to 5-fold in the Wistar 
rat. In each case the ratio of 12- to 11-hydroxylation was 
greater than 1, varying from 1.25 in the Long Evans rat to 
2.27 in the Sprague Dawley rat. The 12-hydroxylation of lauric 
acid was preferentially induced by ciprofibrate in the rat in 
a dose-dependent manner, significant at both low and high dose 
levels (pcO.OOl) (table 4.5). The induction of 
omega-hydroxylation of lauric acid was 10-fold in the Gunn and 
Long Evans rat and 15-fold in the remaining strains. The 
(omega-1)-hydroxylation was induced 3-fold at 20 mg/kg in the
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mouse and a slight increase was seen in the hamster (figure 
4.1). The formation of 11-hydroxylaurate was not significantly 
altered in the guinea pig, rabbit and marmoset. With the 
omega-hydroxylation of lauric acid there was a dose-dependent 
increase in the mouse, hamster and rabbit; the induction at 
the high dose level was 10-, 5.5- and 3-fold respectively
(figure 4.1). The increase was significant at both dose levels 
in the rabbit. A non-significant decrease in omega- 
hydroxylation was observed at the high dose level in the 
marmoset. In the mouse, hamster and rabbit the ratio of 12- to
11-hydroxy metabolites was greater than 1, i.e. 1.99, 1.44 and
1.31 respectively (figure 4.2). In the guinea pig and marmoset 
the ratios were reversed, 0.50 in the guinea pig and 0.24 in 
the marmoset.
Comparison of the above data with published data available 
showed that the administration of a variety of peroxisome 
prolif erators to Wistar rats resulted in a maximal 2.5-fold 
induction of 11-hydroxylation with nafenopin and a 9-fold 
increase in 12-hydroxylaurate with Wy-14,643 (Sharma et 
al.,1988). In the present study the influence of ciprofibrate 
in the Wistar rat was more marked, 5- and 15-fold induction in 
the (omega-1)- and omega-hydroxylation of lauric acid. 
Clobuzarit pretreatment resulted in a 6-fold increase in total 
lauric acid hydroxylation (11- and 12-hydroxylaurate) in the 
rat (Orton et al.,1984). In the mouse and hamster, a 9-fold 
induction of lauric acid omega-hydroxylation was observed with 
clobuzarit and there was no significant alteration to lauric 
acid hydroxylation in the marmoset. The "active" metabolite of
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Figure 4.1
The Effect of Ciprofibrate on Lauric Acid Hydroxylase Activity
in Different Species
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Species
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Hamster
Rat (F-344) [a] 
Guinea pig 
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Marmoset
Low Dose 11-hydroxylaurate 
Low Dose 12-hydroxylaurate 
High Dose 11-hydroxylaurate 
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Absolute Values (control);
nmol hydroxyproduct formed/minute/ 
nmol cyt. P-450
11-hydroxylaurate 
2.63
3.50 +/- 0.94 
2.68 +/- 0.84 
5.20 +/- 1.73 
5.73 +/- 1.94 
13.77 +/- 6.46
12-hydroxylaurate
5.23
5.06 +/- 1.25 
3.52 +/- 1.20 
2.58 +/- 0.78
7.51 +/- 1.50 
3.34 +/- 2.42
[a] Data reproduced from table 4.5.
Dose Levels;
Low Dose : Mouse, Hamster, Rat, Guinea pig and Rabbit: 2mg/kg 
Marmoset: 20mg/kg 
High Dose : Mouse, Hamster, Rat, Guinea pig and Rabbit 20mg/kg 
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Single daily dose
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Figure 4.2
The Ratio of Lauric Acid Hydroxylated Metabolites in Untreated
Animals of Different Species
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ME HP was added to cultured guinea pig and marmoset hepatocytes 
with little effect upon the microsomal hydroxylation of lauric 
acid (Elcombe and Mitchell, 1986).
The specific content of cytochrome P-452 (nmol/nmol total 
P-450), determined using an ELISA technique, was increased at 
both dose levels in the rat and this was dose-dependent in the 
Fischer and Long Evans rat (table 4.5). In the remaining 
strains the specific content was higher at the low dose level 
than the high dose level although the increase was significant 
at both dose levels. It should be noted that the increase in 
total cytochrome P-450 content was only dose-dependent in the 
Long Evans rat - in the other strains the induction was higher
at 2 mg/kg than 20 mg/kg ciprofibrate. Cytochrome P-452 was
increased in a dose-dependent manner in the rat when expressed 
as a percentage of total cytochrome P-450 (table 4.5). This
isoenzyme constitutes between 3-6% of the total CO-discernible 
cytochrome P-450 population in uninduced rat liver microsomes. 
At the high dose level, the percentage increased to 48% in the 
Long Evans rat, representing an induction of 10-fold. In the 
other rat strains the cytochrome P-452 content varied between 
24 and 36% representing induction in the range of 5 to 8-fold. 
A dose-dependent increase in cytochrome P-452 content, 
expressed as specific content and as percentage of total 
cytochrome P-450, was observed in the mouse, hamster and 
rabbit (figure 4.3 and 4.4). This was significant in the 
rabbit. Cytochrome P-452 has not been detected 
immunochemically in liver microsomes of the guinea pig and
marmoset , (the minimum level of detection was 0.002 
pmoles/well, an absorbance of 0.040, double the blank value).
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Figure 4.3.
The Effect of Ciprofibrate on Cytochrome P-452 Specific
Content (nmol/nmol total P-450).
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[a] Rat data reproduced from table 4.5.
N.D. Not Detected
Dose Levels;
Single daily dose.
Low Dose : 2mg/kg
High Dose : 20mg/kg
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Figure 4.4.
The Effect of Ciprofibrate on Cytochrome P-452 Content 
Expressed as Percentage of Tote.! Cytochrome P~450
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Dose Levels;
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(See figure 4.3 for absolute values)
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It is apparent that cytochrome P-452 is a constitutive form of 
the haemoprotein and that ciprofibrate functions as an inducer 
of an endogenous cytochrome P-450 isoenzyme. Constitutive 
cytochrome P-450 isoenzymes are forms present in uninduced 
animals. Using a single radial immunodiffusion technique, 
cytochrome P-452 was previously found to constitute 22% of the 
total cytochrome P-450 population in untreated animals. This 
was increased to 57% on clofibrate administration (Bains et 
al.,1985). These figures have subsequently been revised using 
the more sensitive technique of ELISA, to 4% and 22-25% with 
clofibrate representing a 6-fold induction (Sharma et 
al.,1988). This immunochemical assay was utilised in this 
investigation and the basal level in uninduced rat liver 
microsomes was comparable i.e. 4-6% of the total cytochrome 
P-450 content. The influence of a variety of peroxisome 
proliferators on cytochrome P-452 content has been examined in 
the Wistar rat (Sharma et al.,1988). The assessment of 
cytochrome P-452 levels using immunochemical techniques has 
not previously been reported in different rat strains and 
species.
4.4 MITOCHONDRIAL ENZYME LEVELS
4.4.1 Monoamine Oxidase Activity
Monoamine oxidase is an outer mitochondrial membrane enzyme. 
In the Fischer and Long Evans rat a dose-dependent decrease in 
monoamine oxidase activity was observed and which was 
significant at the high dose level (table 4.6). In the other
Th
e 
Ef
fe
ct
 
of 
Ci
pr
of
ib
ra
te
 
on 
Mi
to
ch
on
dr
ia
l 
En
zy
me
 
Ac
ti
vi
ti
es
 
in 
Di
ff
er
en
t 
Ra
t 
St
ra
in
s
Ed Ei 
<X
Cl. w  
CO COo <  tc z
CU w
o  u  
os o
Cd OS O  O
>H Xj  a  . 
o  w  o
t Q  C  <!X&
G
IhJ
SM
E-*
tH>
►h
E-<
*•« , r—* «— » r—» r —* «—>» ■>—* r—»
o o o o o o o o o o o o o o o
o in in o o o o o m o o o o in in
rH rH tH rH CN r o rH rH rH tH CN HJ* rH CN N 1
w •— w w w w w w
, , r—1 ,__ , r _ r—u _ r— . r—.
g  o G V o T 3  U -l U -l U 4
. J LJ w w U J U -l U -l 1 1
rH tH rH tH tH rH rH 1— I rH rH rH rH rH rH rH
O o o O o O O O O O O O O o O
• • • • • • • * • • • • * • •
O o o o o O O o o o o O © o o
1
s
J
s
1
s
1
s
i
s
1
s
1
s
1
s
1
s
1
s
1
s
i
s
1
s
1
s
1
s
4- 4- 4- 4- 4* 4 - 4- ■4* + + + 4- 4* 4- 4-
CNJ r o r o rH CN r o CN CN r o rH CN H P •N * O co
o o o O o o O O o O O O O rH rH
• • • • • • • • • • • • • • •
o o o o o o o o o o o o o O O
l
I
to I• ii
I
G I
rH I
X) I 
fO I Ei I
> H «— » «— » —
E h O' o u s O r H O — » O
l-H g o C N C N o O C N o to C O o O '
> ■— r H O ' O ' r H r H O ' r H O ' O ' r H O ' co
l-H c ^--* u—»—• «— * *—<'*—• —"T
E h •H
q g
Ed < s
E h X c r H C N in C N HJ* O' o o r- r H C O N *
< Ed u »H o r H C O C - to r H o in r H C N t H
Z 0 3 3 a) • • • • • • r • • • • •t—i<  -a x C N r H « H r H r H r H r H r H O r H r H r H
o
r s
z o o
1 ■ 1 | | | | | | | | |uo Edo
M
04
JH
Qi
I
s
I
'—
1
s s s s s s S s s s
0 3 O 4 - 4 - 4 * 4 - 4- 4 - 4- 4 - 4 - 4 - 4 - 4*
0 2 r H
a o C N to r H O ' cri O O ' m r - to O co
> H g c— r H r H to 0 3 to C O in r H o
X C • • • • • . • • • ■ • • • •
Ed oo OO OO ro ro C N r H r H r H CO ro r H
a r H r H r H r H c4 r H r H r H r H rH r H r H
O  L O  
O  O  rH
T—I r—I Cl
H  Irt 
T-i CO to
H  N  O  
I I I
to r- in 
oo in
Ed \co a< -h
d  g —
►— i \  c
x  X  X  *h 
O  EH U <U 
hEd > G3 O Z tH O W 
in Eh W  CU 2 U Oj
<  cp
1. u . r— * »— u *— *
O c o o r H .— . o — . r— « o *c* o *— * I— *
o o r o o O C O o i n o o N * o m i n
r H r H t o r H r H r - r H C O t o r H r H i n r H c o N *
— * w > w ’ w '— * — ' --- ' *— ' w
_ r— .
X ) u T 3 T 3 V U 4
1 ■ U 4 u— r u u - j
t o 0 3 N * C O C N C N t H O ' C O C O C O C O N * r H
o o t o C O c o r H t o c o C O C N O ' N r i n C O C O m
« • • • • • • • • • • • • • ■ •
o o o o r H  O r H o O o r H o o o o
o
z
o2
i I I
og
c
Ed Ed 
CO >o  wO  X
cp O'r-1 -X .X o w  
w O' cn 4J g g
co o
U  CM CM
z
E h  t-H< cX  X  
Eh 
CO
I I I I I I I I I I I I
— s s s s S s s s s s s s s s
4 - 4 - 4- 4- 4 - 4- 4- 4- 4 - 4 * 4- 4* 4 - 4 - 4 -
m to r- O co m N * r H r~ C— r H E— r H r-
C O C N o to N * N T to m C O in O ' C N C N C N• • • • • • • • • • • • • • •
N* m ro N * cn in N * C O m in C N P- to ro
CO
>
CO
T3
O' O' r-» .X .x
O  *'N. V *U O' O' X g g
co o
O  CM CM
O' O' 
o wM O' O' X g g GO O  
CJ CM CN
O' O'
H i C  J Co w  M O' O' X g g Co o 
CJ cn cn
a) >i 14
3 a) <D M
CP i-4 X 03
c ro > u -P
C ' M ro to to
3 CUO H ■H
O 03 Es< X*
O' O'
HO S S  V4 O' O' X g g
co o
CJ CN CN
to
c
CO>
Ed
O'
c
ox
CD
CO
o
■O'
CO
-O'
O
O)c
co:
rH
o o
M 14
X X
G c
O o
U CJ
CP g
G o
•H 14
c 03 X
C
0) O <—»
jj CU X
o to to
M ID 0)
cu U
M
X
1
O' O X
g U
to
>4 X X
a O c
Or
a)
a
•a
a> CP 3
4J G X
3 X CO
C c
•H a)
g u X •
M c rH
M 0) 0) O
CD CU 14 o
CU 01 •
to X o
CD to X
a •—1 V
G T3 GJ
ro a —
XI to > i X
M to t-H u—I
O (D X
to M - c GJ
XI Or G G
to X
0)
U
•rH
G
G X rH
H to •H O
ID c •
0) 3 CP O
CP rH •—I
G G to V
to >
X G r—•
u a 01 U G
03 M G •—*
to G
rtJ 1 to >>
s to X in
TJ 4- X rH o
ID 01 3 •
to to X to o
to c CJ G
O' ro G 14 s/
U (D M
Or g  X iH •— 1
X O G3
CD 03
M
C
•iH
X *“*
ro to G
X to G M
•rH to G 3 G
> 0) M rH
3 3 G G
X rH 3 * > X
o G •H G
-< > Ed Oi no
• • • • ..
P—»
jO X U
150
rat strains activity was unaffected at 2 mg/kg ciprofibrate 
and was significantly decreased at 20 mg/kg ciprofibrate. The 
decrease in activity varied between 45-7 3% of the control 
value. A dose-dependent reduction in enzyme activity was 
observed in the hamster although this was less marked than in 
the rat. In the mouse, activity was decreased at the high dose 
level (table 4.7). A non-significant reduction in monoamine 
oxidase activity was apparent at 20 mg/kg ciprofibrate in the 
guinea pig. No significant changes were seen in the rabbit. In 
the marmoset, activity increased in a dose-dependent manner 
and which was significant at the high dose level, 100 mg/kg. 
In untreated animals, the highest turnover of kynuramine was 
observed in the Long Evans rat. The remaining rat strains, 
hamster, guinea pig and rabbit exhibited similar monoamine 
oxidase activity. The activity in the mouse was approximately 
2-fold lower than that in the Fischer rat. The decrease in 
activity observed in the rat with ciprofibrate in this study 
was comparable with that resulting from clofibrate 
pretreatment (Gear et al.,1974)
4.4.2 Succinate Dehydrogenase Activity
In the rat the specific activity of succinate dehydrogenase 
was unchanged following ciprofibrate treatment (table 4.6). In 
untreated animals, the mouse and Gunn rat exhibited the 
highest activity whereas in the guinea pig and rabbit it was 
4-fold lower. Activity of this enzyme was unaltered by 
ciprofibrate treatment in the mouse, hamster and guinea pig 
(table 4.7). Succinate dehydrogenase activity was
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significantly decreased at the low dose level in the rabbit 
yet values were similar to control at 20 mg/kg ciprofibrate. A 
dose-dependent elevation in enzyme activity was observed in 
the marmoset and this 1.5-fold induction was significant at 
the high dose level.
In comparison to the present study, succinate dehydrogenase 
activity was decreased in the rat with DEHP and ME HP 
treatment yet activity was unaffected by clofibrate (Lake et 
al.,1984, Mangham et al.,1981). It has been reported that 
administration of ME HP and clofibrate to hamsters 
significantly decreased succinate dehydrogenase activity (Lake 
et al.,1984). In the present study a slight dose-dependent 
decrease in activity was observed in the ciprofibrate treated 
hamster although the statistical significance of this could 
not be determined. Succinate dehydrogenase activity was 
significantly decreased in the ferret following treatment with 
DEHP (Lake et al.,1976). This enzyme has not previously been 
measured in the guinea pig, rabbit and marmoset.
4.4.3 Alpha-Glycerophosphate Dehydrogenase Activity
A significant dose-dependent increase in alpha-glycero- 
phosphate dehydrogenase activity was observed in the Sprague 
Dawley, Wistar and Long Evans rat (table 4.6). Elevation in 
enzyme activity was apparent in the Gunn and Fischer strains 
and this was significant at both dose levels in the Gunn rat 
and at the high dose level in the Fischer rat. The induction 
in the rat varied from 1.5 to 2-fold in the Gunn and Fischer
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strains to 4.5-fold in the Long Evans rat. The activity of 
this enzyme was unchanged following ciprofibrate treatment in 
the mouse, hamster, guinea pig and rabbit (table 4.7). In the 
marmoset, a dose-dependent increase in activity was observed 
and this 3-fold induction was significant at the high dose 
level. In untreated animals the mouse exhibited the highest 
enzyme activity which was 1.5 to 2-fold greater than the Long 
Evans rat and the hamster. In the other rat strains and 
species, alpha-glycerophosphate dehydrogenase activity was 3.5 
to 8-fold lower than that in the mouse.
It has been reported that the administration of clofibrate, 
gemfibrozil, tibric acid and fenofibrate results in the 
induction of alpha-glycerophosphate dehydrogenase in the rat 
(Holloway et al.,1980, Kahonen and Ylikahri,1979). This was 
comparable to the effects observed with ciprofibrate. There is 
no published data regarding the influence of peroxisome 
proliferators on alpha-glycerophosphate dehydrogenase activity 
in the guinea pig, rabbit and marmoset.
4.5 MITOCHONDRIAL AND PEROXISOMAL CARNITINE
ACETYLTRANSFERASE ACTIVITY
In the rat there was a significant dose-dependent increase in 
carnitine acetyltransf erase activity (table 4.8). The 
induction ranged from 16-fold in the Gunn rat to 70-fold in 
the Fischer rat. In the mouse, hamster and rabbit, enzyme 
activity was elevated in a dose-dependant manner and the 
induction at 20 mg/kg ciprofibrate was 6-, 3- and 4-fold
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respectively (figure 4.5). The increase was significant at 
both dose levels in the rabbit. Carnitine acetyltransferase 
activities were unchanged in the guinea pig and marmoset. The 
activity in untreated animals was lowest in the rat;in the 
mouse and hamster the activity was 2.5 to 13-fold higher. 
Enzyme activity was maximal in the untreated guinea pig and 
marmoset.
The administration of a variety of hypolipidaemic agents to 
the Wistar rat resulted in a marked induction in carnitine 
acetyltransf erase activity (Sharma et al.,1988). The extent of 
induction ranged between 5-fold with aspirin to 30-fold with 
nafenopin. However, in the present study a 36-fold induction 
was observed with ciprofibrate. In the Fischer rat a 70-fold 
increase in the activity of this enzyme occurred compared to 
the reported 58-fold increase following the dietary 
administration of ciprofibrate at a concentration of 0.1% 
(w/w) (Lalwani et al.,1983b). It has been reported that MEHP, 
DEHP, clofibrate and fenofibrate administration to hamsters 
caused a significant increase in carnitine acetyltransf erase 
activity in the order of 1.6-,2- and upwards of 10-fold, 
respectively ( Lake et al.,1984, Lake et al.,1986, Pourbaix et 
al.,1984 ). With ciprofibrate the induction, was 3-fold in the 
hamster. This enzyme has not been measured previously in the 
rabbit or marmoset. It has been reported that ciprofibrate 
induced this enzyme in cats, chickens, pigeons, Rhesus and 
Cynomolgus monkeys when using extremely high dose levels 
(Reddy et al.,1984). Hepatocytes from Duncan Hartley guinea 
pigs, treated in vitro with MEHP showed unchanged carnitine
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Figure 4.5
The Effect of Ciprofibrate on Mitochondrial and Peroxisomal 
Carnitine Acetyltransferase Activity in Different Species.
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acetyltransf erase activity (Lake et al.,1986).
4.6 PEROXISOMAL ENZYME ACTIVITIES
4.6.1 Catalase Activity.
In the Sprague Dawley and Wistar rats, the specific activity 
of catalase was significantly increased at the high dose level 
(table 4.9). In the Gunn, Fischer and Long Evans rats, mouse 
hamster the specific activity of catalase was unchanged 
following ciprofibrate treatment (tables 4.9 and 4.10). Enzyme 
activity was unaltered in the guinea pig and marmoset. However 
at 20 mg/kg ciprofibrate (i.e. the high dose) in the rabbit, 
activity was significantly increased by 1.5-fold. Catalase 
activity in the untreated marmoset was 2 to 3-fold lower than 
the basal level in the other species.
By comparison, in the rat and mouse clobuzarit treatment 
resulted in a 2-fold increase in catalase activity; activities 
were unchanged in the hamster and marmoset (Orton et 
al.,1984). A similar increase was seen with ciprofibrate in 
the rat (Lalwani et al.,1983b). It should be noted that in 
this study the liver/body weight ratio (tables 4.1 and 4.2) 
was doubled in the rat and mouse with a significant increase 
at the high dose level in the hamster. Although the specific 
activity of catalase was largely unchanged, the total catalase 
activity would be increased in line with the observed 
hepatomegaly. According to the published data, ciprofibrate at 
high dose levels increased catalase activities in cats,
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chickens, pigeons and Rhesus and Cynomolgus monkeys (Reddy et 
al.,1984). Catalase activity was significantly decreased in 
the ferret following DEHP administration (Lake et al.,1976). 
The effect of peroxisome proliferators on catalase levels in 
the guinea pig and rabbit has not previously been reported.
4.6.2 Peroxisomal Beta-Oxidation
In the rat, ciprofibrate treatment resulted in a significant 
dose-dependent increase (p<0.001) in peroxisomal beta- 
oxidation (table 4.9 ). This induction was 9 to 15-fold in the 
Gunn, Sprague Dawley, Wistar and Fischer strains. In the Long
1
Evans rat, a 34-fold increase was observed. In the mouse, the 
response was dose-dependent with a 45-fold increase at the 
high dose level (figure 4.6). Peroxisomal beta-oxidation was 
elevated approximately 2.5-fold at the 20 mg/kg ciprofibrate 
dose level in the hamster. There was no change in the 
beta-oxidation of palmitoyl-CoA in the guinea pig. In the 
rabbit, beta-oxidation was significantly increased in a dose 
response manner and the induction was 6-fold at the high dose 
level. At 20 mg/kg ciprofibrate, the increase in peroxisomal 
beta-oxidation was 2 fold in the marmoset and at the high dose 
level (100 mg/kg), a 4-fold induction was observed. This was 
significant at both dose levels. In the uninduced state, 
peroxisomal beta-oxidation was lowest in the guinea pig and 
marmoset. The highest activity was exhibited by the hamster 
which was 3 to 4-fold greater than the rat, mouse and rabbit.
It has previously been reported that the administration of a
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Figure 4.6.
The Effect of Ciprofibrate on Peroxisomal beta-Qxidation in
Different Species
PEROXISOMAL B-OXIDATION
LEGEND
—3 
CD 
O' 
£—
CD
CD
Lu
CD
5000
4000
3000
2000
1000
CONTROL 
LOf DOSE 
HIGH DOSE
MICE HAMSTER RAT(F334) G.PI6 RABBIT MARMOSET (CONTROL = 100)
SPECIES 
2 WEEK TREATMENT
Absolute Values (control);
Species nmol product formed/ min/mg protein
Mouse 2.89
Hamster 13.86 + /- 3.89
Rat (F-344) [a] 3.54 +/- 1.48
Guinea pig 0.97 + /- 0.32
Rabbit 2.33 +/- 0.85
Marmoset 1.23 + /- 0.53
[a] Data reproduced from table 4.9.
D o s e  L e v e l s  ;
Low Dose: Mouse, Hamster, Rat, Guinea pig and Rabbit 2mg/kg
Marmoset: 20mg/kg
High Dose: Mouse, Hamster, Rat, Guinea pig and Rabbit 20mg/kg 
Marmoset: lOOmg/kg
Single dai ly dose
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wide range of peroxisome proliferators to Wistar rats caused a 
significant induction of the peroxisomal beta-oxidation 
system. The extent of induction varied from 2.2-fold with MEHP 
to 5.4-fold with nafenopin (Sharma et al.,1988). In the 
current study ciprofibrate administration resulted in an 
11-fold increase in peroxisomal beta-oxidation in the Wistar 
rat. A 12-fold induction was observed in the Fischer rat which 
was comparable to the 14-fold increase reported with the 
dietary administration of ciprofibrate at a concentration of 
0.10% (w/w)(Lalwani et al.,1983a). With clobuzarit treatment, 
a 5-fold increase in peroxisomal beta-oxidation was seen in 
the rat and a 9-fold induction in the mouse (Orton et 
al.,1984). With clofibric acid administration, a 9 to 14-fold 
increase was observed in the mouse and a 7-fold induction with 
DEHP (Kawashima et al.,1983, Osumi and Hashimoto,1978). A 
significant increase in cyanide-insensitive palmitoyl-CoA 
beta-oxidation was exhibited by the hamster with clobuzarit 
treatment; however beta-oxidation was unaffected in the 
marmoset (Orton et al.,1984). Palmitoyl-CoA oxidation in the 
hamster was increased 1.5 to 2-fold by MEHP, clofibrate and 
fenofibrate (Lake et al.,1984, Pourbaix et al.,1984). The 
induction of peroxisomal beta-oxidation was more marked in 
MEHP treated Chinese hamsters than in treated Syrian hamsters 
(Lake et al.,1986a). With DEHP and clofibric acid 
administration, the peroxisomal beta-oxidation system was 
unchanged in the guinea pig (Kawashima et al.,1983, Osumi and 
Hashimoto,1978) The effect of MEHP and one active metabolite 
of MEHP on peroxisomal beta-oxidation in cultured guinea pig 
and marmoset hepatocytes was examined. No stimulation of
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peroxisomal beta-oxidation was observed in the guinea pig 
hepatocytes with either compound. Marmoset cultures 
occasionally showed small increases in palmitoyl beta- 
oxidation but these were not dose-dependent with MEHP or its 
metabolite (Elcombe and Mitchell, 1986). The culture of hamster 
and Duncan Hartley guinea pig hepatocytes with MEHP had no 
effect on peroxisomal beta-oxidation (Lake et al.,1986). 
Administration of clofibrate to Rhesus monkeys and marmosets 
did not alter the activity of peroxisomal fatty acid oxidising 
enzymes (Orton et al.,1984). With high dose levels of 
ciprofibrate, increased palmitoyl-beta-oxidation has been 
reported in cats, chickens, pigeons and Rhesus and Cynomolgus 
monkeys (Reddy et al.,1984). In this study the induction of 
the peroxisomal beta-oxidation system by ciprofibrate was 
observed in the rat, mouse, hamster and rabbit with a minimal 
induction in the marmoset. Peroxisomal beta-oxidation was 
unchanged in the guinea pig by ciprofibrate treatment.
4.6.3 Uricase Activity
In the Gunn, Sprague Dawley and Fischer rat strains, uricase 
activity was unchanged by ciprofibrate treatment (table 4.9). 
A significant decrease (p<0.05) in enzyme activity was
observed at 2 mg/kg ciprofibrate in the Wistar and Long Evans 
rat. However, values returned to normal (i.e. control
activity) at the high dose level. Uricase activity was
unchanged in the mouse and guinea pig (table 4.10). A marked 
dose-dependent decrease in enzyme activity was seen in the 
hamster; at the high dose level activity was half of the
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control value. Ciprofibrate treatment resulted in a 
significant increase in enzyme activity at the high dose level 
in the rabbit. Uricase activity was determined in the marmoset 
homogenate samples and was found to be approximately 100-fold 
lower than in the rat. The standard deviation values were very 
high and in the control were greater than the mean (values not 
shown). This minimal activity probably exceeded the level of 
detection and limits of sensitivity of this assay. No apparent 
treatment-dependent changes could be determined. Man and 
certain non-human primates, including several genera of New 
World monkeys are devoid of uricase (Christen et al.,1970). 
The marmoset is a New World monkey and on the basis of the 
values obtained (i.e. the high standard deviations) and the 
very low activity, uricase is postulated to be absent in the 
marmoset. Uricase activity was reported to be elevated in the 
cat and Rhesus monkey (Old World) by ciprofibrate 
administration (Reddy et al.,1984). This has not been 
substantiated by other published reports.
4.7 CYTOSOLIC ENZYME ACTIVITIES
Two major classes of glutathione peroxidases (GPX) exist. One 
type contains selenium in the form of covalently bound 
selenocysteine in the active site. This selenium-dependent 
enzyme is active with both organic hydroperoxides and hydrogen 
peroxide. The second type is not dependent on selenium for 
catalysis and displays negligible activity with hydrogen 
peroxide. This class constitutes the glutathione-S- 
transferases (Mannervik,1985). In this context, hydrogen
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peroxide is a substrate specific for the selenium dependent 
GPX, however t-butylhydroperoxide and cumene hydroperoxide can 
also be used by the selenium dependent form and the selenium 
independent glutathione-S-transf erases (GST) (Lawrence and 
Burk,1976, Lawrence et al.,1978). A measure of GST activity 
can be determined as the difference between the enzyme 
activity with cumene hydroperoxide and hydrogen peroxide 
(Lawrence et al.,1976, Mohandas et al.,1984). In this study, 
the major interest in the cytosolic enzymes was to examine the 
effect of ciprofibrate on glutathione peroxidase which 
functions as a biological antioxidant.
The activity of GPX was measured using two substrates, 
hydrogen peroxide and t-butylhydroperoxide. In the rat, a 
dose-dependent decrease in enzyme activity was observed with 
both substrates (table 4.11). In each instance the activity 
with hydrogen peroxide was twice that with 
t-butylhydroperoxide. It should be noted that the enzyme 
activity, expressed as a percentage of control, was very 
similar with both substrates (+/-6%), with the exception of 
the Fischer rat in the low dose group. With the rat, the 
values were derived from one cytosolic pool per dose group. At 
the high dose level activity was 40-65% of the control value. 
This decrease in enzyme activity was marked in the Sprague 
Dawley and Wistar rat. The Gunn rat was the least responsive 
rat strain. GPX activity in the untreated rat shows minimal 
strain variation.
GPX/GST activity was measured in the Sprague Dawley and Gunn
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rat using cumene hydroperoxide and hydrogen peroxide (table 
4.12 ). The difference in activity between the two substrates 
was attributed to GST activity. Enzyme activity was greater 
with cumene hydroperoxide than with the other two substrates 
(hydrogen peroxide and t-butylhydroperoxide). There was little 
variation (+/-8%) in GPX activity when expressed as percentage 
of control with these 3 substrates. GST activity was decreased 
in a dose-dependent manner in both rat strains and at the high 
dose level this was 35-50% of the control value. In the mouse, 
a dose-dependent decrease in GPX activity was observed and at 
20 mg/kg ciprofibrate activity fell to 55-60% of the control 
value (table 4.13). In the hamster GPX activity was unchanged 
on treatment however a slight increase was seen at the high 
dose level. With these two latter species there were no 
substrate differences. Activity in the guinea pig was
unaffected by ciprofibrate treatment. There were no 
significant changes in GPX activity in the rabbit. No 
significant changes were apparent in the marmoset but there 
appeared to be an increase at both dose levels. In the 
untreated animal, the guinea pig and marmoset exhibited the 
lowest GPX activity and the highest hydroperoxide turnover was 
in the rabbit, mouse and hamster.
On the basis of the minimal substrate differences between 
hydrogen peroxide and t-butylhydroperoxide and with reference 
to the substrate instability of the former, t-butylhydro­
peroxide would appear to be a suitable substrate for measuring 
selenium-dependent GPX. It has previously been reported that 
clofibrate administration to rats did not decrease GPX
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activity (Antonenkov et al.,1987), yet activity was increased 
by MCPA, a weak peroxisome proliferator (Hietanen et 
al.,1985). It has been reported that both clofibrate and 
fenofibrate decreased GPX activity to 75-80% of the control 
value ( Ciriolo et al.,1982, 1984). With ciprofibrate in this
investigation, the decrease in enzyme activity was more marked 
(40-65%). This was similar to the nafenopin and DEHP mediated 
decrease in GPX activity which was 40-60% of the control value 
(Tomaszewski et al.,198.6, Furukawa et al.,1985). The influence 
of peroxisome proliferators on GPX activity has not previously 
been examined in other species. The distribution of 
non-selenium and selenium dependent GPX activity has been 
studied in several species. Non-selenium GPX activity ranged 
from 35%, 43% and 100% in the rat, hamster and guinea pig
(Lawrence and Burk, 1978). This would infer that activity with 
hydrogen peroxide would be negligible in the guinea pig which 
is in contrast to the present study where similar activity was 
detected using either t-butylhydroperoxide or hydrogen 
peroxide. The reason for this is unclear. The livers from each 
species were perfused prior to homogenisation to remove 
residual blood. Red blood cells and presumably plasma, contain 
only the selenium-dependent GPX so contamination could occur. 
However in the mouse, hamster, rat and guinea pig the tissue 
was well perfused so that contamination with selenium- 
dependent GPX from red blood cells was unlikely.
Clofibrate, fenofibrate, nafenopin, tiadenol and tibric acid 
administration resulted in decreased glutathione-S-transferase 
activity in the rat (Foliot et al.,1984, 1986). Ciprofibrate
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noncompetitively inhibited glutathione-S-transferase in rat 
liver, in vivo and in vitro (Awasthi et al.,1984). This was 
substantiated in part by the observed decrease in GST activity 
in the Gunn and Sprague Dawley rat with ciprofibrate in this 
investigation. It is apparent that ciprofibrate, in common 
with other peroxisome proliferators, decreases the activity of 
cytosolic GPX and glutathione-S-transf erase in the rat.
4.8 THE MOLECULAR BIOLOGY OF CYTOCHROME P-452 AND
GLUTATHIONE PEROXIDASE
The administration of a wide range of peroxisome prolif erators 
to the rat results in the induction of cytochrome P-452, as 
measured catalytically using lauric acid as the substrate and 
immunochemically using an ELISA technique (Sharma et 
al.,1988). During this investigation it became apparent that 
ciprofibrate, in addition to inducing cytochrome P-452 caused 
a decrease in cytosolic GPX activity as determined 
catalytically. Peroxisome prolif erators cause a marked 
increase in the peroxisomal beta-oxidation system with the 
concomitant generation of hydrogen peroxide. The decrease in 
GPX activity was of interest as this enzyme functions as a 
biological antioxidant. The possible implications of this 
reduced defence against "oxygen radicals" in the ultimate 
toxicity, hepatocarcinogenesis, is unclear at present.
The level of cytochrome P-452 was elevated following 
ciprofibrate treatment and this may be due to an overall 
enhanced synthesis of the protein as opposed to alterations to
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catalytic activity and/or protein degradation. The decrease in 
GPX activity may result from in vivo inhibition, protein 
degradation or non-expression of this gene product. It has 
been established that Wy-14,643 administration results in a 
marked increase in the concentration of mRNA species coding 
for 3-ketoacyl-CoA thiolase and enoyl-CoA hydratase 
(C hatter jee et al.,1983). Thus, to clarify this ciprofibrate- 
dependent modulation of GPX and cytochrome P-452 activity, it 
was decided to adopt a molecular approach to study the 
expression of these two genes. A cDNA probe to cytochrome 
P-452 and a genomic probe to GPX are currently available in 
our laboratory and these were used in hybridisation 
experiments with hepatic isolated RNA. It was hoped that by 
studying the gene expression in various species, differences 
in susceptibility to peroxisome prolif erators could be 
rationalised. In preliminary experiments, an attempt to
optimise the yield of RNA from the biological samples prior to 
hybridisation with the radiolabelled probe, was undertaken.
ISOLATION OF TOTAL RNA
In the cell, RNA exists mostly in ribonucleoprotein complexes 
(ribosomal subunits,hn RNPs [histone ribonucleoproteins] and 
mRNPs) which further interact with extraneous proteins 
subsequent to cell disruption. The essence of RNA isolation is
therefore highly dependent on a protein denaturation step in
conjunction with extensive ribonuclease inhibition. To achieve 
this the method of Chirgwin et al.,(1979) was utilised as
outlined in section 2.9.. Guanidinium isothiocyanate and
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guanidine hydrochloride extraction was favoured as both 
inhibit ribonuclease and are potent chaotropic agents 
(Cox,1968). Reducing agents such as 2-mercaptoethanol and 
dithiothreitol, acting as disulphide bound reductants, were 
also included in the isolation procedure.
In general, RNA is isolated from tissue, which is excised as 
rapidly as possible and homogenised in the presence of 
guanidinium isothiocyanate to inhibit ribonuclease activity. 
This results in a high yield and purity as a result of minimal 
RNA degradation. The RNA isolation and subsequent 
hybridisation experiments were completed in the final phase of 
the research. It was hoped that the limited biological samples 
available would be sufficient and adequate for RNA extraction 
to avoid further animal studies. As a result, several 
experiments were completed using tissue from various sources 
though this was in instances unsupported by biochemical and 
immunochemical data. It should be noted that when using frozen 
tissue and homogenate samples, the initial steps prior to 
freezing - perfusion, homogenisation and aliquoting of sample 
- were not completed using sterile techniques. The extent of 
RNA degradation by ribonucleases was a possible concern.
In the first experiment, total RNA was isolated from 6 rat 
liver samples;
1) fresh liver from 2 untreated Wistar rats, (Nos.1,2).
2) frozen homogenate from untreated and ciprofibrate 
(20mg/kg/day, 14 days administration) treated Wistar rats. The 
tissue was excised, perfused with 0.9% saline and homogenised
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in 0.25M sucrose prior to freezing at -80 degrees centigrade 
for approximately 1.5 years before RNA extraction, (Nos 3,4).
3) frozen liver from ciprofibrate treated and untreated 
Fischer rats. Tissues were excised and perfused with 0.9% 
saline prior to freezing at -80 degrees centigrade. Treatment 
duration :9 months at 20mg/kg/day, storage period of 3 months, 
(Nos 5,6).
One gram of fresh or frozen tissue was homogenised in 16ml 
guanidinium isothiocyanate whereas 2ml whole homogenate and 
14ml of guanidinium isothiocyanate was utilised. The RNA was 
isolated as previously described and assessed for purity by 
means of an A260/280 ratio reading and the concentration
determined using the absorbance at 260 nm (table 4.14).
The major disadvantage of this isolation procedure is the
presence - although in the minority - of the RNA species of 
the hnRNAs and also the nuclear precursors of the cytochrome 
P-450 mRNA sequences (Tay lor,1979). With this extraction 
protocol there is little variation in the purity of the 
isolated RNA (1.69-1.74) although the RNA concentration (mg
RNA / g liver ) is considerably higher in samples derived from 
fresh tissue. Horizontal slab gels of the RNA fractions, 
denatured by formamide (Maniatis et al.,1982) were completed 
to determine the structural integrity of the isolated RNA
(figure 4.7).
From the gel it can be seen that there was no appreciable 
degradation of RNA. The two distinct bands correspond to the
Table 4 .14
RNA Purity and Concentration in Samples from Fresh and 
Frozen Livers and Frozen Whole Homoqenates.
Treatment Animal RNA
Number (260/280 ratio)[a]
RNA concentration 
(mg/g liver)
Control
Control
1.69
1.71
1.03
0.91
Control 3 1.74 0.30
Induced[b] 4 1.72 0.29
Control 5 1.71 0.45
Induced 6 1.71 0.53
[a] Ultrapure RNA is indicated by an A260/280 ratio of 2.0.
[b] Treatment with ciprofibrate.
Figure 4.7.
Gel Electrophoresis of RNA Samples Derived from Fresh and 
Frozen Liver Tissue and Frozen Whole Homogenate.
18s
28s
Track 1 ; Fresh untreated tissue.
Track 2 ; Fresh untreated tissue.
Track 3 ; Untreated frozen whole homogenate.
Track 4 ; Ciprofibrate treated frozen whole homogenate. 
Track 5 ; Frozen untreated tissue.
Track 6 ; Ciprofibrate treated frozen tissue.
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28s and 18s subunits of ribosomal RNA. The background smear is 
mRNA, the minimum size being approximately 0.5 kb. If 
appreciable degradation had occurred the majority of the RNA 
would run at <lkb. No tRNA was present. Dot blots were 
prepared with the RNA samples and hybridised with the 
radioactive probes for cytochrome P-452 and glutathione 
peroxidase. For an accurate quantitation of the dot blots 
densitometry can be used, a sensitive procedure where as 
little as 5-10cpm above background can be evaluated reliably. 
This the best method of quantitation when the amount of 
radioactivity is low in the hybrids. Unfortunately this 
technique was not available at the time and the intensity of 
hybridisation signal on the autoradiographs between series of 
dots was compared visually i.e. semi-quantitatively.
A positive hybridisation with the cytochrome P-452 probe was 
observed with all RNA samples indicating that this 
haemoprotein is a constitutive form expressed in untreated 
rats (Nos.1,2,3,5) (figure 4.8). Induction of the mRNA species 
coding for cytochrome P-452 was apparent in the ciprofibrate 
treated animals with a hybridisation signal visible at 1 
ug/dot. In animal no.4 - derived from frozen homogenate - this 
was associated with a 5-fold induction of lauric acid 
omega-hydroxylase activity and a 8-fold increase in cytochrome 
P-452 protein content by comparison with the control. One 
would assume a similar response in animal no.6, although 
biochemical and immunochemical analyses have not been 
completed. The duplicate filter was hybridised with the GPX 
probe. Filter washing was insufficient however to remove the
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Figure 4.8,
Hybridisation of Control and Ciprofibrate Induced Liver RNA, 
Derived from Fresh and Frozen Tissue and Frozen Whole 
Homogenate, with the Cytochrome P-452 cDNA Probe
C o n t r o l
C i p r o f i b r a t e
No. 1
N o . 2
C o n t r o l  No.  3
C i p r o f i b r a t e  •  No . 4
C o n t r o l  N o ' 5
N o . 6
1 10 20 pg RNA
C y t o c h r o m e  P - 4 5 2  Do t  B l o t
Track 1
Track 2
Track 3
Track 4
Track 5
Track 6
Fresh untreated tissue.
Fresh untreated tissue.
Untreated frozen whole homogenate. 
Ciprofibrate treated frozen whole homogenate. 
Untreated frozen tissue.
Ciprofibrate treated frozen tissue.
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unhybridised probe and to dissociate unstable hybrids with the 
resultant autoradiograph being cross^contaminated with a high 
background count (not shown). All samples hybridised with the 
genomic probe but any differences in the intensity of the 
signal could not be detected.
Total liver poly (A)+ enriched from clofibrate treated D2 mice 
has previously been probed with mouse cytochrome P-450b cDNA 
and mouse P-l-450 cDNA clones (PB and 3-MC induced cytochrome 
P-450 isoenzymes respectively) (Stupans et al.,1984). No cross 
hybridisation was detected indicating that the clofibrate 
inducible cytochrome P-450 process involves P-450 genes 
distinct from those involved in the induction by PB and 3-MC 
(Stupans et al.,1984). Laurie acid omega-hydroxylase 
(cytochrome P-450 LAw), thought to be identical to cytochrome 
P-452, has been purified and its cDNA clone isolated and 
sequenced (Earnshaw et al.,1988, Hardwick et al.,1987, 
Tamburini et al.,1984). Total RNA was isolated from untreated 
and clofibrate treated rats and mRNA levels quantitated using 
the cytochrome P-450 LAw cDNA probe. A mRNA of approximately 
2200 bases was detected in control and clofibrate-induced rat 
RNA (Hardwick et al.,1987). In the present study, the presence 
of mRNA coding for cytochrome P-452 was apparent in 
ciprofibrate and untreated rats. Cytochrome P-450 LAw mRNA 
levels in liver increased approximately 3-fold above control 
levels within 3 hr of clofibrate administration and continued 
to increase *5 to 7-fold above control levels at 24 hr after 
treatment. These increases in mRNA closely paralleled the 
increase in immunodetectable enzyme after clofibrate
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administration. In contrast, no significant increases in 
cytochrome P-450 PCN or P-450e mRNAs were detected in induced 
animals. These results verify that cytochrome P-450 LAw and 
its mRNA are specifically induced by clofibrate and it is 
assumed other peroxisome prolif erators. This haemoprotein 
would appear to be a member of a new cytochrome P-450 gene 
family because it shares little overall sequence similarity 
with other cytochromes P-450 characterised to date. 
Prostaglandin omega-hydroxylase (cytochrome P-450 p2) shares 
74% amino acid similarity with cytochrome P-450 LAw suggesting 
that this haemoprotein is also a member of the P-450 IV gene 
family (Matsubara et al.,1987, Nebert et al.,1987).
The cDNA probe to cytochrome P-452 was isolated from a lambda 
gtll expression library. Northern blot analysis revealed a 
single mRNA species in male Wistar rat liver of approximately 
2.4 Kbp hybridising to the radiolabelled probe. No significant 
hybridisation of P-452 cDNA to poly (A)- RNA was observed in 
either control or clofibrate treated liver; poly (A)+ RNA 
levels were barely detectable in control liver but a very 
marked increase in cytochrome P-452 mRNA was observed in 
clofibrate treated liver (Earnshaw et al.,1988). It is 
apparent that in the rat, both clofibrate and ciprofibrate 
pretreatment results in the induction of cytochrome P-452 as 
measured immunochemically and catalytically. This correlated 
to an increase in the respective mRNA species as apparently 
observed in this study.
In the second experiment, RNA was isolated from frozen
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homogenates from untreated and ciprofibrate treated mice, 
hamsters and guinea pigs. In this instance the specific 
activity of the labelled cytochrome P-452 probe was very low. 
When the autoradiograph was developed the level of 
radioactivity in the hybrids was insufficient to visually 
detect dots (not shown).
The results obtained with the GPX probe were inconclusive (not 
shown). This probe cross-hybridised with all species as 
expected but the hybridisation of the probe to filter-bound 
RNA was not linear with dilution and any treatment-induced 
changes to the expression of this gene could not be detected.
At this stage it was decided not to continue investigation 
into the expression of GPX but to concentrate on cytochrome 
P-452 mRNA expression. Total hepatic RNA was isolated from 
frozen homogenates prepared from untreated and treated (20 
mg/kg ciprofibrate for 14 days) mice, hamsters, rats, guinea 
pigs and rabbits. Biological samples from marmosets acutely 
exposed to ciprofibrate were not available but equivalent 
studies were completed on chronically treated marmosets 
(chapter 5).
A clear induction of mRNA species hybridising to the cDNA 
probe for cytochrome P-452 was observed in the mouse and rat 
(figure 4.9). An increase in the level of radioactivity in the 
hybrids from treated hamsters, guinea pigs and rabbits was 
detected. In the hamster and rabbit this was associated with a 
7 to 8- and 2.5-fold increase in lauric acid hydroxylation and
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Figure 4.9.
Hybridisation of Control and Ciprofibrate Induced Mouse, 
Hamster/ Ratf Guinea pig and Rabbit Liver RNA with the 
Cytochrome P-452 cDNA Probe*
1 10 20 |jg RNA
C
Mouse
Hamster
Rat
Guinea
pig
Rabbit
• •
•  %
C
I
Table 4.15.
Correlation of Cytochrome P-452 cDNA Probe Analysis with 
Lauric Acid Hydroxylation and Cytochrome P-452 Content in 
Treated and Untreated Animals.
Lauric Acid
Species Treatment Cytochrome P-452 Hydroxylation
(% of total) 11-hydroxy. 12-hydroxy
(nmol/min/nmol P-450)
Mouse Control 3.30 2.63 5.23
Induced 33.26 7.91 52.68
Rat Control 2.53 2.85 6.14
Induced 24.41 5.47 28.92
Hamster Control 2.04 2.84 4.18
Induced 18.72 6.29 31.27
Guinea Control ND 3.29 1.87
pig Induced ND 4.28 2.92
Rabbit Control 2.71 4.51 8.82
Induced 7.31 4.71 23.37
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a 9- and 2.5-fold induction of cytochrome P-452 content, 
respectively (table 4.15).
In the guinea pig, lauric acid hydroxylation was unchanged on 
treatment and cytochrome P-452 could not be detected 
immunoc hemic ally in hepatic microsomes. The increase in mRNA 
hybridisation to the cytochrome P-452 probe in the guinea pig 
(figure 4.9) was not associated with an increase in 
catalytically active protein. The reason for this apparent 
discrepancy is unclear at present, but may represent a 
post-transcriptional processing event. Accuracy in determining 
RNA concentration (mg/ml) is essential when using visual 
quantitation of autoradiographs where a series of 
concentrations are applied to the filter. On this basis, a 
duplicate filter should be hybridised with a probe to a gene 
product unlikely to be affected by treatment e.g. albumin, 
myosin. This would allow for a more objective analysis of mRNA 
expression to be made and would negate any possible 
inaccuracies in the determined RNA concentrations. An added 
complication in these experiments is the use of a single probe 
to cross-hybridise between species. The assumption is made 
that the rat cytochrome P-452 probe hybridises with equal 
efficiency to mRNA(s) coding for this protein in all species - 
a concept analogous to antigen-antibody affinity. In untreated 
animals the signal was most intense in the rat and as the cDNA 
probe was originally derived from rat liver this probably 
represents an accurate measure of the amount of cytochrome 
P-452 mRNA present. However caution must be exercised when 
making assumptions using low stringency to detect the apparent
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homology between species since the signal intensity here may 
be a combination of the absolute amount of homologous 
sequences in the other species plus a contribution from 
cross-hybridisation of the rat probe with closely related, yet 
heterologous cytochrome P-452 sequences.
It is also possible that under the experimental conditions 
used the cytochrome P-452 cDNA probe hybridised to some extent 
to conserved regions in other cytochrome P-450 mRNAs. Although 
experiments to determine the degree of non-cytochrome 
P-452/P-450 LAw cross-hybridisation have yet to be performed, 
results from other cytochrome P-450 gene family studies would 
indicate that it will make a relatively small contribution to 
the total hybridisation. In the case of the GPX gene this is 
strongly conserved between species, e.g. mouse, rat, cat,
human and bovine forms and cross-species hybridisation is 
specific. The problems of using cDNA probes in the cytochrome 
P-450 system is due to the well documented existence of 
isoenzymes. The cytochrome P-450 superfamily comprises of at 
least 10 gene families, the amino acid sequence of a protein
from any one family being <36% similar to that from the other
9 families. Those cytochromes P-450 genes considered to be in 
the same family have >36% homology, and those in the same 
subfamily have >68% homology (Nebert and Gonzalez,1987). The 
proposed evolution of the cytochrome P-450 gene family is
shown in figure 4.10.
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Figure 4.10
Evolution of the cytochrome P-450 family
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based on rat for families I-IV, cow and human for
families XI, XVII, XIX and XXI; the LI family exists in yeast 
and the Cl family in Pseudomonas (Nebert and Gonzalez, 1987). 
The different isoenzymes are placed in families or subfamilies 
according to the degree of deduced amino acid homology.
The observed homology between different families is primarily 
limited to the active site, a region displaying considerable 
amino acid sequence conservation. The amino acid sequence 
deduced from the full-length cDNA of cytochrome P-450 LAw is 
<33% similar to that encoded by genes in any other family 
(Earnshaw et al.,1988, Hardwick et al.,1987).
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In this study identical procedures were utilised for both 
cytochrome P-452 and GPX hybridisations. If there had been 
sufficient time to optimise hybridisation conditions for both 
probes, several protocols are available for hybridising a 
probe in solution to nucleic acid immobilised on filters. The 
conditions used depend on the purpose of the experiment and in 
general are governed by whether DNA-DNA or DNA-RNA 
hybridisation is involved and whether closely related or 
distantly related sequences are reacting. Reaction conditions 
that permit formation of hybrids which have a high degree of 
mismatching are said to be low stringency while those allowing 
only well matched hybrids to form are said to be high 
stringency (Hames and Higgins, 1985). Conditions favouring the 
detection of well matched hybrids involve high temperatures of 
hybridisation (>42 degrees centigrade in 50% formamide and 6 x 
SSC) combined with washing at higher temperatures and at lower 
salt concentrations. The temperature and salt concentration of 
the washing solution determines which hybrids will remain on 
the filter. In general, washing should be completed under as 
stringent conditions as possible and in practice 60-65 degrees 
centigrade at 0.1 x SSC is usually chosen for hybrids having a 
high degree of homology (75% +) and 42-56 degrees centigrade 
at 0.5-0.2 x SSC for poorly matched hybrids (40-60 %
homology). The washing conditions used in these experiments 
were moderately stringent (0.5 x SSC at 55 degrees centigrade) 
to allow for detection of cross species, reasonably well 
matched hybrids.
The expression of mRNAs coding for cytochrome P-452 and GPX
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has not been previously investigated across species. In the 
present study an increase in mRNA hybridising to the 
radiolabelled cytochrome P-452 cDNA probe was apparent in the 
rat, mouse, hamster and rabbit with a parallel increase in 
cytochrome P-452 levels and activity. A slight increase was 
seen in the guinea pig and this accompanied unchanged lauric 
acid hydroxylation with no immunodetectable protein. The 
absence of increased catalytic activity would suggest that the 
increase in mRNA does not reflect an increased translation of 
the protein.
The mouse genomic GPX probe cross reacted with all species. 
However, the hybridisation procedures have not been optimised 
and as such any changes in mRNA expression resulting from 
treatment could not be discerned. It should be noted that only 
preliminary experiments have been completed and that further 
investigation is required before the precise
inter-relationships between changes in enzyme levels and gene 
expression can be determined and a casual or causal 
association defined.
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4.9 DISCUSSION
The primary aim of this research was to examine and describe 
the short term effects resulting from ciprofibrate treatment 
in different rat strains and different species at a
biochemical and molecular level.
The first objective was to characterise the biological
response in the rat to this hypolipidaemic drug and secondly, 
to clarify the species differences using the rat as the 
reference model. In the rat the induced hepatic responses can 
be sub-divided into;
1) hepatomegaly ; a 1.5 to 2-fold increase in the liver/body 
weight ratio,
2) induction of cytochrome P-452 ; a 6 to 10-fold increase in 
immunodetectable protein with a minimal increase in (omega-1)- 
hydroxylation and a marked induction in the formation of 
12-hydroxylaurate (10 to 16-fold). This correlated to an 
increase in the mRNA species hybridising to the cytochrome
P-452 cDNA probe. The induction of lauric acid
omega-hydroxylase was associated with a marked depression in 
the metabolism of model drug substrates (benzphetamine and 
ethoxyresoruf in).
3) peroxisome proliferation (Lalwani et al.,1983a,b) and 
induction of peroxisomal enzymes; peroxisomal beta-oxidation 
was increased 9 to 34-fold and the specific activity of 
catalase and uricase was unchanged. Total carnitine 
acetyltransferase activity (mitochondrial and peroxisomal) was 
induced 16 to 70-fold.
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4) monoamine oxidase activity was decreased and the specific 
activity of succinate dehydrogenase unchanged. Alpha-glycero­
phosphate dehydrogenase activity was elevated.
5) decreased cytosolic glutathione peroxidase activity,
Gunn rats are unable to esterify bilirubin as this rat strain 
lacks hepatic bilirubin UDPglucuronyltransf erase activity 
(Burchell and Blanckaert,1984). These animals were used in
this study to examine whether modulation of this phase II
enzyme would effect the hepatic toxicity of ciprofibrate. 
Clofibrate and its structural analogues, are hydrolysed to the
free acid (i.e. active compound) prior to conjugation which
gives rise to the acylglucuronide which is rapidly eliminated
in the urine (Emudianughe et al.,1983). Impairment of this 
metabolic pathway could result in an in vivo enhanced response 
to ciprofibrate as this compound would be present only as the
pharmacologically active parent acid. The Gunn rat was the
least responsive rat strain to peroxisome prolif erators 
although the variation in the enzyme parameters tested was 
minimal and the differences were not significant using 
analysis of variation. This would indicate that the enzymic 
capacity for glucuronidation of phenoxyisobutyrates is 
unchanged in the Gunn rat. This has been substantiated by 
recent studies demonstrating that Gunn rats conjugate 
clofibric acid (Burchell and Blanckaert,1984) and that this 
compound specifically induces bilirubin glucuronidation
(Fournel et al.,1986) but not the conjugation of itself (Odum 
and Orton,1983).
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Cytochrome P-450 monooxygenases catalyse the omega- and 
(omega-1)-hydroxylation of fatty acids, arachidonic acid and 
prostaglandins. In rat liver, the isoenzyme cytochrome P-452 
which is induced by peroxisome prolif erators, hydroxylates 
lauric acid and arachidonic acid preferentially at the omega- 
position (Capdevila et al.,1985, Tamburini et al.,1984). 
Hepatic hydroxylation of lauric acid has been reported in the 
rat, rabbit and mouse; the rabbit exhibiting the highest 
activity (Ichihara et al.,1969). Oxidation of laurate at the 
omega-position was observed in guinea pig liver microsomes 
(Kupfer and Orrenius,1970). The administration of PB to rats 
had no effect on omega-hydroxylation of laurate but (omega-1)- 
hydroxylation was elevated 2 to 3-fold (Bjorkhem and 
Danielsson,1970). BNF and 3-MC had no effect on omega- or 
(omega-1)-hydroxylation of lauric acid suggesting that 
distinct cytochrome( s) P-450 mediate the two fatty acid 
hydroxylases in liver microsomes (Okita and Masters, 1980). A 
slight increase in 11-hydroxylation of laurate was seen in the 
mouse and hamster and omega hydroxylation was induced in the 
mouse, hamster and rabbit. In these species it correlated to 
an increase in cytochrome P-452 content and an apparent 
elevation in the mRNA species hybridising to the cytochrome 
P-452 cDNA probe.
Given the high degrees of nucleotide homology within the same 
cytochrome P-450 family, cross hybridisation of cDNA probes 
with more than one homologous mRNA species of similar size 
presents a problem. The cDNA probe to cytochrome P-452 cross 
reacted with all samples indicating a high degree of homology
191
between rat mRNA and that of the different species. With the 
immunochemical ELISA technique, low levels of protein can be 
detected however accessibility of the epitopes to the antibody 
may be affected. Elucidation of the number of related 
cytochrome P-452 mRNA species within a given tissue and
construction of specific cDNA probes is necessary before the
induction role of ciprofibrate at the transcriptional and mRNA 
levels can be deduced. DNA sequences of genomic and cDNA
clones will enable the relationship between cytochromes P-452 
in different tissues, strains and species to be elucidated. It 
should be emphasized that species differences in the
expression of cytochrome P-452 may additionally be 
rationalised by differences in the non-coding, upstream 5' 
regulatory site of the gene. It has been reported that 
transcription of the cytochrome P-450 LAw (i.e.cytochrome 
P-452) gene is elevated as early as 1 hr after clofibrate 
treatment and remains elevated for up to 24 hr ( Hardwick et 
al.,1987). This accompanied a marked increase in the mRNA 
species coding for the protein and immunodetectable protein. 
The specific increase in cytochrome P-450 LAw was due to 
transcriptional activation. Transcriptional activation of 
cytochrome P-450 genes has been observed with PB (Pike et 
al.,1985) and 3-MC (Gonzalez et al.,1984). The GPX probe cross 
hybridised with all 6 species. It was not possible however to 
correlate the decrease in enzyme activity in the rat to 
alterations in mRNA levels and quite clearly further 
experimentation is required.
In the guinea pig and marmoset lauric acid hydroxylation was
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unaffected by ciprofibrate treatment and there was no immuno- 
detectable protein. Immu.)rioquantitation of cytochrome P-452 was 
completed using an antibody raised to the pure protein. This 
antibody did not cross react with the major PB and 3-MC 
inducible cytochromes P-450 and was therefore described as 
monospecific for the clofibrate induced isoenzyme although the 
antibody was polyclonal in origin. When a pure protein is 
injected into an animal a series of antibodies are produced 
which recognise certain components in the antigen. These 
resulting polyclonal antibodies bind to a wide range of 
different epitopes. Monomeric proteins like serum albumin 
carry 10 or more antigenic determinants. Monoclonal antibodies 
(Mabs) are characterised by high specificity for a single 
epitope - often a sequence of 4-7 amino acids - on a protein. 
With cytochrome P-452, the antibody cross reacted with the 
rat, mouse, hamster and rabbit microsomes. The catalytic 
activity of the fatty acid hydroxylase system in the guinea 
pig and marmoset and the lack of cross reactivity with the rat 
cytochrome P-452 antibody using ELISA would indicate a 
fundamental difference between species. Preliminary 
experiments in our laboratory using Western blotting and ELISA 
techniques indicates the presence of a cytochrome P-450 
isoenzyme in human liver biopsy samples. The extent of cross 
reactivity with the cytochrome P-452 antibody suggested the 
existence of a closely related but distinct gene product. In 
these human samples antibody inhibition of lauric acid 
hydroxylation was less extensive than in the corresponding rat 
sample which was commensurate with the above results.
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A Mab to rat liver epoxide hydrolase did not recognise this 
enzyme in hamster, rabbit, monkey or human microsomes 
(Telakowski-Hopkins et al.,1983). However, rabbit polyclonal 
antibodies produced a strong cross reaction with purified 
human liver epoxide hydrolase and a weak to strong reaction 
with the other species. This would suggest that the Mab was 
specific for an epitope present only in the rat protein 
whereas the raised polyclonal antibodies recognised "common" 
antigenic determinants. A series of 9 Mabs raised against 
purified rat liver cytochrome P-450c reacted with 6 different 
epitopes and one of these was shared by cytochrome P-450d 
(Thomas et al.,1984). Two proteins immunorelated to cytochrome 
P-450c and P-450d were observed in the rabbit, hamster, guinea 
pig and C57BL/6J mouse. The conservation of the number of rat 
cytochrome P-450c epitopes among these species varied from 2 
(guinea pig) to 5 (C57BL/6J mouse and rabbit). It is apparent 
that cytochrome P-450 proteins carry several epitopes. These 
may be specific to one isoenzyme or one or more epitopes may 
be shared between haemoproteins forming a family of 
immunochemically related forms (Thomas et al.,1987). Antigenic 
determinants may be conserved across species reflecting the 
extent of sequence homology between cytochrome P-450 
isoenzymes. An advantage of using polyclonal antibodies as 
opposed to Mabs is that antibodies are raised to a variety of 
epitopes thereby increasing the probability of cross reaction 
between species although the specificity is affected. In this 
study the ELISA results suggested that rat cytochrome P-452 
epitopes were shared by the mouse, hamster and rabbit and that 
these were absent in the guinea pig and marmoset. However
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there may be antigenic determinant(s) common to all 6 species 
to which there was no antibody raised. Positive antibody 
binding indicates that the epitopes are present, located on 
the antigen surface and easily accessible to the antibody. Low 
or no binding may be due to either the absence of a cytochrome 
P-450 with an appropriate epitope or inaccessibility of the 
epitope owing to steric hindrance by other microsomal 
components such as reductase or membrane. This latter 
explanation is unlikely as the microsomes were solubilised 
prior to ELISA.
It would be useful to raise a series of Mabs to cytochrome 
P-452 to examine the distribution of the antigenic 
determinants. However, the cDNA probe hybridised to mRNA from 
all 6 species and this would infer that there is considerable 
homology in this cytochrome P-450 isoenzyme between species. 
This is a more sensitive technique than using a polyclonal 
antibody which may be raised to a single epitope on the 
protein which may or may not be conserved across species.
The ratio of 12- to 11-hydroxylaurate was less than 1 in the 
guinea pig and marmoset but this ratio was reversed in the 
species exhibiting cytochrome P-452 induction, measured 
catalytically and immunochemically. It is possible that in the 
guinea pig and marmoset the complement of monooxygenases 
responsible for fatty acid oxidation are different to those in 
the rat. In these latter species, the cytochrome( s) P-450 
display a regioselectivity for (omega-1)-hydroxy lation of 
lauric acid. The incubation of PGA-1 and PGE-1 with guinea pig
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liver microsomes resulted in the corresponding omega- and 
(omega-l)-hydroxylation products; the latter was the major 
route (Kupfer et al.,1.97.8). A possible explanation is that the 
hydroxylation at the two positions are catalysed by different 
enzymes and that there is a higher affinity of PGA-1 for the 
omega-hydroxylation enzyme. The classic inducers, DDT, 
benzapyrene and Aroclor 1254, induced (omega-1)-hydroxylation 
but omega-hydroxylation was unaffected (Kupfer et al.,1979). 
In the rabbit omega- and (omega-1)-hydroxylations are 
catalysed by different cytochrome P-450 isoenzymes
(Theoharides and Kupfer,1981). The km values for 
omega-hydroxylation are lower than for (omega-1)- 
hydroxylation. At low substrate concentrations therefore 
omega-hydroxylation will predominate but at saturating levels 
of substrate, (omega-1)-hydroxylation will be greater
(Kupfer, 1982). A similar system is possible in the guinea pig 
and marmoset where the concentration of laurate could be 
saturating with respect to (omega-1)-hydroxylation giving this 
apparent reversal in regioselectivity. However, in the rabbit 
it appears that the monooxygenases catalysing the 
hydroxylation of PGs are different to those catalysing laurate 
hydroxylation (Theoharides and Kupfer,1981). The
administration of clofibrate and DEHP to rabbits resulted in a
significant and paralleled increase in the PGA-1 omega-
hydroxylase and laurate hydroxylase systems in liver 
microsomes (Yamamoto et al.,1986). Hamster liver microsomes 
convert PGF 2-alpha to 19- and 20 hydroxy products in the 
ratio of 1:2 whereas in the rat the ratio is 10:1 (Powell, 
1978). The hydroxylation of various PGs is evident in
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mammalian species, however the relative ability to form omega- 
vs (omega-1)-hydroxy products varies extensively between the 
species examined. It would seem that the oxidation of fatty 
acids is widely variant, with the guinea pig and marmoset 
displaying regioselectivity towards (omega-1)-hydroxylation. 
No induction of cytochrome P-452, as measured catalytic ally, 
was observed indicating that the omega-hydroxylase system in 
the guinea pig and marmoset is controlled differently to the 
rat at the gene level. The cytochrome P-450 system is 
inducible in these species for example, Aroclor 1254 with the 
guinea pig (Kupfer et al.,1979) and PB in the marmoset 
(Challiner et al.,1980). There was no response to 
ciprof ibrate.
In the mouse a doubling in liver/body weight ratio was 
observed, however in the hamster hepatomegaly was significant 
but minimal. No change was seen in the other species. 
Benzphetamine-N-demethylase activity was decreased in the 
mouse and rabbit and ethoxyresorufin-deethylase activity in 
the mouse alone. Monoamine oxidase activity was decreased in 
the mouse and hamster and increased in the marmoset. The 
specific activity of succinate dehydrogenase and 
alpha-glycerophosphate dehydrogenase was elevated in the 
marmoset. Carnitine acetyltransf erase was induced in the 
mouse, hamster, and rabbit yet was unchanged in the guinea pig 
and marmoset. Catalase was unaffected by treatment except at 
the high dose level in the Sprague Dawley and Wistar strains 
and rabbit, where it was elevated. Uricase was induced at 20 
mg/kg ciprofibrate in the rabbit and activity was decreased in
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the hamster. This enzyme appeared to be absent in the 
marmoset. Peroxisomal beta-oxidation was induced in the mouse, 
hamster and rabbit and was unchanged in the guinea pig. A 
minimal increase was seen in the marmoset and at the high dose 
level activity was comparable to the basal levels in the 
untreated mouse, rat and rabbit. Glutathione peroxidase was 
decreased in the mouse.
The major response in the rat to peroxisome proliferators is 
the coordinate induction of cytochrome P-452, carnitine 
acetyltransferase and peroxisomal beta-oxidation enzymes with 
unchanged/slight increased catalase activity and decreased GPX 
activity. It is apparent that ciprofibrate administration 
results in similar biochemical responses in the rat and mouse 
liver. In the hamster and rabbit, induction of lauric acid 
omega-hydroxylation, peroxisomal beta-oxidation and carnitine 
acetyltransferase was observed. These parameters were 
unchanged in the guinea pig. In the marmoset a slight increase 
in only peroxisomal beta-oxidation was seen. This would 
suggest that the mechanism of induction of peroxisomal 
beta-oxidation in the absence of other enzymatic changes in 
the marmoset is different to the rat which exhibits coordinate 
induction. Hepatomegaly was observed in the mouse, rat and 
hamster but not in the rabbit. However, in the rat induction 
of peroxisomal beta-oxidation dissociated from hepatomegaly 
and peroxisome proliferation has been reported (Lazarow et
al.,1982). The induction of a novel long chain acyl-CoA
/
hydrolase in rat liver by clofibrate, DEHP and acetylsalicylie 
acid has been demonstrated (Miyazawa et al.,1981). The
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induction of two cytosolic hydrolases was later found to occur 
with clofibrate and DEHP administration (Kawashima et
al.,1982) with the activity being greater in male rats than 
females with both peroxisome prolif erators. The induction of 
long chain acyl-CoA hydrolase by clofibrate was studied in 
rats, mice and guinea pigs (Kawashima et al.,1983). Two
hydrolases were detected in rats and one hydrolase was
demonstrated in mice corresponding to the low weight species 
(hydrolase 2). No hydrolase induction was exhibited in the 
guinea pig. DEHP, DEHA, 2,4,5-T, clofibric acid and tiadenol 
induced both hydrolases whereas acetylsalicylic acid and 2,4-D 
induced hydrolase 2 only (Katoh et al.,1984). Induction of 
acyl-CoA hydrolase 2 appeared to be associated with enhanced 
peroxisomal beta-oxidation activity. A selective increase in 
microsomal 1-acyl-glycerophosphoryl choline acy1-transferase 
has been observed with DEHP, clofibric acid, tiadenol and 
acetylsalicylic acid (Kawashima et al.,1984). Treatment with 
clofibric acid increased the activity in mice and rats but not 
in guinea pigs, suggesting a common induction with the long 
chain acyl-CoA hydrolases. Although the role of these enzymes 
in the toxicology of peroxisome prolif erators requires 
elucidation, it is apparent that induction occurs in the rat 
and mouse but not the guinea pig. In the rat, mouse, hamster 
and rabbit induction of cytochrome P-452 is associated with a 
parallel increase in peroxisomal beta-oxidation and carnitine 
acetyltransf erase. It would be of interest to examine the 
induction of long chain acyl-CoA hydrolase in the hamster, 
rabbit and marmoset. It would be tempting to predict enzyme 
induction in the hamster and rabbit but not in the marmoset as
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the guinea pig clearly does not respond in this manner.
The lack of response in the marmoset to ciprofibrate cannot be 
attributed to non/poor absorption of the drug. In the marmoset 
there was a linear relationship between plasma ciprofibrate 
levels and dose. At 50 mg/kg ciprofibrate for a duration of 
fourteen days the concentration of drug in the plasma was 
approximately 230 ug/ml ( Sterling Winthrop, personal 
communication). In the rat, following repeated oral doses of 
30 mg/kg ciprofibrate every 24 hours the plasma level of drug 
was in the range of 300-350 ug/ml (Edelson et al.,1979).
Assuming a linear relationship with dose, this would 
correspond to 200-235 ug ciprofibrate/ml at a dose level of 20 
mg/kg per day in the rat. It is possible to make an assumption 
that the initial plasma levels (measured 4hr post dose) in the 
marmoset at the high dose level (lOOmg/kg) are 1.5 to 2 fold 
higher than that in the rat. The pharmacokinetics of 
ciprofibrate in the other species investigated in this study
has not been examined. The marmoset and guinea pig do not 
exhibit enzyme induction in vivo and in vitro. The species 
differences in the metabolic conjugation of clofibrate and 
clofibric acid have been studied (Emudianughe et al.,1983). 
The rat, guinea pig, rabbit and man form only the ester 
glucuronide. In the rat ciprofibrate is excreted as the free
drug and glucuronide and it is probable that a similar 
metabolic pathway is seen with ciprofibrate in the guinea pig 
and rabbit. It is also assumed that the ester glucuronide of 
ciprofibrate is formed in the hamster and marmoset. The lack 
of induction in the guinea pig and presumably the marmoset is 
not due to reduced bioavailability of the drug i.e lack of
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absorption or to a different route of metabolism.
On the basis of biochemical and immunochemical data, a species 
dependent response occurs with ciprofibrate administration, 
the order of susceptibility being the rabbit < hamster < mouse 
< rat. The marmoset and guinea pig are non-susceptible, 
bearing in mind that the high dose level is 100 mg/kg in the 
marmoset and 20 mg/kg in the other species.
Chapter 5
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COMPARATIVE RESPONSES IN THE RAT AND MARMOSET FOLLOWING 
CHRONIC ADMINISTRATION OF CIPROFIBRATE
5.1 INTRODUCTION
In chapter 4, the species and strain differences in various 
hepatic responses to the short term administration of 
ciprofibrate were studied. The results clearly indicated 
differences in response between species, the order of 
susceptibility being the rat> mouse> hamster> rabbit. The 
marmoset and guinea pig were relatively non-responsive. 
Consequently the study was expanded to investigate the chronic 
effects of ciprofibrate in the Fischer rat and marmoset, in an 
attempt to identify the fundamental differences which may 
exist between rodents and primates. In addition the effect of 
the chronic administration of clofibric acid and bezafibrate 
on microsomal enzyme parameters was investigated in the 
Fischer rat.
An additional group of animals was included in the primate 
study in order to assess the reversibility of the induced 
hepatic responses. Animals in this latter treatment group were 
administered ciprofibrate for 26 weeks and received no further 
treatment for a 4 week recovery period prior to sacrifice at 
30 weeks. The low dose level in the marmoset was 20 mg/kg/day 
and was 80 mg/kg in the high dose level and recovery group. 
Animals in the high dose group i.e. 26 weeks continuous
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treatment (i.e. the non-recovery group) received the maximum 
amount of drug which could be tolerated by the marmoset on a 
daily basis. Initially, a top dose of 100 mg/kg was chosen, 
however during the course of the study this was reduced to 80 
mg/kg at week 21 to maintain the health status of the animals. 
This was based on clinical examination of the animals and was 
indicated by deterioration of general condition, body weight 
loss and lethargy.
The dose levels chosen for the three hypolipidaemic drugs were 
based on comparative lipid lowering potencies derived from 
published data (Sterling-Winthrop, personal communication).The 
objectives of this study were primarily to characterise the 
biochemical, molecular and morphological changes associated 
with the liver in both species and to assess the importance of 
a recovery period following treatment.
5.2 HEPATOMEGALY
In the treated rat, there was a sustained increase in the 
liver/body weight ratio characterised by a maximal 2-fold 
induction with ciprofibrate and a minimal but significant 
increase with clofibric acid (table 5.1). The liver/body 
weight ratio in the marmoset was not affected by ciprofibrate 
treatment at either time point (26 or 30 weeks) (table 5.2). 
The positive response in the rat to ciprofibrate was 
consistent with the published data (Lalwani et al.,1983a,b). A 
similar increase in liver/body weight ratio was seen the 
Wistar rat as opposed to the Fischer rat with bezafibrate and
Table 5.1.
Comparison of Different Hypolipidaemic Agents on Liver Size
and Cytochrome P-450 Content in the Fischer Rat Following
. . .Chronic Administration.
Dose Level Liver/Body weight 
Ratio (%) Tal
Total Cytochrome 
P-450 
Specific Content 
(nmol/mg)
Control 3.10+/-0.24[b] (100)[c] 0.51+/-0.10 (100)
Ciprofibrate 7.19+/-0.31[e ] (232)
(20 mg/kg)
0.41+/-0.03 (82)
Clofibric acid 3.84+/-0.13[d] (124) 0.60+/-0.13 (118)
(50 mg/kg)
Bezafibrate 5.06+/-0.26[e] (163) 0.96+/-0.11[d] (188)
(100 mg/kg)
5|c Single dai ly dose  for 2 6  w e e k s
[a] Data reproduced from table 3.1.
[b] Values are means +/- S.D.
[c] Figures in brackets are values expressed as a % of 
corresponding control.
P values for results significantly different (Students T-Test) 
from control data are [d] p<0.01 and [e] p<0.001.
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clofibrate following a 3 day treatment period (Sharma et 
al.,1988). There is no published data with respect to the 
assessment of liver/body weight ratio in the marmoset 
following chronic administration of peroxisome prolif erators. 
In the Rhesus monkey (Old World) a slight non-significant 
increase was seen in liver weight with DL-040, a newly 
developed peroxisome prolif erator [figure 5.1] (Lalwani et 
al.,1985).
Figure 5.1.
Chemical Structure of DL-040 T4-((( 1,3-benzodioxol)-5-yl) 
methyl)aminobenzoic acid]
0
II
0
C H o - N H
DL -  040
5.3 THE MICROSOMAL DRUG METABOLISING ENZYME SYSTEM
5.3.1 Cytochrome P-450 Content
In the bezafibrate treated rat, an approximate 2-fold 
induction in cytochrome P-450 content was seen (p<0.01) (table
5.1). In the ciprofibrate treated group a non-significant
decrease in the specific content of cytochrome P-450 was 
observed (table 5.1 and 5.2). No significant changes were seen 
at either time point in the marmoset (table 5.2). The basal 
level in the untreated marmoset was lower than that in the 
rat.
In the rat, a dose-dependent increase in cytochrome P-450 
content was seen with clobuzarit treatment, however levels 
were unchanged in the marmoset (Orton et al.,1984). With a 
treatment period of 3 days in the Wistar rat, similar 
increases to that in the Fischer rat with bezafibrate and 
clofibrate, were observed (Sharma et al.,1988).
5.3.2 Benzphetamine -N- Demethylase Activity
A marked decrease in benzphetamine-N-demethylase activity was 
observed in the treated rat (table 5.3). With ciprofibrate, 
activity was 25% of the control value and with clofibric acid 
and bezafibrate administration activity was halved. In the 
marmoset the metabolism of benzphetamine was not significantly 
altered on ciprofibrate treatment (table 5.4). The basal 
activity was greater in the recovery group and there was a 
slight decrease in activity on treatment which was not 
statistically significant due to a large inter-group variation 
in response.
With bezafibrate and clofibrate, a decrease in activity was 
seen in the Fischer rat similar to that in the Wistar rat 
following a 3 day treatment period (Sharma et al.,1988). In
Table 5.3.
Comparison of Different Hypolipidaemic Drugs on the Microsomal
Drug Metabolising Enzyme System in the Fischer Rat
*Following Chronic Administration.
Dose Level Benzphetamine-N- 
Demethylase 
(nmol product/min/ 
nmol P-450)
Ethoxyresorufin- 
O-Deethylase 
(nmol product/min 
/nmol P-450)
Control 25.93+/-2.76[a] (100)[b] 0.02+/-0.01 (100
Ciprofibrate 6.13+/-1.36[e] (24) 0.01+/-0.01[d] (50)
(20 mg/kg)
Clofibric acid 14.31+/-3.91[c] (55)
(50mg/kg)
0.01+/-0.01 (50)
Bezafibrate 12.43+/-1.47[d] (48)
(100 mg/kg)
0.01+/-0.01[d] (50)
& Single daily dose for 26  weeks  
a V a lu e s  a r e  means + / -  S . D .
b Figures in brackets are values expressed as a percentage of 
corresponding control.
P values for results significantly different (Students T-Test) 
from control data are [c] p<0.05, [d] p<0.01 and [e] p<0.001.
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the marmoset this enzyme has not previously been studied using 
benzphetamine as the substrate. An alternative substrate, 
aminopyrine has been used in past studies. With clobuzarit 
treatment, aminopyrine demethylase activity was not 
significantly changed however at the high dose level a slight 
decrease was observed (Orton et al.,1984). Using the classic 
cytochrome P-450b inducer, phenobarbitone, a marked 3-fold 
increase in activity was observed in the marmoset (Challiner 
et al.,1980). It is interesting to note that this 
phenobarbitone induction was not accompanied by an increase in 
liver mass as has been observed in other species.
5.3.3 Ethoxyresorufin-O-Deethylase Activity
In the rat, ethoxy resorufin-O-deethylase activity was halved 
(table 5.3). In the marmoset, activity was unaffected by 
ciprofibrate treatment (table 5.4), although the inter-group 
variation in response was marked and no apparent trends could 
be detected.
In the Wistar rat the decrease in ethoxyresorufin-O- 
deethylase activity resulting from a 3 day clofibrate and 
bezafibrate treatment, was greater than that in the Fischer 
rat following chronic administration with these compounds 
(Sharma et al.,1988). Activity was unchanged in the marmoset 
following the administration of clobuzarit (Orton et 
al.,1984).
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5.3.4. Induction of Cytochrome P-452
The induction of cytochrome P-452 was assessed catalytically 
and immunochemically in liver microsomes. In the rat there was 
a slight increase in the 11-hydroxylation of lauric acid in 
treated animals which was significant with bezafibrate and 
clofibric acid (table 5.5). The 12-hydroxylation of lauric 
acid was induced, 8-, 12- and 20-fold with clofibric acid,
bezafibrate and ciprofibrate, respectively (table 5.5). In the
marmoset, the 11-hydroxylation of lauric acid was
significantly decreased to 60% of the control value at the 
high dose level at 26 weeks and in the recovery group (figure 
5.2). At the high dose level at 26 weeks lauric acid 
12-hydroxylase activity was significantly decreased to 60% of 
the control value.
The increase in the formation of 11-hydroxylaurate in the 
Fischer rat was in the order of 2.25 to 2.5-fold with 
clofibric acid and bezafibrate. This was less marked in the 
Wistar rat following a 3 day treatment period (Sharma et
al.,1988). A similar differential induction was seen with the
12-hydroxylation of lauric acid. With clobuzarit treatment, 
total lauric acid hydroxylation (11- and 12-) was unchanged in 
the marmoset (Orton et al.,1984). The (omega-1)-oxidation 
product of ME HP, the metabolite VI active in the rat, had no 
effect (in vitro) on marmoset hepatocytes (Elcombe and 
Mitchell,1986). In these latter 2 studies, total lauric acid 
hydroxylation was measured. In the current study the omega- 
and (omega-l)-hydroxy products were separated and quantitated
Table 5.5.
Comparison of Hypolipidaemic Drugs On Lauric Acid Hydroxylase
ftActivity in the Fischer Rat Following Chronic Administration.
DOSE LEVEL LAURIC ACID HYDROXYLASE ACTIVITY 
(nmol product per min per nmol P-450)
11-hydroxy laurate 12-hydroxy laurate
Control 2.13+/-0.51[a] (100)[b] 2.80+/-0.24 (100)
Ciprofibrate 6.74+/-3.80 (316)
(20 mg/kg)
57.7+/-11.3[d] (2060)
Clofibric Acid 4.74+/-0.98[c] (223) 
(50 mg/kg)
23.2+/-5.17[d] (829)
Bezafibrate 
(75 mg/kg)
5 .55+/-0.27[e] (261 32.7+/-2.43[e ] (1167
[a] Values are means +/- S.D.
[b] Figures in brackets are values expressed as percentage 
of corresponding control.
P values for results significantly different (Students T-Test) 
from control data are [c] < 0.05, [d] < 0.01 and [e] < 0.001.
#  Single daily dose for 26  weeks
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Figure 5.2.
The Effect of Ciprofibrate on Lauric Acid Hydroxylase Activity 
in the Rat and Marmoset Following Chronic Administration.
LEGEND
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500
RAT.F-344 MARM. 26 WKS HARM. REC
CONTROL 
L.D. 11-OH 
L.D. 12-OH 
JH.D. 11-OH 
1 H.D. 12-OH
( COHTR0L=100 )
SPECIES 
6 MONTH TREATMENT
Legend: L.D.11-OH Low Dose 11-hydroxylaurate
L.D.12-OH Low Dose 12-hydroxylaurate
H.D.ll-OH High Dose 11-hydroxylaurate
H.D.12-OH High Dose 12-hydroxylaurate
See following page for the absolute values and dose levels.
Figure 5.2.(cont.)
Absolute Values (control);
Species/ nmol hydroxyproduct formed/min/nmol P-450
Dose Group 11-hydroxylaurate 12-hydroxylaurate
2.80 +/.- 0.24 
2.50 +/- 0.32 
3.07 +/- 1.84
Rat [a] 2.13 +/- 0.51
Marmoset (26 wks) 12.31 +/- 2.00
Marmoset (4 wk rec.) 11.57 +/- 1.50
Dose Levels;
Low Dose Marmoset (26 wks): 20mg/kg
High Dose Rat: 20mg/kg
Marmoset(26 wks): 80-100mg/kg
Marmoset(4 wks rec.): 80mg/kg
Single daily dose
[a] Data reproduced from table 5.5.
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individually. In the untreated rat, the ratio of 12- to 
11-hydroxylaurate was greater than 1 (1.30) however in the
marmoset this was reversed (0.20-0.30). The omega-1 
hydroxylation of lauric acid predominated in the marmoset.
In the rat, cytochrome P-452 content, expressed as the 
specific content (nmol/nmol P-450), was induced on 
hypolipidaemic treatment and this was in the order of 18-, 11- 
and 8-fold for bezafibrate, ciprofibrate and clofibric acid 
(figure 5.3). When cytochrome P-452 content was expressed as 
percentage of total cytochrome P-450, it was markedly 
increased on treatment. The induction was 13-, 9- and 6.5-fold 
with ciprofibrate, bezafibrate and clofibric acid respectively 
(figure 5.4). It should be noted that the specific content of 
cytochrome P-450 was increased with clofibric acid and 
bezafibrate yet was non-significantly reduced with 
ciprofibrate treatment. This would account for the cytochrome 
P-452 content, expressed as percentage of total, being highest 
in the ciprofibrate treated animals yet the specific content 
being lower than the bezafibrate treated animals. Cytochrome 
P-452 was not detected immunoc hemic ally in marmoset liver 
microsomes (the minimal level of detection was an absorbance 
change of double the blank reading corresponding to 0.002 
pmoles/well).
In the untreated rat, cytochrome P-452 constitutes 3-4% of the 
total CO-discernible cytochrome P-450 population. With a 3 day 
clofibrate treatment period this was increased to 22-25% in 
the Wistar rat (Sharma et al.,1988).This is comparable to the
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Figure 5.3.
Comparison of Different Hypolipidaemic Agents on Cytochrome
P-452 Specific Content in the Rat Following Chronic
Administration.
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Figure 5.4.
Comparison of Different Hy.poJLipidaemic Agents on Cytochrome 
P-452 Content in the Rat Following Chronic Administration
Cytochrome P-452 Content; nmol cyt. P-452 as percentage of
total cytochrome P-450.
( See figure 5.3 for absolute values)
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present study where chronic clofibric acid administration 
caused an increase to 24%. In bezafibrate treated animals 
cytochrome P-452 content constituted 33-35% of the total and 
ciprofibrate 45-50%.
5.4. MITOCHONDRIAL ENZYME LEVELS
5.4.1 Monoamine Oxidase Activity.
In the rat, monoamine oxidase activity was significantly 
decreased by ciprofibrate treatment to 55-60% of the control 
value (figure 5.5). Activity in the marmoset was unchanged by 
treatment although a slight non-significant increase was seen 
at both dose levels with 26 weeks ciprofibrate administration 
(figure 5.5).
5.4.2 Succinate Dehydrogenase Activity.
In the rat, succinate dehydrogenase activity was elevated on 
ciprofibrate treatment (figure 5.6). In the marmoset there was 
a dose-dependent increase in enzyme activity and which was 
significant at both dose levels (figure 5.6). The increase in 
enzyme activity was significant in the recovery group although 
induction was less extensive than in the 26 week dose groups.
Figure 5.5.
The Effect of Ciprofibrate on Mitochondrial Monoamine Oxidase
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Activity in the Rat and Marmoset Following Chronic
Administration.
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Figure 5.6.
The Effect of Ciprofibrate on Mitochondrial Succinate
Dehydrogenase Activity in the Rat and Marmoset Following
Chronic Administration.
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5.4.3 Alpha-glycerophosphate Dehydrogenase Activity
Alpha-glycerophosphate dehydrogenase activity was
significantly induced 2-fold in the rat by ciprofibrate
(figure 5.7). With a 26 week ciprofibrate administration in 
the marmoset, enzyme activity was increased in a 
dose-dependent manner and the 2-fold increase at the high dose
level was significant (figure 5.7). In the recovery group
where treatment was discontinued for 4 weeks prior to 
sacrifice, alpha-glycerophosphate dehydrogenase activity was 
unchanged.
5.5. MITOCHONDRIAL AND PEROXISOMAL CARNITINE
ACETYLTRANSFERASE ACTIVITY.
In the rat, a 64-fold induction in total carnitine 
acetyltransferase activity was observed with ciprofibrate 
pretreatment (figure 5.8). In the marmoset, enzyme activity 
was unchanged by treatment (figure 5.8) and in the recovery 
group values were similar to control. The observed increase in 
the rat was consistent with the published report of a 58-fold 
increase following the dietary administration of ciprofibrate
for 14 days (Lalwani et al.,1983b). This enzyme has not 
previously being measured in the marmoset. However, a newly 
developed peroxisome proliferator DL-040 (as shown in figure
5.1) induced this enzyme in the Rhesus monkeys (Lalwani et 
al.1985) and ciprofibrate administration was reported to 
increase enzyme activity in the Rhesus and Cynomolgus monkey 
(Reddy et al.1984).
Figure 5.7.
The Effect of Ciprofibrate on Mitochondrial 
Alpha-Glycerophosphate Dehydrogenase Activity in the Rat and
Marmoset Following Chronic Administration.
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Figure 5.8.
The Effect of Ciprofibrate on Total Carnitine 
Acetyltransferase Activity in the Rat and Marmoset Following
Chronic Administration.
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223
5.6 PEROXISOMAL ENZYME ACTIVITIES
5.6.1 Catalase Activity.
Catalase activity was significantly decreased to 50% of the 
control activity in the rat following the chronic 
administration of ciprofibrate (table 5.6). In the marmoset, 
catalase activity was unaffected by treatment at both time 
points. A 2-fold increase in total liver catalase activity has 
been reported in the Fischer rat following the dietary 
administration of ciprofibrate (0.10% w/w) (Lalwani et 
al.,1983a,b). With the short term administration of 
ciprofibrate it was found that the specific activity of 
catalase was unchanged in the Fischer rat but that the 
doubling in liver/body weight ratio accounted for the reported 
2-fold increase in total liver catalase activity. However, 
with the chronic administration of ciprofibrate, hepatomegaly 
was maintained and the specific activity of catalase decreased 
indicating that synthesis of catalase was not maintained. 
Catalase activity was unaffected by clobuzarit administration 
in the marmoset (Orton et al.,1984), but in the DL-040 treated 
Rhesus monkey catalase activity was reported to be doubled 
(Lalwani et al.,1985).
5.6.2 Peroxisomal Beta-Oxidation.
In the rat, ciprofibrate treatment resulted in a significant 
35-fold induction in peroxisomal beta-oxidation (figure 5.9). 
With a 26 week ciprofibrate treatment in the marmoset, a
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Figure 5.9.
The Effect of Ciprofibrate on Peroxisomal Beta-Oxidation in
the Rat and Marmoset Following Chronic Administration.
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significant dose-dependent increase in peroxisomal 
beta-oxidation was observed (3.5-fold) although this 
represented a response considerably lower than that in the rat 
(figure 5.9). In the marmoset recovery group activity was 
similar to control levels.
Comparing the above data to that previously reported, a 
14-fold increase in peroxisomal beta-oxidation in the Fischer 
rat was observed following the short term dietary 
administration of ciprofibrate (0.10% w/w) (Lalwani et 
al.,1983b). In contrast, clobuzarit (45 mg/kg) treatment in 
the marmoset did not induce peroxisomal beta-oxidation (Orton 
et al.,1984). Consistent with the above, is the report that 
the (omega-1)-oxidation product of ME HP induced peroxisomal 
beta-oxidation in rat hepatocyte cultures yet had little 
effect on marmoset hepatocytes (Elcombe and Mitchell, 1986). A 
slight increase was observed but this was not dose-dependent. 
Using excessively high doses of ciprofibrate, an increase in 
peroxisomal beta-oxidation was demonstrated in the Rhesus and 
Cynomolgus monkey (Reddy et al.,1984). In a similar manner 
DL-040 induced peroxisomal beta-oxidation in the Rhesus monkey 
(Lalwani et al.,1985). The administration of LY-171883, 
(tetrazole-substituted alkoxyacetophenone, figure 5.10), a 
rodent peroxisome proliferator, to Rhesus monkeys at the 
maximum tolerated dose revealed no changes in peroxisomal 
beta-oxidation or catalase levels (Eacho et al.,1986). In the 
current study the maximal 3.5-fold increase in peroxisomal 
beta-oxidation in the marmoset was clearly of much less 
significance when compared to the 34-fold induction in the
227
Figure 5.10.
Chemical Structure of LY- 171883, a Tetrazole-Substituted
;scher rat considering the dose levels were 20 and 80-100 
/kg for the rat and marmoset, respectively.
5.6.3 Uricase Activity
Uricase activity in the rat was unaffected by the chronic 
administration of ciprofibrate (table 5.6). In these studies 
in the marmoset no uricase activity could be detected in 
contrast to the Rhesus monkey (Old World genus) where an 
increase in uricase activity was observed following 
ciprofibrate and DL-040 administration (Reddy et al.,1984, 
Lalwani et al.,1985).
5.7 CYTOSOLIC GLUTATHIONE PEROXIDASE ACTIVITY.
Glutathione peroxidase activity was measured using 
t-butylhydroperoxide as the substrate. In the rat, treatment
Alkoxyacetophenone
0 
II
H
228
with ciprofibrate and bezafibrate resulted in a significant 
decrease in enzyme activity (65 and 78% of the control value 
respectively) (table 5.7 and figure 5.11). By comparison, 
glutathione peroxidase activity was unchanged in the rat 
following clofibric acid administration. In the marmoset 
enzyme activity was unchanged by ciprofibrate treatment (table 
5.7).
5.8 THE MOLECULAR BIOLOGY OF CYTOCHROME P-452 AND
GLUTATHIONE PEROXIDASE
As shown previously (chapter 4), ciprofibrate administration 
to the rat resulted in the induction of cytochrome P-452, as 
measured catalytically and immunochemically. In addition, 
following a 14 day treatment period this induction correlated 
to a marked increase in the amount of mRNA hybridising to the 
cytochrome P-452 cDNA probe. It was not possible to correlate 
the decrease in glutathione peroxidase activity with gene 
expression as technical difficulties were encountered using 
this glutathione peroxidase probe (chapter 4).
Tissue from chronically treated rats and marmosets was limited 
and in the following studies was unsupported by biochemical 
and immunochemical data in the rat. It should be remembered 
that the objective at the start of the research work was to 
examine species and strain differences at a biochemical level 
only and that the decision to implement a molecular approach 
to study species susceptibility was a late development.
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Comparison of Different Hypolipidaemic Agents on Cytosolic
Glutathione Peroxidase Activity in the Fischer Rat Following
Chronic Administration.
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Total hepatic RNA was isolated from;
1) frozen tissue from untreated Fischer rats and animals from 
the following treatment protocols; ciprofibrate - 20 mg/kg by 
gavage once every 48 hr., clofibric acid - 75 mg/kg by gavage 
twice a day and bezafibrate - 150 mg/kg by gavage twice a day. 
The twice daily administration was separated by 8-12 hr and 
the duration of treatment was 9 months. With a similar dosing 
regimen for 6 months it was found that the relative potencies 
of the compounds were similar with respect to mitochondrial,
peroxisomal and cytosolic enzyme parameters (chapter 3).
Unfortunately there was no data at this 9 month time point 
however the effects at 6 months with daily dosing were very 
similar to that at 2 weeks and it was therefore assumed that 
lauric acid hydroxylase activity and cytochrome P-452 were 
probably elevated in the treated groups and glutathione
peroxidase activity decreased.
2) untreated and treated marmoset frozen tissue. The treatment 
period was 26 weeks with daily dosing at 80-100 mg/kg (100 
mg/kg for 21 weeks with the final 5 weeks at 80 mg/kg).No
samples were available from the recovery group.
Duplicate RNA dot filters were prepared using the isolated RNA 
with the following concentrations: 0.01, 0.10. 1, 10 and 20 ug
RNA/dot. The filters were hybridised with the cytochrome P-452 
cDNA and genomic GPX probes which hybridised to all the RNA 
samples (figures 5.12 and 5.13). In the rat, the levels of 
mRNA coding for cytochrome P-452 were markedly increased in 
treated animals (figure 5.12). By inspection, it appeared that
232
Figure 5.12.
The Effect of Ciprofibrate, Bezafibrate and Clofibric Acid
Treatment on Hepatic Cytochrome P-452 mRNA Concentration in 
the Rat and Marmoset After A 26 Week Administration Period.
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the intensity of the hybridisation to RNA dots from the 
clofibric acid and bezafibrate treated rats appeared to be 
slightly higher than that in the ciprofibrate sample but as 
mentioned previously more accurate comparisons could not be 
made. It should be noted that in acutely treated rats the 
increase in the concentration of mRNA hybridising to the 
cytochrome P-452 cDNA probe accompanied a marked induction of 
lauric acid omega-hydroxylase enzyme activity and an increased 
cytochrome P-452 specific content (chapter 4). In the marmoset 
there was a minimal increase in the hybrid intensity in the 
treated animal indicating a slight increase in the mRNA coding 
for cytochrome P-452 (figure 5.12). However, this accompanied 
no immunodetectable cytochrome P-452 protein and a 4 0 and 60% 
decrease in (omega-1)- and omega-hydroxylation of lauric acid, 
respectively. Accordingly, this apparent increase in mRNA 
hybridising to the probe did not appear to correspond to 
increased translation of catalytically active protein.
The genomic GPX probe cross-hybridised with both the rat and 
marmoset (figure 5.13). In the ciprofibrate and clofibric acid 
treated rats the intensity of hybridisation was very similar 
or slightly less intense than the control sample suggesting 
treatment-induced differences in glutathione peroxidase mRNA 
synthesis. By comparison in the bezafibrate treated animal, 
the hybridisation response did not appear to be a linear 
function of the RNA loaded and was clearly more intense than 
the control sample. In both control and ciprofibrate treated
with the
marmosets a non-linear hybridisation was 
(figure 5.13).
probe
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Figure 5.13.
The Effect of Ciprofibrate, Bezafibrate and Clofibric Acid on
Hepatic Glutathione Peroxidase mRNA Concentration in the Rat 
and Marmoset After A 26 Week Administration Period.
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The evaluation of changes in hybrid signal intensity should be 
made with caution especially when low amounts of radioactivity 
are involved. Accuracy in determining RNA concentrations is of 
paramount importance. It should be emphasized that these 
experiments with the GPX probe were preliminary and that 
further experimentation is required to;
1) optimise hybridisation conditions,
2) complete biochemical and immunochemical analyses, and,
3) use more animals instead of making comparisons between one 
untreated and one treated animal.
As described in chapter 4, the GPX gene is strongly conserved 
between species whereas the cytochrome P-450 system comprises 
of at least 10 gene families.
With respect to hybridisation with the cytochrome P-452 cDNA 
probe, two assumptions are made;
1) the cytochrome P-452 probe hybridises equally to mRNA(s) 
coding for this protein in the rat and marmoset, and
2) the cDNA probe does not hybridise to other cytochrome P-450 
mRNA(s) to any great extent. It has been established that in 
the rat, clofibrate administration resulted in a 5 to 7-fold 
increase in cytochrome P-450 LAw (P-452) mRNA levels which 
closely paralleled the increase in immunodetectable protein 
(Hardwick et al.,1987). This accompanied a marked elevation in 
the transcription of the cytochrome P-450 LAw gene. One would 
assume a similar transcriptional activation in the rat with 
ciprofibrate treatment as a marked increase in mRNA 
hybridising to the probe with an associated induction of 
cytochrome P-452, measured catalytically and immunochemically,
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was observed. The small increase in cytochrome P-452 mRNA in 
the marmoset was accompanied by a reduction in catalytic 
activity and no immunodetectable protein, indicating that 
there was no increase in mRNA translation. This implies that a 
distinct species difference in gene expression and regulation 
exists.
5.9 DISCUSSION
The main objective of these studies was to examine and 
describe the chronic effects resulting from ciprofibrate 
treatment in the rat and marmoset. The biological response in 
the rat following short term administration has been 
documented in the previous chapter. In summary, the chronic 
hepatic responses in the rat are;
1) hepatomegaly,
2) an induction of cytochrome P-452 with an associated 
decrease in the metabolism of model drug substrates,
3) increased peroxisomal beta-oxidation, unchanged catalase 
activity and induction of total carnitine acetyltransferase 
activity,
4) mitochondrial enzyme changes, and
5) decreased glutathione peroxidase activity.
Essentially, the short term responses are duplicated in the 
chronically treated rat. Hepatomegaly and the observed 
cytochrome P-450 changes persisted in animals treated with all 
three hypolipidaemic agents. An increase in the 
11-hydroxylation of lauric acid was apparent but this was not 
significant with ciprofibrate. The specific activity of
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catalase was halved in the ciprofibrate and bezafibrate 
treated animals. With a 14 day treatment period, monoamine 
oxidase activity was decreased, succinate dehydrogenase 
activity unchanged and alpha-glycerophosphate dehydrogenase 
activity increased. A similar series of enzyme changes were 
seen in chronically treated animals except that succinate 
dehydrogenase activity was increased in the ciprofibrate 
treated group. Glutathione peroxidase activity was decreased 
with ciprofibrate and bezafibrate treatment but not with 
clofibric acid.
It is instructive for the purposes of this discussion to 
reiterate the acute hepatic changes occurring in the marmoset;
1) an increase in monoamine oxidase, succinate dehydrogenase 
and alpha-glycerophosphate dehydrogenase activities,
2) a 3.5 fold increase in peroxisomal beta-oxidation and no 
apparent uricase activity suggesting that the marmoset is a 
member of a New World genus devoid of this enzyme, and,
3) an increase in total cytochrome P-450 specific content 
associated with a decrease in benzphetamine-N-demethylase 
activity and unchanged lauric acid hydroxylation and 
ethoxyresorufin-O-deethylase activity. Cytochrome P-452 was 
not detected immunochemically.
It should be noted that the regioselectivity in lauric acid 
hydroxylation was different in the rat and marmoset with 11 - 
hydroxylation predominating in the marmoset. With 2 6 weeks 
continuous ciprofibrate treatment, the increases in succinate 
dehydrogenase and alpha- glycerophosphate dehydrogenase
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activities were maintained. A slight non-significant elevation 
in monoamine oxidase activity was observed. Similarly a 3.5 
fold increase in peroxisomal beta-oxidation was apparent but 
the specific content of cytochrome P-450 was unchanged on 
treatment. The hydroxylation of lauric acid was significantly 
decreased at both positions in the high dose group. In the 
recovery group (26 weeks treatment at 80-100 mg/kg/day
followed by 4 weeks with no treatment), a minimal but 
significant increase in succinate dehydrogenase activity 
persisted and the 11-hydroxylation of lauric acid was
similarly decreased 60% of the control value.
It is clear that marked differences exist between the rat and 
marmoset. In both species the hepatic changes resulting from 
chronic administration were very similar to the responses 
observed with short term treatment. In the rat the fundamental 
change was in catalase activity. The specific activity was 
unchanged at 2 weeks but this was associated with a doubling 
in liver/body weight ratio which would account for the 
published 2-fold induction in total catalase activity (Lalwani 
et al.,1983b). At 26 weeks, the specific activity was halved 
although hepatomegaly was maintained suggesting that with 
chronic administration, synthesis of new protein does not
occur or that the proliferated peroxisomes contain very low 
enzyme levels. The toxicological implications arising from the 
observed decrease in catalase activity are discussed in 
chapter 7. The difference in regioselectivity of lauric acid 
hydroxylation in the marmoset may be the result of enzyme 
kinetics dependent on substrate concentration for the
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competing omega- and (omega-1)-fatty acid hydroxylases.
A subchronic (3 month) toxicity study was completed in the 
Fischer rat with dose levels of 0.4, 1.6, 6.4, 25 and 100
mg/kg/day ciprofibrate (Sterling-Winthrop, personal
communication). In terms of liver weight, a no-effect dose 
level was not achieved as hepatomegaly was observed in all 
groups. No biochemical analyses were completed but increased 
lauric acid hydroxylation and peroxisomal beta-oxidation was 
assumed to occur as hepatomegaly has always been associated 
with enzyme changes but not vice versa (Lazarow et al.,1982). 
In the 2 week ciprofibrate study, a marked increase in 
peroxisomal beta-oxidation, carnitine acetyltransferase 
activity and cytochrome P-452 content was observed at 2 mg/kg. 
The pharmacokinetic dose response relationship in the rat for 
2 and 20 mg/kg was not linear (figure 5.14). This would 
indicate that the 2 mg/kg dose level was on the plateau region 
of the dose-response curve. In figure 5.15, it is apparent 
that following a 3 month continuous ciprofibrate treatment, 
the plasma concentration in rats administered 25 and 100 
mg/kg/day ciprofibrate was very similar 24 hr post dose 
indicating that as the dose increases, absorption decreases 
(Sterling-Winthrop personal communication). Steady state 
levels were achieved within 7 days with once daily dosing 
(Sterling-Winthrop, personal communication). This would 
suggest that the drug absorption capacity was saturated at 
high dose levels. In the marmoset, the high dose level of 
80-100 mg/kg ciprofibrate would likewise appear to correspond 
to a maximal dose/response relationship (figure 5.16) and
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Figure 5.14.
Dose Response Curve in the Fischer Rat Following the Short
. . ^Term Administration of Ciprofibrate.
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Figure 5.15.
Plasma Concentrations of Ciprofibrate in Albino Rats Medicated 
Orally Once a Day For 3 Months.
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Figure 5*16.
Dose Response Curve in the Marmoset Following the Short Term
Administration of Ciprofibrate.
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it should be emphasized that the dose level was the maximal 
tolerated dose on a daily basis.
A 13 week recovery period was incorporated into the 3 month 
rat study (Sterling-Winthrop, personal communication). Slight 
histopathological liver changes were seen in the 25 and 100 
mg/kg dose levels, 13 weeks following cessation of treatment. 
The hepatic enlargement and eosinophilic change in the
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cytoplasm of hepatic parenchymal cells seen in this study were 
similar to those described by Paget,(1959). In another study, 
animals were treated with ciprofibrate (0.2, 1, 5 and 25
mg/kg) for 6 months followed by a 3 month recovery period 
(Sterling Winthrop, personal communication). With respect to 
liver weight, a no-effect dose was not achieved and 
significant liver enlargement was seen at 25 mg/kg 13 weeks 
following the cessation of treatment. It is unfortunate that 
no biochemical analyses were completed to ascertain the 
relationship between hepatomegaly and enzyme levels following 
an extensive recovery period. However, reversal of biochemical 
parameters has been reported in rats administered clofibrate 
for 14 days with a 6 day recovery period prior to sacrifice 
(Orton et al.,1982). Cytochrome P-450 content and 
ethoxycoumarin deethylation were still significantly increased 
and the inhibition of ethoxyresorufin O-deethylation was 
reversed. The liver enlargement was maintained unchanged for 6 
days after treatment (Orton et al.,1982). Peroxisomal 
beta-oxidation, carnitine acetyltransf erase and lauric acid 
hydroxylase assays were not completed. The increases in liver 
weight and peroxisomal beta-oxidation in the rat resulting 
from a 14 day treatment period with LY-171883 were reversed 
within 16 days of discontinuing treatment (Eacho et al.,1986). 
In this study the increase in peroxisomal beta-oxidation in 
the marmoset was readily reversible following a 4 week 
recovery period although mitochondrial succinate dehydrogenase 
and microsomal (omega-1)-lauric acid hydroxylase activities 
were still Effected (p<0.05).
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Total hepatic RNA was isolated from rats treated with
clofibric acid (2 x 24 hr), bezafibrate (2 x 24 hr) and
ciprofibrate (1 x 48 hr) for a period of 9 months and from
untreated and ciprofibrate treated marmosets. The samples were 
hybridised with the cytochrome P-452 cDNA and GPX genomic 
probes. A marked increase in the mRNA hybridising to the 
cytochrome P-452 cDNA probe was observed in the treated rat 
samples. A slight increase in the treated marmoset was 
apparent but this did not correlate to increased catalytic 
activity and was associated with no immunodetectable protein. 
No clear treatment differences were visible with hybridisation 
to the GPX genomic probe. The inability to detect cytochrome 
P-452 in marmoset liver microsomes using an immunochemical 
technique (ELISA) was discussed in the previous chapter.
In the rat, transcription of the cytochrome P-450 LAw (P-452) 
gene was elevated as early as 1 hr after clofibrate treatment 
and this accompanied an increase in the mRNA species coding 
for the protein and increased levels of immunodetectable 
protein (Hardwick et al.,1987). A similar transcriptional 
activation of the gene is assumed in the rat treated with 
ciprofibrate and bezafibrate. The apparent, albeit small 
increase in mRNA-cDNA hybridisation for cytochrome P-452 in 
the treated marmoset was not accompanied by an increase in 
catalytically active protein. It is possible that either the 
level at which cytochrome P-452 gene expression is controlled 
is different in the two species, e.g. ribosome selection among 
mRNAs, mRNA degradation control or, more likely, that the 
small increase in mRNA synthesis was insufficient to give a
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marked increase in active enzyme. It should be remembered that 
the control of gene expression is multifaceted with complex 
regulatory mechanisms.
The peroxisome prolif erator-induced cytochrome P-452 is a 
member of the cytochrome P-450IV gene family and the amino 
acid sequence is <33% similar to that encoded by genes in any 
of the other 7 mammalian P-450 gene families (Hardwick et 
al.,1987). The rat cytochrome P-452 cDNA probe hybridised with 
mRNA from 6 different species (treated and untreated animals) 
indicating that cytochrome P-452 is a constitutive form with 
strong gene conservation across species. By comparison, liver 
microsomes prepared from rabbit, hamster, gerbil and mouse 
contain inducible cytochrome(s) P-450 that resemble cytochrome 
P-450p (rat liver cytochrome P-450 induced by steroids), both 
catalytically and immunoc hemic ally (Wrighton et al.,1985). 
These proteins were encoded for by mRNAs of sufficient 
homology to hybridise specifically to cloned cDNAs to P-450p 
mRNA. However in this case, there were striking qualitative 
and quantitative interspecies differences in the responses to 
inducers (Wrighton et al.,1985). In all species examined there 
was a notable disparity in the magnitude of induction of 
immunoreactive protein as compared to catalytic activities 
with immunoreactive protein exceeding enzyme activity. In the 
current studies the reverse was true for the rat chronically 
treated with ciprofibrate, bezafibrate and clofibric acid and 
in the hamster following a 14 day treatment period. With short 
term ciprofibrate administration, the increase in 
immunodetectable protein matched the induction of
omega-hydroxylation in the mouse, rabbit and Long Evans rat. 
In the remaining rat strains the induction of cytochrome P-452 
measured catalytically exceeded that determined
immunoc hemic ally. These strain and species differences may be 
explained by unequal synthesis of the apoprotein and 
holocytochrome.
The conservation of highly homologous gene sequences across 
species is well documented . in the cytochrome P-450 
monooxygenase system (Nebert et al.,1987). The existence of at 
least two cytochrome P-450 genes in humans that are highly 
homologous to the TCDD-inducible cytochromes P-450 in rabbits 
and mice has been demonstrated (Quattrochi et al.,1985). 
Regions known to be highly conserved in cytochrome P-450 
isoenzymes isolated from rat, rabbit and mouse were found to 
be conserved in the amino acid sequence derived from pHP450(l) 
[cDNA clone to PB-inducible cytochrome P-450e] (Philips et 
al.,1985). TCDD induced P-4504 and P-4506 mRNAs in the rabbit 
and the sizes of these mRNAs differed from their analogues in 
the mouse as a result of divergence in the 3' untranslated 
portions of the mRNAs (Okino et al.,1985).
In general the control of protein synthesis may be due to 
transcription, processing, transport, translation or 
degradation of mRNA. The control of gene expression seems to 
operate at the level of DNA transcription i.e. the synthesis 
of the primary pre-mRNA transcript. This is thought to involve 
a relatively small set of gene regulatory proteins e.g. growth 
factors, differentiation factors, receptors, DNA-binding
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proteins etc., that modulate mRNA synthesis in order to 
produce and maintain a large number of different cell and 
tissue types. The actual mechanisms by which most eukaryotic 
gene regulatory proteins act are not clearly defined. However 
chromatin must be selectively decondensed prior to 
transcription, and this is probably the primary role of gene 
regulatory proteins. Other further levels of control of gene 
expression have now been documented for the cytochrome P-450 
superfamily. For example, PB and 3-MC elevate the level of rat 
liver glutathione S-transferases primarily by augmenting the 
transcriptional rates of their respective genes (Ding and 
Pickett, 1985), possibly by enhancing RNA polymerase binding. 
On the other hand, nuclear RNA transport has been implicated 
in the regulation of cytochrome P-450c induction (Foldes et 
al.,1985). In diabetic rats cytochrome P-450j mRNA increased 
10-fold but this was not due to transcriptional activation but 
rather to specific stabilisation of the cytochrome P-450j mRNA 
(Song et al.,1987). To assess the conservation of the 
cytochrome P-452 gene between species requires further 
investigation, and the precise molecular mechanisms governing 
gene expression, the influence of peroxisomal proliferators on 
DNA binding proteins, transcriptional activation and mRNA 
accumulation need to be clarified. The functional control of 
the peroxisomal beta-oxidation enzymes and glutathione 
peroxidase genes are clearly areas that need to be examined.
The administration of Wy-14,643 to the rat causes a marked 
increase in the concentration of mRNA species coding for the 
bifunctional protein - 3-ketoacyl-CoA thiolase and enoyl-CoA
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hydratase (Chatter jee et al.,1983). In DEHP treated animals, 
the hepatic levels of translatable mRNAs coding for acyl-CoA 
oxidase and the bifunctional protein were elevated (Furuta et 
al.,1982). The cDNA probe to the latter protein has been 
sequenced and the enzyme has no terminal peptide extension as 
a signal for translocation into peroxisomes (Osumi et 
al.,1985). With ciprofibrate and clofibrate administration, 
mRNA levels coding for catalase, fatty acyl-CoA oxidase and 
the bifunctional protein were elevated and the rate of 
transcription of the beta-oxidation enzyme genes were 
increased (Reddy et al.,1986). The rate of transcription was 
nearly maximal by 1 hr post dose and was maintained for at 
least 16 hr. In Wy-14,643 treated animals there was no 
increase in the transcriptional rate of the bifunctional 
protein at 5 hr post dose and a 2- and 11-fold increase was 
seen at 10 and 20 hr post dose (Chatterjee et al.,1987). The 
increased activity of this protein was attributed to an 
enhancement of the rate of transcription of the bifunctional 
protein gene. However, the relatively long lag period 
suggested that the induction of the bifunctional protein mRNA 
involves an indirect effect (binding of these peroxisome 
proliferators to DNA has not been demonstrated) on the 
transcription of this gene (Chatterjee et al.,1987). The cause 
of this apparent discrepancy between the rate of transcription 
in these two studies is unclear at present. W y - 14,64 3 is 
considered a more potent peroxisome proliferator than 
clofibrate so it cannot be attributed to relative potencies of 
the compounds. With clofibrate, the transcription rate of the 
cytochrome P-450 LAw gene was increased dramatically within 1
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hr of administration which would tend to support the rapid 
increase in the transcription of the bifunctional protein as 
demonstrated by Reddy et al.,(1986), (Hardwick et al.,1987).
Chlorophenoxyacetic acids structurally related to clofibric 
acid and arylacetic acids induce bilirubin UDPglucuronosyl- 
transferase activity in a structure-dependent fashion. The 
nature of the chemical group fixed in the alpha-position of 
the carboxyl moiety and the number of methyl substituents 
appears to be of great significance in the inductive process 
(Fournel et al.,1985). A close linkage was established between 
bilirubin UDPglucuronosyltransferase induction and that of 
cytochrome P-452 (Fournel et al.,1985). It has been suggested 
that both processes could be under coordinate regulation, 
mediated by a molecular interaction dependent on the 
physiochemical/sterospecific properties of the inducers 
(Fournel et al.,1986).
The major responses in the rat to peroxisome proliferators is 
the coordinate induction of cytochrome P-452, carnitine 
acetyltransferase and peroxisomal beta-oxidation enzymes. In 
addition, the induction of bilirubin UDPglucuronosyl­
transferase and long chain acyl-CoA hydrolases occurs in 
treated rats (Fournel et al.,1985, Katoh et al.,1984). It 
would be of interest to examine the activity of the latter two 
enzymes across a wide range of species to clarify the 
response. No induction of peroxisomal beta-oxidation enzymes, 
carnitine acetyltransferase, cytochrome P-452 and long chain 
acyl-CoA hydrolases occurred in the guinea pig (chapter 4,
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Kawashima et al.,1983). In the marmoset, a minimal induction 
of peroxisomal beta-oxidation was observed in the absence of 
other enzyme changes. This would suggest in the rat and 
presumably other responsive species (mouse, hamster and 
rabbit) that these enzymes are members of a gene battery 
regulated by peroxisome proliferators (Nebert et al.,1987).
With respect to the hybridisation experiments with the 
cytochrome P-452 cDNA probe it would be useful to perform a 
control experiment, hybridising a duplicate filter to a rat 
albumin cDNA probe. This gene was transcribed at a rate 
approximately equal to that seen in the nuclei of normal rat 
liver following ciprofibrate and clofibrate administration 
(Reddy et al.,1986). The translatable mRNA level for albumin 
was not significantly changed by DEHP treatment (Osumi et 
al.,1985). Using the rat albumin probe would allow for a more 
comparative analysis in the guinea pig and marmoset where a 
slight increase in mRNA-cDNA hybridisation occurred with no 
associated increase in catalytic activity or immunodetectable 
protein.
The species responses to ciprofibrate have been documented at 
a biochemical level in this work. To delineate which changes 
are a prerequiste for the ultimate expression of toxicity with 
this class of compounds requires further investigation using 
the cloned genes to cytochrome P-452, peroxisomal 
beta-oxidation enzymes and glutathione peroxidase, a logical 
extension of the work presented in this thesis.
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Liver sections for electron microscopy were prepared from all 
animals treated with ciprofibrate for 14 days and from 
marmosets in the 6 month treatment and recovery groups. 
Unfortunately technical problems were encountered and no 
sections could be used except the primate samples. In the 
marmoset at each time point, 2 week, 6 month and recovery 
groups, there were no obvious treatment-related 
ultrastructural changes (figures 5.17 to 5.22). It was not 
possible to make any definite conclusions, however there was a 
marked decrease in glycogen content in treated animals making 
organelle distribution comparisons difficult. There was no 
proliferation of the SER and peroxisomes and no apparent 
structural changes to these organelles. Mitochondria appeared 
elongated with a slight increase in number although this would 
not be considered significant. In the recovery group the 
glycogen content was increased with levels similar to the 
control group. In the ciprofibrate treated rat (administration 
for 14 days) there was an obvious increase in peroxisome 
number has been observed in hepatocytes (Lalwani et al.,1983b, 
Sterling Winthrop, personal communication). The R.E.R appeared 
more diffusely distributed and the endoplasmic cisternae were 
dilated in the treated groups. From the photographs it is 
apparent that the reported hepatic ultrastructural changes in 
the treated rat were not reproduced in the marmoset by 
ciprofibrate treatment. In the marmoset study, full autopsies 
were completed which included tissue pathology, haematology 
and blood biochemistry analyses (appendix 1). No significant 
treatment-related effects were observed.
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14 Day Study With Ciprofibrate in the Marmoset. 
Figure 5.17. ; Micrograph from the control group.
Figure 5.18. ; Micrograph from the 100 mg/kg dose group.
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26 Week Study With Ciprofibrate in the Marmoset.
Figure 5.19. Micrograph from the control group.
Figure 5.20. Micrograph from the 80—100 mg/kg dose group.
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26 Week Treatment Period with Ciprofibrate in the Marmoset
Followed by a 4 week Recovery period.
Figure 5.21. Micrograph from the control group.
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Figure 5.22. Micrograph from the treated recovery group.
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By comparison, clobuzarit treatment resulted in a 
proliferation of peroxisomes in the mouse, rat and to a lesser 
extent in the hamster (Orton et al.,1984). No such changes 
were observed in the marmoset by these latter authors. The in 
vitro exposure of rat hepatocytes to ME HP resulted in a marked 
proliferation of peroxisomes and a concomitant increase in 
beta-oxidation (Elcombe and Mitchell, 1986). No significant 
peroxisome proliferation was induced in cultured marmoset 
hepatocytes. In the Rhesus monkey, gemfibrozil administration 
caused an increase in peroxisome number per hepatocyte with an 
increased volume fraction in aged animals (Gray and De La 
Iglesia,1984). In young Rhesus monkeys peroxisome numbers were 
unchanged. Ciprofibrate treatment was reported to cause
peroxisome proliferation in Rhesus and Cynomolgus monkeys and 
DL-040 administration in Rhesus monkeys (Reddy et al.,1984, 
Lalwani et al.,1985). The marmoset is considered a
non-responsive species to peroxisome prolif erators with
respect to both catalytic and morphological analyses. It is 
possible that there is a fundamental difference between the 
marmoset and Rhesus monkey (New World versus Old World) and 
that the latter may be considered responsive. However, no 
measurement of lauric acid hydroxylase activity has ever been 
made in these Old World genera and peroxisomal proliferation 
remains questionable at the very high dose levels used.
The importance of metabolism and drug bioavailability with 
respect to species differences in the response to peroxisome 
proliferators must be considered. The major problem
encountered in anticipating the fate of a xenobiotic is not in
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predicting the possible routes of metabolism but rather in 
predicting which of these potential reactions will occur in 
particular animal species (Caldwell, 1981). Interspecies 
differences in metabolism may be attributed to;
1) inability of a species to carry out a metabolic pathway,
2) occurrence of a unique reaction in a particular species,
3) variations in relative extents of two or more competing 
reactions which a compound may undergo.
On the basis of available data it would appear likely that Old 
World monkeys, notably the Rhesus monkey, resembles man most 
closely in metabolic terms (Caldwell, 1981), and therefore that 
the marmoset resembles the Rhesus monkey more closely than 
rodents. Clofibric acid, the hydrolysis product of its ethyl 
ester clofibrate, is the active metabolite and in the rat, 
rabbit, guinea pig and man is excreted as the free acid and 
ester glucuronide (Emudianughe et al.,1983). In this thesis, 
the term ciprofibrate refers to 2-[-4-(2,2- dichloro- 
cyclopropyl) phenoxyl]-2-methyl-propanoic acid, the
pharmacologically active compound. Therefore, in the short 
term and chronic studies using ciprofibrate, any compounding 
influence of possible species differences in initial 
hydrolytic biotransformation are eliminated by using the 
active compound.
On a similar theme, DEHP is hydrolysed in the intestine to 
ME HP and it is absorbed in this form (Lake et al.,1977). By 
using MEHP in in vivo and in vitro studies negates species 
differences in absorption and bio avail ability (Elcombe and
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Mitchell, 1986). Peroxisome proliferation and enzyme induction 
was observed in vivo and in vitro in the rat with ME HP yet no 
induction was demonstrated in guinea pig and marmoset cultured 
hepatocytes (Lake et al.,1986, Elcombe and Mitchell, 1986). To 
avoid possible species divergence in metabolism, the active 
metabolite of ME HP was isolated. This proximate prolif erator 
(metabolite VI) was added to rat, guinea pig, marmoset and 
human hepatocyte cultures (Elcombe and Mitchell, 1986).
Induction of peroxisomal beta-oxidation and lauric acid 
hydroxylation occurred only in rat hepatocytes. Cinnamyl 
anthranilate, a synthetic food flavouring, is a peroxisome 
prolif erator in the mouse but not the rat. This has been 
attributed to a species difference in metabolism with the 
active metabolite being formed by hydrolysis in the mouse only 
(Caldwell et al.,1985, Caldwell et al.,1987).
Pharmacokinetic parameters have been established for 
clobuzarit in the rat, mouse, hamster, dog and marmoset after 
oral administration (Orton et al.,1984). These parameters were 
used to select dose levels which resulted in peak or steady 
state serum levels of 100-200 ug/ml in a 14 day oral 
administration study. Peroxisomal proliferation and enzyme 
induction were observed in the rat, mouse and hamster 
(descending order of response magnitude) only. The 
interspecies differences in hepatic response were probably not 
due to differences in exposure since the systemic levels of 
the compound in responsive (rat) and non-responsive (dog) 
species were similar (Orton et al.,1984).
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The half life of ciprofibrate in the rat is 3-4 days whereas 
with bezafibrate it is 6-16 hr and with clofibrate 5-8 hr 
(Baldwin et al.,1980, Cayen et al.,1977, Edelson et al.,1979, 
Schmidt et al.,1980, Sterling-Winthrop, personal communication 
and Thorp,1972). This increased exposure of ciprofibrate in 
the rat, resulting from the sustained high drug concentration 
in the plasma would account for its high potency when compared 
to clofibrate and bezafibrate, assuming that plasma levels are 
directly proportional to active tissue levels. The maximal 
plasma ciprofibrate concentration was attained at 2 hr after a 
single oral dose to rats, monkeys and man (Davison et al., 
1975). The drug was slowly eliminated in all three species and 
in the Rhesus monkey and man elimination appeared to follow 
the kinetics of a two-compartment model. The long half lives 
of ciprofibrate may be attributed to;
1) enterohepatic circulation,
2) accumulation of drug in fat, and,
3) extensive plasma binding of ciprofibrate which may inhibit 
clearance from the plasma compartment (Davison et al.,1975). 
Ciprofibrate was excreted as the free acid and glucuronide in 
the rat, monkey and human. The ratio of ciprofibrate excreted 
as unchanged drug to glucuronide is unknown. In the marmoset 
and rat steady state levels of ciprofibrate were achieved 
within 7 days (Sterling-Winthrop,personal communication). 
Assuming a linear relationship of ciprofibrate dose with 
plasma concentrations, plasma levels in the marmoset at the 
high dose level (100 mg/kg) were 1.5 to 2-fold higher than 
that in the rat at the 20 mg/kg dose level (chapter 4). It has 
been estimated that in the marmoset, elimination in the high
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dose group is biphasic [tl/2 a 4,5 hr, tl/2 b 8.2 hr]
(Sterling Winthrop,personal communication). The half life is 
clearly shorter in the marmoset than in the rat. Assuming (by 
extrapolation) plasma concentrations (measured 4 hr post 
dose), at the high dose level in the marmoset were 500 ug/ml 
and 45-50 ug/ml at the low dose level (2 mg/kg) in the rat the 
plasma concentrations at 24 hr post dose were not markedly 
different in the two species i.e. 50-80 ug/ml (calculated
using a minimal and extensive duration of the a tl/2) and
37-44 ug/ml (1/3-1/4 of a half life) in the marmoset and rat
respectively. At the high dose level in the rat (20 mg/kg),
the plasma concentration of ciprofibrate was approximately 250 
ug/ml and this would correlate to between 215 and 225 ug/ml 24 
hr post dose (1/3-1/4 of a half life). Although the values are
derived from a theoretical basis and as such should be treated
with caution, some indication of ciprofibrate exposure in the 
rat and marmoset can be made. Although there are clear
differences in the bioavailability of ciprofibrate in these 
two species it should be noted that in the marmoset that the 
initial plasma concentration was considerably higher than in 
the rat. Enzyme induction was apparent at both dose levels in 
the marmoset following 2 and 26 weeks ciprofibrate treatment 
although it should be remembered that with peroxisomal 
beta-oxidation, induction was considerably less extensive in 
the marmoset in comparison to the rat. The difference in the 
pattern of enzyme changes in the marmoset - induction of 
peroxisomal beta-oxidation accompanied by increases in the 
activities of mitochondrial enzymes and in the absence of 
carnitine acetyltransf erase and lauric acid hydroxylase
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induction, is unlikely to be due to differential drug exposure 
but more probably to a fundamental species difference in gene 
expression.
An additional factor to consider in induction potency is the 
extent of binding to plasma proteins and this has been 
examined in the rat, human and Rhesus monkey with ciprofibrate 
(Davison et al.,1975). A greater proportion of ciprofibrate 
was unbound at the higher concentration of available drug in 
the three species. There was less ciprofibrate bound to rat 
plasma at the higher concentration than to plasma from the 
other two species studied (Davison et al.,1975). A similar 
trend was observed with clofibric acid in the rat, dog and man 
(Cayen et al.,1977). Unfortunately there is no data with 
respect to ciprofibrate plasma binding in the marmoset 
although a pattern similar to the Rhesus monkey might be 
expected (Davison et al.,1975). In figure 5.23, the percentage 
of unbound ciprofibrate versus plasma drug concentration 
(ug/ml) for the rat and Rhesus monkey is shown. Assessment of 
the percentage of unbound ciprofibrate at both dose levels in 
the rat and the high dose level in the marmoset can be made 
from the graph if it is assumed that:-
1) the relationship between increasing dose and decreasing 
plasma binding is linear, and
2) the pattern observed in the Rhesus monkey is similar to 
that in the marmoset.
In the rat the percentage of free ciprofibrate was 2.1 and 
8.6% for 2 and 20 mg/kg dose levels respectively and at 100
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mg/kg in the marmoset it was 1.7% (figure 5.23). There was no 
difference in the percentage of free drug in the low dose 
level (2 mg/kg) in the rat and the high dose level (100 mg/kg) 
in the marmoset. Therefore, the difference in hepatic enzyme 
induction between both dose levels in the rat is clearly not a 
product of the percentage of free drug as both 2 and 20 mg/kg 
dose levels are on the plateau region of the dose response 
curve (figure 5.14). Similarly, the difference in hepatic 
response between the rat (low dose level) and marmoset (high 
dose level) is due to differences in the inherent response of 
these two species and cannot be attributed to tissue drug 
availability. Therefore the extent of ciprofibrate plasma 
binding is not of significance in the induction phenomenon and 
is not the reason for species differences in response to 
peroxisome prolif erators.
In recent years, growing concern has arisen with respect to 
the long term exposure of man to hypolipidaemic drugs and 
industrial plasticisers and the possible effects on human 
health. This is based largely on the ever increasing evidence 
that peroxisome prolif erators are, as a class, hepatic 
carcinogens in rodents (Reddy et al.,1980). Extrapolation from 
rodent carcinogenesis studies to other species is rarely 
satisfactory as both qualitative and quantitative differences 
exist between the respective responses. It should be noted 
that predictions are based on a direct interspecies comparison 
and that it is assumed that the mechanism of action in the 
animal model is both identical and reproducible in man.
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Figure 5.23.
Ciprofibrate Plasma Protein Binding In The Rat and Rhesus
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The percentage of "free ciprofibrate” at different dose levels 
for both species was determined graphically;
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Ciprofibrate is negative in a wide range of mutagenicity 
tests;
1) no induction of unscheduled DNA synthesis in rat 
hepatocytes (Glauert et al. 1984),
2) negative in strains TA 1535, 1537, 1538, 98 and 100 of
Salmonella typhimurium in the Ames test both with and without 
metabolic activation,
3) inactive in mouse Lymphoma Forward Mutation Assay without 
metabolic activation, active with metabolic activation, and
4) inactive in Balb/3T3 in vitro transformation assay and 
Balb/3T3 rat hepatocyte mediated transformation assay 
(Sterling Winthrop,personal communication).
However, in vivo long term ciprofibrate treatment in the 
Fischer rat results in the development of hepatocellular 
adenomas and carcinomas in the high dose group [10 mg/kg/day] 
(Sterling Winthrop,personal communication). Histologically 
hepatic lesions were classified as altered areas, nodules or 
hepatocellular carcinomas and on the basis of this criteria a 
100% incidence of hepatocellular carcinomas was observed in 
the treated animals (10 mg/kg/day) (Rao et al.,1984). With 
short term and chronic ciprofibrate administration in the rat, 
hepatomegaly and induction of peroxisomal beta-oxidation, 
cytochrome P-452 and carnitine acetyltransf erase has been 
demonstrated in this work. These hepatic changes induced by 
ciprofibrate are typical of those obtained with other 
peroxisome prolif erators such as bezafibrate and clofibric 
acid.
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The magnitude of the hepatic responses appears to correlate 
with the relative lipid lowering potency of the compound and 
is markedly influenced by pharmacokinetic characteristics, 
particularly biological half life. It is suggested that these 
liver changes serve as early indicators of the ultimate 
toxicity, hepatocarcinogenesis, in rodents. It is also 
possible that hepatomegaly and enzyme induction are a 
prerequiste for the final expression of toxicity in this class 
of compounds as will be mechanistically enunciated in chapter 
7.
There is an obvious need to clarify the rodent response as 
species specific or species common in order to make an 
assessment of the potential risk to man. With reference to the 
short term and chronic ciprofibrate studies, a clear species 
difference in susceptibility exists. The marmoset and guinea 
pig may be considered as refractory species whereas the rat, 
mouse, hamster and rabbit are susceptible. These latter 4 
species exhibited marked differences in the magnitude of 
response indicating that both a species specific and dose 
dependent induction may occur. The relative advantages and 
disadvantages of using the marmoset and rat as models for 
extrapolation purposes to assess potential toxicity in man is 
discussed in chapter 7.
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CHAPTER 6
SPECIES AND RAT STRAIN DIFFERENCES IN RENAL RESPONSES TO 
CIPROFIBRATE ADMINISTRATION.
6.1. INTRODUCTION
In the three previous chapters the results from several 
different investigations were discussed. In essence, these 
studies examined ;
a) the hepatic response in the rat to the short term 
administration of ciprofibrate, and,
b) compared the treatment-induced changes in five rat strains 
and six species.
The chronic effects of ciprofibrate on hepatic enzyme
parameters in the marmoset and rat were studied. In the rat, 
the relative potencies of three peroxisome proliferators were 
investigated following chronic administration.
The hepatic changes in the rat included hepatomegaly,
differential effects on the microsomal drug metabolising 
enzyme system, induction of peroxisomal beta-oxidation, 
mitochondrial enzyme changes and a decrease in glutathione 
peroxidase activity. A considerable variation in species
response was apparent and the order of induction
susceptibility was shown to be the rat > mouse > hamster > and 
rabbit. The marmoset and guinea pig were relatively
non-responsive.
f
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The objectives of the research work presented and discussed in 
this chapter were two-fold;
1) to ascertain if the rat response is tissue specific or
tissue common, and
2) to study rat strain and species variation in the kidney.
The effects of a wide range of peroxisome prolif erators on 
renal peroxisomal and mitochondrial enzymes has been examined 
at length in our laboratory (Sharma et al.,1988a). In the
current study, the influence of the short term administration
of ciprofibrate on the drug metabolising enzyme system was
examined in five rat strains and five species. In addition, 
renal glutathione peroxidase activity was measured in the rat. 
The chronic effects of ciprofibrate, clofibric acid and 
bezafibrate on the microsomal drug metabolising enzyme system 
were also studied in the rat. No statistical analysis could be 
completed on the data due to an insufficient number of kidney 
samples. In the rat and mouse there was one microsomal pool 
per dose level whereas in the hamster, guinea pig and rabbit 
there were 2 microsomal pools per dose level. No results are 
reported for the marmoset as the specific content of 
cytochrome P-450 was too low to be detected 
spectrophotometrically and no further assays were completed.
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6.2. THE MICROSOMAL DRUG METABOLISING ENZYME SYSTEM.
6.2.1. Cytochrome P-450 Content.
In the Gunn and Sprague Dawley strains there was a 
dose-dependent increase in the specific content of cytochrome 
P-450 (table 6.1). At the high dose level in the Fischer rat 
the cytochrome P-450 content was induced. In both the Long 
Evans and Wistar rat, the specific content of cytochrome P-450 
was increased and the extent of induction was similar at both 
dose levels. In the treated rat, the increase in cytochrome 
P-450 content varied between 1.35- and 1.7-fold. In the mouse 
and hamster the cytochrome P-450 content was unchanged by 
ciprofibrate administration (table 6.2). The specific content 
of cytochrome P-450 was decreased at the low dose level in the 
guinea pig. The induction of cytochrome P-450 was dose 
dependent in the rabbit. In the marmoset the specific content 
of cytochrome P-450 was too low to be spectrophotometrically 
detected. Chronic treatment of Fischer rats with bezafibrate 
resulted in a 1.5-fold increase in the specific content of 
cytochrome P-450 (table 6.3). For ciprofibrate and clofibric 
acid the cytochrome P-450 specific content was 50 and 70% of 
the control value, respectively. There was little strain or 
species variation in the basal level of cytochrome P-450 
content i.e. in untreated animals.
Treatment of Wistar rats for 3 days with Wy-14,64 3 and 
clobuzarit caused an increase in cytochrome P-450 content. 
Induction with Wy-14,643 was minimal whereas a 1.5-fold
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Table 6.3.
The Effect of Hypolipidaemic Drugs on Renal Cytochrome P-450
Content and Ethoxyresorufin-O-Deethylase Activity in the
#
Fischer Rat Following Chronic Administration.
Treatment Cytochrome P-450 
Specific Content 
(nmol/mg protein)
Ethoxyresorufin-O- 
Deethylase Activity 
(pmol product/ 
min/nmol P-450)
Control 0.23[a] (100)[b] 4.01 (100
Clofibric Acid 0.16 (70)
(50 mg/kg/day)
3.09 (77)
Bezafibrate 0.34
(75 mg/kg/day)
(148) 2.90 (72)
Ciprofibrate 
(20 mg/kg/day)
0.22 (48) 5.11 (127)
K Single dai ly dose for 2 6  w e e k s
[a] Values are expressed as an average of two experimental 
results .f
[b] Figures in brackets are values expressed as a 
percentage of corresponding control.
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increase was apparent following clobuzarit treatment (Sharma 
et al.,1988a). With clofibrate administration a slight 
decrease in the specific content of cytochrome P-450 occurred 
in the rat. In contrast, a slight increase in cytochrome P-450 
content has been described with a single dose of clofibrate, 
72 hours after administration (Makowski, 1985). A 2.5-fold 
induction of cytochrome P-450 has been reported with 
clobuzarit in the rat following a 14-day treatment period 
(Parker and Orton, 1980). In the present study an increase in 
cytochrome P-450 content was observed with ciprofibrate in the 
rat with minimal strain differences. A similar increase was 
seen in the hamster with a marked dose-dependent increase in 
the rabbit. However, following chronic administration of 
ciprofibrate a marked decrease in cytochrome P-450 specific 
content occurred. This would appear to be a characteristic of 
ciprofibrate alone as a decrease with clofibric acid occurred 
at both time points and a 1.5-fold induction with bezafibrate 
was maintained following chronic administration.
6.2.2. Benzphetamine - N - Demethylase Activity.
Benzphetamine-N-demethylase activity was measured in the 
acutely treated rat only. In the other species - mouse, 
hamster, guinea pig, rabbit and marmoset there were 
insufficient microsomal samples to determine the activity of 
this enzyme. In the chronically treated rat no enzyme activity 
was detected when using similar conditions to assaying samples 
from animals treated with ciprofibrate for 14 days.
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A slight increase in benzphetamine-N-demethylase activity was 
observed in the Sprague Dawley rat at the high dose level 
(table 6.4). A dose-dependent decrease in activity occurred in 
the Wistar rat. With both the Fischer and Long Evans rat, 
activity was decreased at the high dose level. These
treatment-induced changes to enzyme activity did not appear to
correlate with changes observed in the specific content of 
total cytochrome P-450, with the exception of the Sprague
Dawley rat. In this latter rat strain, a dose-dependent
increase in cytochrome P-450 content and
benzphetamine-N-demethylase activity occurred. However at the 
low dose level the extent of induction between these two 
parameters was not equivalent. The variation in enzyme 
activity in untreated animals between rat strains was minimal. 
Following a single dose of clofibrate, a slight increase in 
benzphetamine turnover was observed at 6 hr post dose yet by 
12 hr, activity had returned to control levels (Makowski, 
1985).
6.2.3. Ethoxyresoruf in - 0 - Deethylase Activity.
Ethoxyresorufin-O-deethylase activity was decreased in a 
dose-dependent manner in the Wistar and Long Evans rats (table 
6.4). Activity was decreased at the high dose level in the 
Gunn and Fischer rats. Enzyme activity was decreased to 
approximately 50% of the control value in the Sprague Dawley 
rat at both dose levels. It should be noted that the 
treatment-induced changes occurring in ethoxyresorufin-O- 
deethylase and benzphetamine-N-demethylase activities were
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very similar in the Fischer rat. The decrease in 
ethoxyresorufin-O-deethylase activity in the mouse was 
dose-dependent (table 6.5). Enzyme activity in the hamster and 
guinea pig was unchanged and in the treated rabbit activity 
was 20% of the control value. Considerable strain variation in 
the basal levels of ethoxyresorufin-O-deethylase activity 
(i.e. in untreated animals) was evident. The Wistar and Gunn 
rats exhibited high activity whereas basal levels in the Long 
Evans, Sprague Dawley and Fischer strains, mouse, hamster and 
rabbit were 3 to 12-fold lower. Activity in the untreated 
guinea pig was barely detectable.
The chronic administration of ciprofibrate, bezafibrate and 
clofibric acid had no effect on the activity of 
ethoxyresorufin-O-deethylase (table 6.3). Activity in the 
control group was lower than that in the Fischer rat at 2 
weeks. This may represent an aging process.
A decrease in ethoxyresorufin-O-deethylase activity was 
observed with clofibrate and bezafibrate in the Wistar rat 
following a 3 day treatment period (Sharma et al.,1988a). 
Several other peroxisome prolif erators caused an equivalent 
decrease in activity although ciprofibrate was not included in 
the same study (Sharma et al.,1988a). Following a single dose 
of clofibrate in the rat, a decrease in enzyme activity was 
demonstrated at 6, 12, 24 and 72 hr after administration
(Makowski,1985). The decrease in ethoxyresorufin-O-deethylase 
activity was observed in the current study at the high dose 
level in all rat strains as well as in the mouse and rabbit.
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It should be noted that in liver microsomes, 
ethoxyresorufin-O-deethylase activity was expressed as nmol 
product/min/nmol P-450 as opposed to pmol product/min/nmol 
P-450 in the kidney. A point of concern is that these low 
levels of activity in the kidney may exceed the levels of 
detection and sensitivity that can be accurately determined 
with this assay.
6.2.4. Induction of Cytochrome P-452.
Laurie acid hydroxylation at the 11-position was increased at 
both dose levels in the Gunn and Wistar rat and induction was 
1.9 to 2.5-fold (table 6.6). A slight increase in 11-hydroxy- 
laurate was observed at the high dose level in the Sprague 
Dawley rat. Activity was unchanged in the Long Evans and 
Fischer rats. The 12-hydroxylation of lauric acid was 
unaffected by treatment in both Wistar and Long Evans strains. 
Dose-dependent increases in 12-hydroxylaurate were 
demonstrated in the Gunn rat and activity was increased at the 
low dose level in the Sprague Dawley rat.
The 11-hydroxylation of lauric acid was decreased at the high 
dose level in the mouse and increased at both dose levels in 
the hamster (table 6.7). The increase in 11-hydroxylaurate was 
observed at the low dose level in the guinea pig whereas 
activity was decreased at the high dose level in the rabbit. 
The 12-hydroxylation of lauric acid was increased at both dose 
levels in the mouse. The increase in 12-hydroxylaurate was 
dose-dependent in the hamster and a decrease in activity was
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observed in the rabbit at the high dose level.
With the chronic administration of clofibric acid and 
ciprofibrate, a 2-fold induction in both 11- and 
12-hydroxylaurate was observed (table 6.8). A slight increase 
in both hydroxyproducts was demonstrated in the bezafibrate 
treated group. The basal levels of 11- and 12-hydroxylation of 
lauric acid were lowest in the untreated guinea pig. Activity 
for both products was similar in the remaining species and in 
all rat strains.
It should be noted that in each species and rat strain the 
extent of 12-hydroxylation was greater than the 11- 
hydroxylation of lauric acid. In the rat the ratio 
(12-hydroxylaurate to 11-hydroxylaurate) varied from 3.0 in 
the Sprague Dawley rat to 8.0 in the Wistar rat. In the mouse, 
guinea pig and rabbit the ratio of metabolites was in the
order of 2 to 4. Hamster renal microsomes displayed a 9-fold 
higher omega-hydroxylation than (omega-1)- hydroxylation.
It has been reported that Wy-14,643, DEHP, bezafibrate, 
nafenopin, clofibrate and clobuzarit administration resulted 
in a 1.5 to 3-fold increase in renal 11- and 12-hydroxylation 
of lauric acid in the Wistar rat (Sharma et al.,1988a). The
extent of clofibrate induction following this 3 day treatment 
period was similar to my results for the chronically treated 
group as described above. Higher activities have been reported 
with bezafibrate at a dose level of 200 mg/kg (Sharma et
al.,1988a) as opposed to a dosing level of 75 mg/kg in the
Table 6.8.
The Effect of Hypolipidaemic Drugs on Renal Lauric Acid 
Hydroxylase Activity in the Fischer Rat following Chronic
Administration.
Treatment Lauric Acid Hydroxylase Activity 
(nmol product/min/nmol P-450)
11-hydroxylaurate 12-hydroxylaurate
Control 10.04[a] (100)[b] 30.37 (100)
Clofibric Acid 23.05
(50 mg/kg/day)
(230) 75.46 (248)
Bezafibrate 11.28 (112) 37.40
(75 mg/kg/day)
(123)
Ciprofibrate 
(20 mg/kg/day)
21.68 (216) 74.39 (245
^  Single daily dose for 26 weeks
[a] Values expressed as an average of two experimental 
results.
[b] Figures in brackets are values expressed as a percentage 
of corresponding control.
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in the present study. A 2 to 3-fold increase in 11- and
12-hydroxylauric acid formation (expressed as nmol 
product/min/mg protein) was observed in the rat following a 14 
day clobuzarit treatment (Parker and Orton, 1980). However, 
when expressed as nmol product/min/nmol P-450, there were no 
treatment induced changes. The omega- and (omega-1)-lauric 
acid hydroxylase activities in the rabbit were enhanced 
approximately 2-fold by clofibrate and DEHP, unlike the 
effects seen in this study with ciprofibrate (Yamamoto et 
al.,1986).
Cytochrome P-452 content was also determined immunochemically 
using an ELISA technique. The specific content of cytochrome 
P-452, (expressed as nmol P-452/nmol P-450), was increased in 
a dose-dependent manner in the Sprague Dawley, Wistar and Long 
Evans rat (table 6.6). This represented a 1.5 to 3-fold 
induction. In the Gunn rat the specific content was increased
2-fold at both dose levels yet was unchanged in the Fischer 
rat. When cytochrome P-452 content was expressed as percentage 
of total cytochrome P-450 content, a dose-dependent increase 
was observed with all rat strains except the Fischer rat which
exhibited a dose-dependent decrease in cytochrome P-452
content. The 1.5 to 3-fold induction (nmol P-452/nmol P-450)
did not reflect a similar induction when expressed as 
percentage of total cytochrome P-450 content and did not 
correlate to treatment induced changes in total cytochrome 
P-450 content and lauric acid hydroxylase activity.
An increase in cytochrome P-452 specific content (nmol
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P-452/nmol P-450) was observed at both dose levels in the 
mouse and at the high dose level in the hamster (table 6.7). 
This induction was in the order of 1.5 to 2-fold. Cytochrome 
P-452 was not detected immunochemically in guinea pig 
microsomes. A 3-fold increase in cytochrome P-452 content was 
observed at the high dose level in the rabbit. Induction of 
cytochrome P-452 content (expressed as percentage of total 
cytochrome P-450) was observed at the high dose levels in the 
hamster and rabbit. In the . mouse an increase in cytochrome 
P-452 content occurred at both dose levels. The extent of 
cytochrome P-452 induction (nmol P-452/nmol P-450) in the 
mouse and hamster correlated to the increase in cytochrome 
P-452 content when expressed as percentage of total cytochrome 
P-450 content and to the increased 12-hydroxylation of lauric 
acid. These treatment induced changes did not reflect the 
extent of total cytochrome P-450 content. The 2 to 3-fold 
increase in cytochrome P-452 (nmol P-452/nmol P-450) in the 
rabbit, accompanied decreased omega- and (omega-1)- 
hydroxylation of lauric acid.
The basal levels of cytochrome P-452 (i.e. in untreated
animals) when expressed either as specific content or as 
percentage of total cytochrome P-450, exhibited little strain 
or species variation. Lauric acid hydroxylase activity could 
not be detected at 3 mg protein/ml incubate for renal marmoset 
microsomes. In the rat and other species, activity was 
detected between 0.5 and 1.5 mg protein/ml incubate. It was 
not possible to immunochemically detect cytochrome P-452 in 
these marmoset samples. Cytochrome P-452 levels were not
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quantitated in chronically treated rats following 
ciprofibrate, bezafibrate and clofibric acid administration.
The immunochemical assessment of cytochrome P-452 has not 
previously been carried out in renal microsomes of different 
species. In addition there is little published data concerning 
renal cytochrome P-452 quantitation in the rat. This ELISA 
technique was developed in our laboratory and early results 
indicate that a wide range of peroxisome proliferators, 
ciprofibrate not examined, caused a 1 to 2-fold increase in 
cytochrome P-452 content (Sharma et al.,1988a). In the present 
study, a 1 to 1.6-fold increase was observed in different rat
f
strains. After treatment of rats with clofibrate, kidney 
microsomes showed an increased amount of cytochrome P-450 LAw 
[cytochrome P-452] (Hardwick et al.,1987). A slight increase 
in immunodetectable cytochrome P-452 in rat renal microsomes 
would appear to be a treatment-induced change associated with 
peroxisome proliferators.
6.3. GLUTATHIONE PEROXIDASE ACTIVITY.
The selenium dependent glutathione peroxidase (GPX) utilises 
hydrogen peroxide and organic hydroperoxides as substrates 
whereas glutathione-S-transferase (selenium independent) 
metabolises only organic hydroperoxides. As described 
previously (chapter 4) the hepatic GPX activity (expressed as 
percentage of control), with the substrates hydrogen peroxide 
and t-butylhydroperoxide, was very similar. As a result, 
t-butylhydroperoxide was used as a substrate for the selenium
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dependent glutathione peroxidase.
There appeared to be little change in renal glutathione 
peroxidase activity in the rat following ciprofibrate 
administration (table 6.9). Activity was unchanged in the 
Gunn, Sprague Dawley, Wistar and Long Evans rats. However in 
the Fischer rat, glutathione peroxidase activity was decreased 
at both dose levels to 50-60% of the control value. Cytosolic 
samples from the remaining species and chronically treated 
rats were not available for enzyme determination. The effect 
of peroxisome proliferators on renal glutathione peroxidase 
activity has not previously been determined.
6.4. DISCUSSION.
The renal metabolism of fatty acids occurs either by 
beta-oxidation through the mitochondrial pathway or by omega- 
and (omega-1)-oxidation in the microsomal subcellular 
fraction. In addition, an extra-mitochondrial beta-oxidation 
pathway has also been demonstrated with this being located in 
peroxisomes in the medulla and medullary rays (Le Hir and 
Dubach,1982).
The distribution of omega-fatty acid hydroxylase activity was 
studied in various rat tissues and in the extra hepatic 
tissues examined, only the kidney was highly active (Ichihara 
et al.,1969). Marked omega-hydroxylase activity was observed 
in rabbit, mouse and guinea pig renal microsomes. Rat kidney
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cortex microsomes catalysed the omega-oxidation of laurate at 
a similar rate to liver microsomes (Jakobsson et al.,1970). 
However renal metabolism of the drug substrate aminopyrine and 
testosterone was negligible. The dietary administration of 
laurate enhanced renal cytochrome P-454 content and stimulated 
omega-hydroxylation of lauric acid 1.5-fold. In the kidney 
laurate hydroxylation occurs at both positions yielding the
12- and 11-hydroxyproducts in the ratio of 2:1 (Ellin et 
al.,1972). The ratio of omega- to (omega-1)-hydroxylation of 
fatty acids decreases with increasing chain length of the 
substrate (Ellin et al.,1973). The kidney cytochrome P-450 
system is specifically involved in omega- and (omega-1)- 
hydroxylation of fatty acids and in contrast to the liver, 
metabolism of model drug substrates is minimal in the kidney.
COMPARISON OF HEPATIC AND RENAL RESULTS.
Ciprofibrate administration caused an increase in total renal 
and hepatic cytochrome P-450 content in the Fischer, Wistar, 
Sprague Dawley and Long Evans rat, hamster and rabbit (tables
4.1, 4.2, 6.1 and 6.2). Cytochrome P-450 content was elevated
in the Gunn rat renal microsomes and hepatic cytochrome P-450 
was increased in the mouse (table 4.2 and 6.1). Guinea pig 
cytochrome P-450 content was unchanged by treatment in both 
organs (tables 4.2 and 6.2). Following the chronic
administration of clofibric acid and bezafibrate the hepatic 
cytochrome P-450 content was increased yet decreased with 
ciprofibrate administration (table 5.1). In the kidney, both
clofibric acid and ciprofibrate caused a decrease in
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cytochrome P-450 content whereas bezafibrate administration 
increased the renal cytochrome P-450 content (table 6.3). The 
specific content of cytochrome P-450 in untreated rat liver 
microsomes was 5 to 10-fold higher than in the kidney. In the 
mouse, hamster, guinea pig and rabbit the renal cytochrome 
P-450 content was 3 to 7-fold lower than in the hepatic 
samples.
With benzphetamine-N-demethylase activity in the kidney there 
were differential treatment changes: activity was increased at 
the high dose level in the Sprague Dawley rat and unchanged in 
the Gunn rat. Activity was decreased in the other rat strains 
(table 6.4). Hepatic metabolism of benzphetamine was decreased 
in the rat to approximately 20-50% of the control value at the 
high dose level in all strains (table 4.3). The rat hepatic 
metabolism of benzphetamine was 2 to 3-fold higher than in 
renal microsomes (comparing basal levels in untreated 
animals).
Hepatic and renal ethoxyresorufin-O-deethylase activity was 
decreased in the rat and mouse (table 4.3, 4.4, 6.4 and 6.5).
Enzyme activity was reduced in rabbit kidney microsomes and 
was unchanged in liver microsomes (table 4.4 and 6.5). 
Ethoxyresorufin-O-deethylase activity was unchanged in both 
organs in the hamster and guinea pig (table 4.4 and 6.5). With 
the chronic administration of peroxisome proliferators, renal 
ethoxyresorufin-O-deethylase activity was unchanged yet was 
markedly decreased in liver microsomes (table 5.5 and 6.3). 
Ethoxyresorufin-O-deethylase activity in liver microsomes in
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the rat and all species examined was expressed as nmol 
product/min/nmol P-450, as opposed to pmol product/min/nmol 
P-450 in renal metabolism.
It is clear that the hepatic cytochrome P-450 system is 
directed towards the metabolism of model drug substrates and 
xenobiotics whereas it would appear that the renal 
contribution to xenobiotic metabolism is minimal.
In the rat, hepatic (omega-1)- and omega-hydroxylase activity 
was induced 2 to 5-fold and 10 to 15-fold respectively, 
whereas in the kidney, the increase was 1.5 to 2.5-fold for 
omega- and (omega-1)-hydroxylation (table 4.5 and 6.6). There 
was considerable strain variation in response. With chronic 
administration of peroxisome proliferators the increase in 
lauric acid hydroxylation was 1 to 2.5-fold at both positions 
(table 6.8). However in the liver, omega-hydroxylation was 
induced 8 to 20-fold (table 5.5). In the mouse and hamster 
hepatic (omega-1)- hydroxylation was induced between 1.5 to 
3-fold whereas the increase in 12-hydroxylase activity was 3-, 
5- and 10-fold in the rabbit, hamster and mouse respectively 
(figure 4.1). In the rabbit, renal omega- and (omega-1)- 
hydroxylase activity was decreased (table 6.7). Kidney 
(omega-1)-hydroxylation was induced 2-fold in the guinea pig 
and 1.5-fold in the hamster (table 6.7). The increase in 
omega-hydroxylase activity was between 1.5 and 2-fold in the 
mouse and hamster (table 6.7). In the rat hepatic cytochrome 
P-452 content (% of total P-450) was induced 5 to 10-fold 
(figure 4.3). In the kidney cytochrome P-452 induction was
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less than 2-fold (table 6.6). Likewise marked hepatic 
induction was observed in the mouse, hamster and rabbit with 
minimal renal treatment-induced changes.
Kidney microsomal (omega-1)- and omega-hydroxylation of lauric 
acid was 3 to 14-fold and 9 to 22-fold higher than in liver 
microsomes. In the mouse, renal hydroxylation of lauric acid 
at both positions was 7-fold higher than the liver, whereas in 
the hamster and guinea pig only renal omega-hydroxylation was 
greater, 7- and 3.5-fold, respectively. (Omega-1)- and 
omega-hydroxylase activity was 2- and 5-fold higher in rabbit 
kidney as opposed to the liver. It is interesting to note that 
in guinea pig liver microsomes (omega-1)-hydroxylation 
predominated whereas in the kidney the reverse was true.
DISCUSSION
This information reiterates the belief that renal cytochrome 
P-450 metabolism is directed towards omega- and (omega-1)- 
hydroxylation of fatty acids as opposed to the liver where 
xenobiotic metabolism predominates in the untreated animal. It 
is interesting to note that in the rat, the basal levels of
cytochrome P-452 (nmol P-452/nmol P-450) in the liver and
kidney were similar. However when these were expressed as a 
percentage of total P-450, they were markedly different i.e.
3-6% in the liver as opposed to 18-30% in the kidney. A
similar observation was demonstrated in the mouse, hamster and
rabbit.
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It is apparent that in the untreated animal there is 
considerable variation in enzyme activity between the liver 
and kidney and that with the cytochrome P-450 system, this 
represents fundamental differences in the metabolic role of 
these two organs. It has been demonstrated that species and 
rat strain variation in response occurs. Treatment-induced 
changes (whether observed as increased or decreased enzyme 
activities) were exhibited in the kidney, reflecting a similar 
but more marked response in the liver. In general the renal 
responses are an order of magnitude lower than in the liver. 
The induction of cytochrome P-452, measured immunochemically 
and catalytically, was considerably lower in the kidney of the 
Gunn and Sprague Dawley rat, hamster and mouse. Renal omega- 
and (omega-1)-hydroxylase activity was unchanged in the 
Fischer and Long Evans rat and induction of only the 
(omega-1)-hydroxylase occurred in the Wistar rat. Similarly 
renal (omega-1)-hydroxylase activity was induced in the guinea 
pig yet was unchanged in the liver. The increase in cytochrome 
P-452 content in the rabbit was not associated with an 
increase in catalytically active protein but with decreased 
omega- and (omega-l)-hydroxylation of lauric acid. The reason 
for this is unclear. It is possible that in the rabbit, liver 
cytochrome P-452 is responsible for hydroxylation of fatty 
acids. However in the kidney a haemoprotein with strong 
homology to cytochrome P-452 but with minimal activity towards 
omega- hydroxylation, may be recognised by the antibody under 
the ELISA conditions used. The chronic administration of 
peroxisome proliferators would appear to result in more marked 
renal enzyme changes. In comparison with other peroxisome
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prolif erators, ciprofibrate although a highly potent compound 
in the liver, has minimal effects in the kidney suggesting 
that the hepatic response is tissue specific as opposed to 
tissue common.
It has been suggested that the renal omega- and (omega-1)- 
hydroxylation of lauric acid is catalysed by a single 
monooxygenase enzyme (Ellin and Orrenius,1975). Two kidney 
cortex haemoproteins, cytochrome P-450k-l and P-450k-2, were 
purified from untreated rats (Yoshimoto et al.,1986). Both 
forms catalysed omega- and (omega-1)-hydroxylation of fatty 
acids. In addition P-450k-l metabolised prostaglandin A-l and 
prostaglandin A-2 at the omega-position. Cytochrome P-450k-5 
was similarly isolated from untreated rats and this isoenzyme, 
with an absorption maximum at 452nm, catalysed the omega- and 
(omega-1)-hydroxylation of lauric acid (Imaoka and Funae, 
1986). Guinea pig renal cytochrome P-450 monooxygenases have 
also been found to metabolise prostaglandin E-l at the omega- 
and (omega-1) positions (Navarro et al.,1978). Cytochrome 
P-450ka, isolated from untreated rabbit kidney cortex 
microsomes catalysed omega-hydroxylation of prostaglandin A-l 
and prostaglandin A-2 and the omega- and (omega-1)- 
hydroxylation of fatty acids (Kusunose et al.,1985). This 
cytochrome P-450 isoenzyme was induced by clofibrate and DEHP 
(Yamamoto et al.,1986).
It has been reported that rabbit kidney cortex microsomes 
metabolise arachidonic acid to the 19- and 20-hydroxyproducts, 
presumably via a cytochrome P-450 monooxygenase (Morrison and
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Pascoe,1981, and Oliw et al.,1981). The formation of the 
omega- and (omega-1) products of arachidonic acid occurred 
preferentially (75%) in the cortex whereas the formation of 
prostaglandins predominated in the medulla (60%) (Chacos et 
al.,1983). The omega- and (omega-1) hydroxylation of 
arachidonic acid can occur prior to or after epoxidation via 
the epoxygenase pathway (Needleham et al.,1986). Epoxy- 
eicosatrienoic acids have been isolated and purified from 
female rabbit kidneys (Falck et al.,1987). In the rabbit, 
cytochrome P-450 isoenzyme(s) specific for arachidonic acid 
metabolism are primarily localised in the outer medulla 
(Schwartzman et al.,1986).
It is apparent that in the kidney considerable omega- and 
(omega-1)-hydroxylation of fatty acids (such as lauric acid, 
arachidonic acid and prostaglandins) occurs. It is equally 
clear that there is more than one renal cytochrome P-450 
isoenzyme capable of omega- and ( o m e g a -1)-hydroxylation of 
fatty acids. Cytochrome P-450 LAw was purified from livers of 
clofibrate treated rats (Hardwick et al.,1987). Immunoblot 
analysis with anti cytochrome P-450 LAw antibody revealed the 
presence of two clofibrate-induced cytochrome P-450 proteins 
in both the liver and kidney. The second protein of higher 
molecular weight was thought to be a closely related isoenzyme 
in the same cytochrome P-450 family or a modified form of 
cytochrome P-450 LAw. Similarly, western blot analysis of 
control and clofibrate liver microsomes with anti cytochrome 
P-452 antibody revealed two protein bands (Earnshaw et 
al.,1988). Total RNA samples prepared from control and
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clofibrate induced hepatic and renal microsomes were 
hybridised with the cytochrome P-452 cDNA probe (Earnshaw et 
al.,1988). Comparable levels of hybridisation to a mRNA 
species of approximately 2 Kbp were observed with control 
liver and kidney RNA preparations. A marked induction in 
cytochrome P-452 mRNA levels occurred in rat liver following 
clofibrate administration; this induction was less marked in 
the kidney (Earnshaw et al.,1988). It should be noted that 
rabbit pulmonary prostaglandin omega-hydroxylase (cytochrome 
P-450 p-2) shares 74% amino acid similarity with rat hepatic 
cytochrome P-450 LAw suggesting that both forms are members of 
the same cytochrome P-450 gene family (Hardwick et al.,1987, 
and Matsubara et al.,1987).
There may be a tissue specificity for the presence or 
inducibility of these cytochrome P-452 enzymes. Further 
investigation is required to clarify the renal cytochrome 
P-450 isoenzymes responsible for omega- and (omega-1)- 
hydroxylation. Correlation using catalytic and immunochemical 
techniques and analysis of RNA levels and gene expression of 
these renal hydroxylase forms with hepatic cytochrome P-452, 
should be attempted. DNA sequence analysis of genomic and cDNA 
clones will enable the relationship between cytochromes P-452 
in different tissues, strains and species to be elucidated.
Rat hepatic glutathione peroxidase activity was 1.75 to 4-fold 
higher than in the kidney. Renal GPX activity was unchanged 
following ciprofibrate administration with the exception of 
the Fischer rat where activity was shown to be decreased. In
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the hepatic cytosolic fractions, GPX activity was decreased to 
50% of the control value.
The effects of a wide range of peroxisome prolif erators on 
renal mitochondrial and peroxisomal enzymes has been studied 
in the Wistar rat (Sharma et al.,1988a). A 1.5 to 3-fold 
induction in peroxisomal beta-oxidation was observed with 
DEHP, bezafibrate, nafenopin and clofibrate. A maximal 2-fold 
induction in carnitine acetyltransferase, carnitine
palmitoyltransferase (mitochondrial enzyme), total enoyl-CoA 
hydratase (mitochondrial and peroxisomal) and peroxisomal 
enoyl-CoA hydratase activities resulted from treatment (Sharma 
et al.,1988a). The relative potencies of the compounds tested 
varied widely. The induction of renal enzymes was considerably 
lower than in the liver. Peroxisome proliferation has been 
demonstrated in clofibrate treated kidney cells (Svoboda et 
al.,1969). This proliferation was sex-related with male rats 
displaying more extensive peroxisome proliferation than 
females at the same dose levels (Henry and De Morrow, 1985). 
Induction of peroxisomal beta-oxidation, enoyl-CoA hydratase 
and PPA 80 with an associated peroxisome proliferation was 
reported in mouse kidney following methyl clofenapate, BR-931 
and Wy-14,643 treatment (Lalwani et al.,1981).
Induction of peroxisomal enzymes occurs in the kidney of 
treated rats and mice. In each instance, renal response was 
minimal compared to the enzyme changes demonstrated in the 
liver. Renal peroxisomal enzyme parameters have not been 
studied in the hamster, guinea pig and rabbit although with
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reference to the hepatic response, species susceptibility 
varied with the rat > mouse > hamster > rabbit. The guinea pig 
was not responsive to ciprofibrate treatment.
The absorption and pharmacokinetic properties of ciprofibrate 
in the rat have been discussed in the previous chapters. The 
treatment-induced changes in the kidney, in comparison to the 
liver, were minimal indicating that the hepatic response was 
probably tissue specific. This may be caused by unequal 
distribution of ciprofibrate in vivo i.e. low levels of the 
drug in the kidney versus high levels in the liver. However 
the tissue distribution of radiolabelled ciprofibrate has been 
studied in rats (Davison et al.,1975). Autoradiographs were 
developed at 24 hours and 16 days following administration (3 
mg/kg). At the 24 hour interval, ciprofibrate levels were 
similar in both organs: 11.2 to 11.4 ug ciprofibrate/g tissue
for the liver and kidney respectively. At 16 days the 
ciprofibrate distribution was not markedly different in these 
tissues (1.0 to 0.3 ug ciprofibrate/g tissue for the liver and 
kidney). Assuming that in both instances all the detected 
radiolabel was ciprofibrate, the apparent tissue specific 
response of the liver as opposed to the kidney, was not due to 
a tissue selective distribution of the compound. The lack of 
response in the kidney following administration of peroxisome 
prolif erators is likely to be due to inherent tissue 
differences in response.
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Chapter 7
DISCUSSION
7.1. INTRODUCTION
The aims of the work presented in this thesis were fourfold;
i) to utilise the pharmacokinetic properties of peroxisome 
proliferators to rationalise the selection of both dose levels 
and frequency of dosing for subsequent induction studies,
ii) to examine the species variability in hepatic response to 
ciprofibrate,
iii) to compare and contrast hepatic and renal responses to 
ciprofibrate, and
iv) to consider the validity of using laboratory animal 
studies to predict the biological response to ciprofibrate in 
a non-human primate, and ultimately in man.
7.1.1. Influence of pharmacokinetics on the inductive potency
of three hypolipidaemic drugs in the Fischer rat.
It has been established that the pharmacokinetic properties of 
clofibric acid, bezafibrate and ciprofibrate are markedly 
different with ciprofibrate exhibiting a long half life (3-4 
days) and a prolonged pharmacological action (Edelson et 
al.,1979). With once daily dosing, the inductive potencies of 
these three compounds were dissimilar and the order of 
response was ciprofibrate (20mg/kg/day) > bezafibrate
(75mg/kg/day) > clofibric acid (50mg/kg/day). My results have 
shown that by altering the dosing regimen with respect to
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pharmacokinetic parameters (i.e. clofibric acid and 
bezafibrate administration twice daily and ciprofibrate once 
every 48 hours) the different inductive potencies of the three 
compounds were ablated. Accordingly, the importance of 
utilising pharmacokinetic properties to select dose regimens 
in comparative studies cannot be ignored or underestimated.
7.1.2 Species Variability in the Hepatic Response to
Ciprofibrate Administration
In all rat strains, the mouse, hamster and rabbit, peroxisomal 
beta-oxidation and carnitine acetyltransf erase activity was 
increased and the elevation in lauric acid omega-hydiroxylase 
activity was associated with an increase in the specific 
content of cytochrome P-452. No treatment related enzyme 
changes were observed in the guinea pig. In the riiarmoset 
peroxisomal beta-oxidation was increased only slightly with 
unchanged carnitine acetyltransf erase and lauric acid 
omega-hydroxylase activities. Cytochrome P-452 could not be 
detected immunochemically in marmoset or guinea pig liver 
microsomes. In the marmoset, mitochondrial enzyme activities 
were elevated. The responses in the rat and marmoset to the 
chronic administration of ciprofibrate were similar to those 
observed following acute exposure. In the marmoset the 
increase in succinate dehydrogenase activity and the decrease 
in (omega-1)-lauric acid hydroxylase activity was maintained 
after a one month recovery period. The induction of the 
peroxisomal beta-oxidation system was found to be readily 
reversible. In the marmoset, peroxisomal beta-oxidation was
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increased and additionally succinate dehydrogenase and 
alpha-glycerophosphate dehydrogenase activities were elevated 
whereas in the rat only mitochondrial alpha-glycerophosphate 
dehydrogenase activity was stimulated.
There is a marked species variability in the hepatic response 
to ciprofibrate. The rat, mouse, hamster and rabbit are termed 
responsive due to induction of a similar pattern of enzymes 
(cytochrome P-452 and lauric acid omega-hydroxylase, carnitine 
acetyltransferase and peroxisomal beta-oxidation). The guinea 
pig and marmoset were designated non-responsive.
7.1.3. The Rat and Species Renal Response to the
Administration of Ciprofibrate
The effect of ciprofibrate on the renal drug metabolising 
enzyme system was examined in different rat strains and 
species. Renal enzyme changes occurred but in each case the 
response was less marked than that in the liver. The basal 
levels (i.e. in the untreated animal) of cytochrome P-450 
(specific content) and benzphetamine-N-demethylase and 
ethoxyresorufin-O-deethylase activities were considerably 
lower in the kidney in comparison to the liver whereas renal 
lauric acid omega- and (omega-1)-hydroxylation was more 
extensive. The increase in omega- and (omega-1)-hydroxylation 
of lauric acid was minimal in the rat and induction did not 
occur in every strain or species. Cytochrome P-452 content was 
slightly increased in responsive species yet did not correlate
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with catalytic activity. In the rat, renal glutathione
peroxidase activity was unchanged. The comparison of liver and
kidney responses in the rat, mouse, hamster and rabbit,
<
treated with ciprofibrate, indicates that the tissue response 
is largely specific to the liver.
7.1.4. Extrapolation of Animal Data to Predict the Response
in Non-human Primates.
The rat, mouse, hamster and rabbit are considered responsive 
species whereas the guinea pig and marmoset are 
non-responsive. It is clear that using rodent data to predict 
the response in the non-human primate (i.e. marmoset) in this 
instance, is questionable as the pattern of hepatic enzyme 
changes in these two species were different. All the 
peroxisome prolif erators that have been tested for 
carcinogenic potential, cause hepatocarcinogenesis in rats and 
mice and whether or not this can be considered as a possible 
outcome in man is of obvious concern. It is important to 
consider the mechanisms of induction of enzyme changes and 
hepatocarcinogenesis in the rat. This may be a useful 
consideration when comparing the species response to 
ciprofibrate and may reveal a greater insight into the
I
apparent species specificity of the hepatic response.
7.2. MECHANISMS OF TOXICITY IN THE RAT
A hypothesis is presented in figure 7.1 to explain the 
induction of enzyme parameters and hepatocarcinogenesis in the
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rat. This is based largely on the data described in the 
previous chapters with ciprofibrate in the rat, although a 
similar response by all peroxisome prolif erators would be 
expected. Induction of the hepatic response in different 
species will be examined in a later section. The liver changes 
observed in the rat on acute exposure :- hepatomegaly, 
increased omega-lauric acid hydroxylase, carnitine 
acetyltransf erase and peroxisomal beta-oxidation activities - 
are sustained at 26 weeks and in long-term bioassays accompany 
hepatocarcinogenesis. With acute and chronic treatment these 
enzyme changes are not associated with liver toxicity per se 
(i.e. cell necrosis) and may be used as an index of toxicity 
to predict the probability of ultimate liver damage, 
hepatocarcinogenesis.
Peak plasma levels of ciprofibrate were achieved two hours 
post dose (Edelson et al.,1979). Metabolism of the peroxisome 
prolif erator to the active compound may be necessary, for 
example clofibrate (ethyl ester) is converted to clofibric 
acid. On treatment an increase in liver/body weight ratio was 
observed and this was probably due to hyperplasia and 
hypertrophy (Mann et al.,19.85). A midzonal and periportal 
accumulation of fat was observed with treatment and this was 
similar to the fatty change produced by an excess intake of 
lipid (Mann et al.,1985). The composition of the accumulated 
lipid has not been defined. A shift in the composition of free 
fatty acids in the liver was observed in rats fed a partially 
hydrogenated fish oil diet with a significant increase in the 
levels of 19; 1 and 18:1 fatty acids and a decrease in the
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Figure 7.-1.
Possible Mechanisms of Induction of Enzyme Changes and 
Hepatocarcinogenesis in the Rat.
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levels of 18:2 and 20:4 fatty acids (Nilsson et al.,1987). In
clofibrate treated mice, the composition of individual free
fatty acids of the liver triacylglycerols showed a shift 
towards shorter fatty acids and nutritionally essential
alpha-linolenic acid (Jones and Neill,1982). A substrate
overload linked induction of cytochrome P-452 may occur as
this isoenzyme utilises medium and long chain saturated and
unsaturated fatty acids [e.g. lauric and arachidonic acids]
(Bains et al.,1985, Tamburini et al.,1984). Cytochrome P-452 
was increased several fold on treatment. Microsomal oxidation 
of fatty acids results in omega- and (omega-l)-hydroxy medium 
and long chain fatty acids and subsequent oxidation by
cytosolic alcohol and aldehyde dehydrogenases to dicarboxylic 
fatty acids may occur (Mitz and Heinrikson,1961). The short 
chain fatty acids are probably metabolised by mitochondria 
prior to microsomal oxidation. According to their chain length 
substrate specificity, medium and long chain monocarboxylic- 
and omega- hydroxymonocarboxylic fatty acids can be 
metabolised by mitochondria but the dicarboxylic fatty acids 
are substrates for peroxisomal beta-oxidation only (Vamecq and 
Draye, 1987). The end products of omega- and (omega-1)- 
hydroxylation may ultimately initiate peroxisomal 
proliferation and induction of peroxisomal beta-oxidation 
enzymes. Long chain dicarboxylic fatty acids would undergo 
several cycles of the peroxisomal beta-oxidation pathway until 
the chain length was sufficiently shortened to provide 
suitable substrates for the mitochondrial beta-oxidation 
system.
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Induction may similarly occur by substrate overload. Induction 
of microsomal, peroxisomal and mitochondrial oxidising 
pathways have been observed in rats fed a partially
hydrogenated fish oil / high fat diets (Ishii et al.,1980, 
Krahling and Tolbert,1982 and Nilsson et al.,1987). The 
hepatic peroxisomal beta-oxidising system and fatty acyl-CoA 
oxidase activity were significantly increased with a high
cholesterol diet (Hayashi et al.,1986). Cholesterol may be a 
physiological substrate for liver peroxisomes leading to a 
substrate overload induction, however as yet, there is no 
evidence for peroxisomal metabolism of cholesterol. The effect 
of this diet on the microsomal omega-oxidation system was not 
studied. It has recently been demonstrated that 3-hydroxy-3- 
methylglutary1-coenzyme A reductase, the key regulatory enzyme 
in cholesterol biosynthesis, is localised in peroxisomes in 
addition to the endoplasmic reticulum (Keller et al.,1985). A 
diet rich in (n-3) fatty acids has been associated with
increased peroxisomal beta-oxidation activity and lowered
plasma triacylglycerol levels (Yamazaki et al.,1987).
Chlorpromazine administration causes a slow accumulation of 
lipid in large droplets in centrilobular hepatocytes (Price et 
al.,1985). Peroxisomal beta-oxidation and microsomal 
omega-oxidation of fatty acids was unchanged, and these latter 
authors concluded that hepatic lipid accumulation does not 
automatically induce fatty acid oxidising enzymes. However, 
accumulation of a specific fatty acid or lipid may be 
necessary to trigger cytochrome P-452 induction and the 
pattern of lipid accumulation observed in peroxisome
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proliferator treated animals was different to that in animals 
administered chlorpromazine (Price et al.,1985).
If the hypothesis accounting for induction of the microsomal, 
peroxisomal and mitochondrial oxidising systems in hepatocytes 
is attributed to substrate overload as outlined above, the 
chronological sequence of induction must be established. By 
increasing the microsomal omega-oxidation pathway, there is a 
shift in fatty acid substrates from the mitochondria to 
peroxisomes as evidenced by an increase in long chain 
dicarboxylic fatty acids (Vamecq and Draye,1987). Peroxisomal 
beta-oxidation of long chain dicarboxylic acids would give 
rise to short and medium chain fatty acids, substrates for the 
mitochondrial system. However it has been reported that in 
treated rats, mitochondrial beta-oxidation proceeds at a 
maximum rate before enhancement of peroxisomal beta-oxidation 
occurs (Berge and Aarsland,1985). The mechanism of induction 
was attributed to the cellular level of long chain acyl-CoA. A 
time-course study examining the induction of peroxisomal 
beta-oxidation and microsomal omega-oxidation following a 
single dose of clofibrate has been examined (Milton et 
al.,1988a). There was no apparent time lag between induction 
of fatty acid oxidation in the separate subcellular fractions. 
However this experiment was conducted in vivo and may have 
been insufficiently sensitive to differentiate induction in 
the two subcellular organelles. The use of primary hepatocytes 
at frequent time periods after ciprofibrate challenge may be a 
useful experimental system to clarify the precise temporal 
relationships between induction of fatty acid oxidation in the
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endoplasmic reticulum and peroxisomes.
Administration of medium to long chain dicarboxylic acids to 
rats had no effect on peroxisomal beta-oxidation indicating 
that the products of microsomal omega-oxidation do not cause 
peroxisomal proliferation and induce peroxisomal enzymes 
(Nilsson et al.,1987). However these dicarboxylic acids were 
administered by oral gavage and considerable metabolism may 
have occurred prior to entry into the liver causing an 
inadequate intra-hepatic lipid accumulation. The hypothesis
that long chain dicarboxylic acids may cause peroxisome
proliferation and induce peroxisomal enzymes is substantiated 
by a series of experiments recently completed with tiadenol. 
Tiadenol, (bis( hydroxy ethylthio)- 1.10-decane, is a rodent 
peroxisome prolif erator (Berge et al.,1984). The tiadenol 
molecule is characterised by two primary alcohol groups 
(figure 7.2). The compound, (bis( carboxy  ethylthio)-1.10- 
decane, a possible dicarboxylic metabolite of tiadenol, was 
synthesised [figure 7.3] (Berge et al.,1987). Normal 
beta-oxidation of this derivative would be blocked because of 
the sulphur atoms in the beta positions of the carbon chain. 
The administration of this dicarboxylic derivative to rats 
caused a decrease in serum cholesterol and triglyceride
levels, hepatomegaly and induction of peroxisomal 
beta-oxidation, responses similar to that seen with the parent 
compound, tiadenol (Berge et al.,1987). Cytosolic acyl-CoA 
hydrolase and enzyme activities involved in the formation and 
breakdown of long chain acyl-CoA/xenobiotic acyl-CoAs were 
increased in treated animals. It was suggested that the
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Ficure 7.1.
Chemical Structure of Tiadenol (bis( hydroxyethvlthio) - 1.10'
Decane
HOCH2-CH2-S-(CH2),o-S-CH2-CH2OH
Figure 7.2.
Chemical Structure of The Dicarboxylic Derivative of Tiadenol,
(bis (carboxy-ethylthio) -1.10-Decane
HOOC-CH2-S-(CH2),o-S-CH2-COOH
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CoA-ester of this dicarboxylic derivative of tiadenol may 
initiate peroxisome proliferation and induction of peroxisomal 
enzymes (Aarsland et al.,1987, Berge et al.,1987). The in vivo 
formation of this derivative has yet to be established.
The mitochondrial fatty acid beta-oxidation system is 
dependent on carnitine acetyltransf erase as an intermediate 
carrier of acyl-substrates into the mitochondrial matrix. 
Carnitine is not involved in the entry of fatty acids into 
peroxisomes but may play a role in the removal of end products 
which could be shuttled to the mitochondria for further 
oxidation or conversion into ketone bodies (Lazarow, 1982). 
Carnitine acetyltransf erase activity was induced on treatment 
and this represented an increase in enzyme activity in 
mitochondria and peroxisomes. Long chain acyltransferase 
activity is observed only in mitochondria and this was 
increased 2 to 4-fold on treatment (Sharma et al.,1988). This 
marked increase in enzyme activity would facilitate the 
transfer of fatty acyl substrates out of the peroxisome and 
into the mitochondria. Induction could be associated with a 
substrate overload or altered lipid metabolism as indicated in 
figure 7.1. The stimulation of mitochondrial beta-oxidation 
following clofibrate treatment reflects increased activity of 
non-latent CoA-carnitine acyltransferase and increased 
activity of beta-oxidation enzymes (Mackerer,1977). Hepatic 
synthesis of carnitine and its esterification to 
acylcarnitines was increased (Paul et al.,1986). The induction 
of cytochrome P-452 by peroxisome proliferators has been shown 
to correlate well with the increase in peroxisomal and
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mitochondrial parameters (Gibson and Sharma, 1987).
Induction of fatty acid metabolism could also result from an 
interaction of the peroxisome proliferator itself and/or a 
metabolite with a receptor in the cytoplasm of hepatocytes 
(Reddy and Lalwani, 1983), in a similar fashion to the 
glucocorticoid receptor (Heuman et al.,1982) and the Ah 
receptor (Poland and Knutson,1982). Tritiated nafenopin was 
shown to bind to a specific saturable pool of binding sites in 
cytosols from rat liver and tissue levels of this protein 
correlated with the ability of nafenopin to induce hepatic 
peroxisomal enzymes (Lalwani et al.,1983). This 
peroxisome-prolif eration binding protein has been purified and 
may play an important role in the regulation of the induced 
response (Lalwani et al.,1987). It is both plausible and 
tempting to speculate that a cytosolic receptor binding 
protein is responsible for the induction of a "battery" of 
enzymes. However the existence of this putative receptor has 
not been universally accepted with the original binding 
studies still to be verified in other laboratories. Our 
laboratory has found no evidence of specific binding of 
peroxisome prolif erators to hepatic cytosolic proteins or 
receptor material (Milton et al.,1988).
Peroxisome prolif erators and/or their metabolites could act as 
substrates for the different oxidation pathways thereby 
initiating enzyme induction. The limited formation of 
hydroxybezafibrate by a cytochrome P-450 mediated process has 
been demonstrated in vitro (Facino et al.,1981). Tiadenol is
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metabolised by an S-oxidative hepatic microsomal cytochrome 
P-450 dependent monooxygenase (Facino et al.,1986). Similarly 
in vitro metabolism of ME HP to omega-, (omega-1)- and 
(omega-2)-hydroxy products has been observed and this was 
thought to be by cytochrome P-450 isoenzymes associated with 
hydroxylation of fatty acids (Albro et al.,1984). Phthalate 
ester plasticisers may undergo mitochondrial or peroxisomal 
beta-oxidation. This mechanism lacks evidence and would not 
account for the marked variation in enzyme induction observed 
with this class of structurally diverse compounds.
Acute toxicity in rats following exposure to a variety of 
xenobiotics may result in carcinogenicity. With the 
administration of peroxisome prolif erators, enzyme induction 
occurs but this is not related to gross toxicity, however 
hepatocarcinogenesis develops in treated rats between 1 and 2 
years (Reddy and Lalwani, 1983). These compounds are uniformly 
negative in a wide range of mutagenicity tests indicating a 
class of non-genotoxic carcinogens. No binding of clofibrate 
or fenofibrate to hepatic nuclear DNA has been detected (Von 
Daniken et al.,1981) and nafenopin and Wy-14,643 exhibited no 
significant binding to DNA in vivo or in vitro (Goel et 
al.,1985). No hepatic DNA damage has been observed in rats 
treated with DEHP and DEHA (Ruddick et al.,1981, Von Daniken 
et al.,1984) and single and sub-chronic dosing of DEHP to rats 
was not associated with initiating potential (Garvey et 
al.,1987). Both DEHP and its metabolite MEHP were non- 
genotoxic in a range of short term in vitro mutagenicity 
assays (Schmezer et al., 1988). No peroxisome proliferator DNA
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adducts were detected in hepatocytes under in vivo and in 
vitro conditions with clofibrate, ciprofibrate, W y - 14,643 or 
DEHP (Gupta et al.,1985).
How then does one explain the rodent carcinogenicity of 
peroxisome prolif erators? It has been suggested that the 
marked increase in peroxisomal beta-oxidation leads to an 
excessive production of hydrogen peroxide by fatty acyl-CoA 
oxidase. The specific activity of catalase was unchanged by 
treatment (total activity was increased in parallel with 
hepatomegaly) and this may be insufficient to remove excessive 
hydrogen peroxide produced in stimulated peroxisomes. In 
animals treated for 26 weeks with bezafibrate or ciprofibrate 
the specific activity of catalase was significantly decreased. 
It has been suggested that stimulated peroxisomes may be 
"leaky" and that hydrogen peroxide diffuses into the cytoplasm 
of the cell. The hydrogen peroxide may interact with a non-DNA 
target producing active oxygen species. The decrease in 
hepatic glutathione peroxidase activity (to approximately 50% 
of control value) observed with ciprofibrate in my studies may 
potentiate oxidative stress by inadequate removal of cytosolic 
hydrogen peroxide. The active oxygen species may cause lipid 
peroxidation, DNA attack and hepatocarcinogenesis. Consistent 
with this lipid peroxidation proposal of neoplastic 
transformation is the observed accumulation of lipofuscin in 
the livers of treated rats (Reddy et al.,1982).
Hydrogen peroxide may also be produced in the endoplasmic 
reticulum by the uncoupling of cytochrome P-450 mixed function
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oxidase activity. Metabolic pathways involving cytochrome 
P-450 enzymes may initiate or modulate oxidative damage due to 
oxygen radicals (Gonder et al.,1985). In mice, oxygen toxicity 
has been shown to parallel the genetic control of cytochrome 
P-450 enzyme induction and toxicity developed at a time when 
the cytochrome P-450 enzyme system was induced by oxygen. With 
clofibrate administration microsomal and cytosolic epoxide 
hydrolases were induced and this may be a protective 
mechanism (Moody et al.,1985). Under physiological conditions 
the hydrogen peroxide produced in peroxisomes is largely 
disposed of by catalase whereas hydrogen peroxide arising from 
mitochondria, endoplasmic reticulum or cytosolic enzymes such 
as superoxide dismutase, is acted upon by glutathione 
peroxidase (Halliwell and Gutteridge,1985).
Evidence for the involvement of hydrogen peroxide and or free 
radicals in hepatocarcinogenesis has been indicated by the 
inhibitory influence of the antioxidants, ethoxyguin and 
2( 3)-tert-butyl-4-hydroxyanisole (BHA) on ciprofibrate-induced 
hepatic tumourigenesis (Rao et al.,1984). This was believed to 
be due to the ability of antioxidants to scavenge hydrogen 
peroxide and/or free oxygen radicals. DNA damage occurred when 
purified tritiated SV40 DNA was co-incubated with a system 
containing purified peroxisomes, palmitate and the cofactors 
required for beta-oxidation (Fahl et al.,1984). The extent of 
DNA damage correlated with the level of hydrogen peroxide 
generated by the control and W y - 14,643 treated peroxisomes. 
Catalase has a relatively minor role in hydrogen peroxide 
catabolism at low rates of hydrogen peroxide generation in the
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endoplasmic reticulum however enzyme function increases as the 
rate of production is enhanced (Jones et al.,1981). Catalase 
readily leaks from peroxisomes (Alexson et al.,1985). It has 
been shown that liver peroxisome-enriched fractions from 
animals treated with peroxisome prolif erators can produce
increased levels of hydrogen peroxide and hydroxyl radicals by 
the fatty acyl-CoA oxidase system, the contribution of such 
reactive oxygen species to any genotoxicity in vivo remains to 
be firmly established (Elliot et al.,1986).
Hepatic lipid peroxidation was observed in rats treated with 
ciprofibrate and Wy - 14,643 and this was associated with 
increased hydrogen peroxide generation and decreased
glutathione peroxidase and glutathione reductase activities, 
indicative of oxidative stress (Goel et al.,1986). Hepatic
glutathione peroxidase and superoxide dismutase activities
were decreased with fenofibrate administration with a
concomitant increase in malonyl dialdehyde production (Ciriolo 
et al.,1984). Lipid peroxidation is an efficient source of 
peroxyl radicals (Marnett,1987). The extent of hepatic lipid
peroxidation in DEHP treated rats displaying peroxisome
proliferation, did not differ from that in controls (Ruddick 
et al.,1981). The role of lipid peroxidation in preneoplastic
change has yet to be clarified. The extent of radical
production in the livers of rats exposed to peroxisome
proliferators is estimated to be insufficient to result in a 
biologically significant degree of DNA damage (Elliot and
Elcombe,1987). However the hepatocarcinogenic potency of
ciprofibrate, DEHP and DEHA correlated with their ability to
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induce peroxisome proliferation, peroxisomal beta-oxidation 
and PPA80 (Reddy et al.,1986a).
Reactive fatty acid epoxides could also be formed in 
hepatocytes and these may lead to a direct covalent 
interaction with cellular macromolecules and DNA. The liver 
microsomal cytochrome P-450 system metabolises polyunsaturated 
fatty acids, notably arachidonic acid, to a variety of 
oxygenated products such as hydroxyeicosatetraenoic acids 
(HETEs), epoxyeicosatrienoic acids (EETs) and omega- and 
(omega-l)-hydroxylated acids (Capdevila et al.,1981, 1982,
Chacos et al.,1982, 1983, Manna et al.,1983). It has been
reported that ciprofibrate administration stimulated the 
omega- and (omega-1)-oxidation of arachidonic acid in rat 
liver microsomes, concomitant with a net decrease in the 
formation of both HETEs and EETs (Capdevila et al.,1985), 
whereas phenobarbitone administration enhanced the metabolism 
of arachidonic acid to the 11-/12- and 14-/15-epoxides (Oliw 
et al.,1982).
Peroxisome prolif erators are potent promoting agents. The 
altered hepatic areas, neoplastic nodules and hepatocellular 
carcinomas induced by peroxisome prolif erators are negative 
for gamma-glutamyltransf erase (G-GT) and placental 
glutathione-S-transferase unlike the hepatic lesions induced 
by classical liver carcinogens (Rao et al.,1986a). Peroxisome 
prolif erators do not appear to derepress the activity of the 
G-GT gene during hepatocarcinogenesis.
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The specific content of cytochrome P-450 was decreased in rats 
treated with ciprofibrate for 65-70 weeks and aryl hydrocarbon 
hydroxylase activity was similarly reduced (Rao et al.,1987). 
With a 26 week ciprofibrate treatment period, the activities 
of benzphetamine-N-demethylase and ethoxyresoruf in-0-
deethylase were decreased to approximately 50% of the control 
value. The specific content of cytochrome P-452 was increased 
11-fold and lauric acid omega-hydroxylase activity elevated 
20-fold. Induction of cytochrome P-452 by peroxisome 
prolif erators showed a negative correlation when compared to 
benzphetamine-N-demethylase and ethoxyresorufin-O-deethylase 
activities indicating a specific gene switch on for cytochrome 
P-452 concomitant with a gene switch off for these two 
activities (Gibson and Sharma, 1987).
These chemicals may promote tumour formation from cells 
altered through effects other than induced initiation eg. 
spontaneous mutation or inherited genetic abnormalities 
(Williams,1981). It has been demonstrated that livers of 
untreated aged Wistar rats of both sexes contain putative 
preneoplastic cells and rates of DNA synthesis in these foci 
were higher than in normal liver and were stimulated by a 
single dose of nafenopin (Schulte-Hermann et al.,1983). 
Non-genotoxic carcinogens could produce liver tumours if they 
promote development from preneoplastic foci susceptible to 
endogenous and exogenous growth stimuli. Depending on the 
strain and the conditions, liver tumours are not particularly 
uncommon in elderly, untreated SPF (specified pathogen free) 
rats fed ad libitum. The percentage of liver tumours in
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untreated 2 year old rats of different strains varied between 
0.4 to 22% (ECETOC, 1982).
In the rat hepatomegaly is a characteristic response to 
administration of peroxisome prolif erators and is due to 
hyperplasia and hypertrophy. With prolonged drug 
administration continued stimulation of non-reparative cell 
division could eventually lead to tumour formation. In DEHP 
and methyl clofenapate induced hepatic hyperplasia, a 
reduction in the frequency of binucleated cells was 
demonstrated and an increase in the tetraploid: diploid ratio 
was observed due to the continued conversion of newly formed 
binucleates to tetraploid mononucleates (Styles et al.,1987). 
In animals treated with genotoxic carcinogens there was a
permanently depressed tetraploid: diploid hepatocyte ratio
(Styles et al.,1987). The role of increased mitotic activity 
as a determinant of tumour development has undergone much
speculation. The occurrence of somatic mutation with
hyperplasia has been suggested with increased hepatic ploidy
acting as a promotional event (ECETOC, 1982). However it must 
be emphasised that the ploidy of tumours resulting from
peroxisome proliferator administration has not been
determined.
7.3. TISSUE SPECIFICITY OF THE RESPONSE TO PEROXISOME
PROLIFERATORS IN THE RAT.
A considerable rat strain and species variation was
demonstrated in the kidney response to ciprofibrate. These
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enzyme changes were minimal compared to that observed in the 
liver and the statistical significance could not be
determined. This suggested that the hepatic response in the 
rat and other species was tissue specific, not associated with 
a similar response in the kidney. With ciprofibrate this was 
attributed to an inherent tissue difference in induction 
responsiveness between the liver and kidney as distribution 
studies revealed an identical ciprofibrate burden (ug/g 
tissue) in these two organs (Davison et al.,1975). No kidney 
enlargement has been observed in treated rats and similarly 
renal lipid accumulation is absent or has not been assessed. A 
1.5 to 3-fold increase in the 11- and 12-hydroxylation of 
lauric acid has been observed in the Wistar rat on
administration of peroxisome prolif erators (Sharma et 
al.,1988a). The induction was 1.5 to 2.5-fold with 
ciprofibrate but this did not occur in every rat strain. A 
slight increase in cytochrome P-452 content was observed. The 
minimal increase in cytochrome P-452 protein and catalytic 
activity would indicate a slightly increased fatty acid 
substrate overload. A diet supplemented with 10% lauric acid 
has been reported to increase the level and activity of a 
cytochrome P-450 isoenzyme catalysing lauric acid 
omega-hydroxylation (Jakobsson et al.,1970). A lipid overload 
could induce renal cytochrome P-452, increasing renal levels 
of dicarboxylic fatty acids. It should be remembered that 
basal levels of microsomal fatty acid oxidation are
considerably higher in the kidney than in the liver.
A 1.5 to 3-fold increase in renal peroxisomal beta-oxidation
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has been observed in treated animals (Sharma et al.,1988a). A 
2-fold induction in carnitine acetyltransferase, carnitine 
palmitoyltransferase, total enoyl-CoA hydratase and 
peroxisomal enoyl-CoA hydratase activities has been observed 
with treatment (Sharma et al.,1988a). Analysis of various 
tissues of ciprofibrate treated rats revealed only subtle 
increases in renal peroxisome number, peroxisomal 
beta-oxidation activity and the mRNA levels of the peroxisomal 
fatty acyl-CoA oxidase and enoyl-CoA hydratase (Reddy et 
al.,1985). These increases in mitochondrial, microsomal and 
peroxisomal fatty acid metabolism would appear to be linked to 
an excess of substrate. An intermediate of lipid metabolism 
such as a fatty acid or fatty acyl-CoA derivative may be 
responsible for induction. An increase in hepatic and renal 
long chain acyl-CoA hydrolase has been reported with 
clofibrate and tiadenol administration (Katoh et al.,1987).
There is no reported occurrence of renal carcinomas in 
response to peroxisome proliferators. The increase in hepatic 
peroxisomal beta-oxidation on treatment has been estimated to 
be up to 25 and 30-fold (Reddy and Rao,1986). Clearly the 
2-fold increase in renal peroxisomal beta-oxidation is less 
likely to result in oxidative stress and lipid peroxidation. 
In addition, unlike the liver, renal glutathione peroxidase 
activity was unchanged by treatment.
It is possible that these compounds exert their effect by a 
ligand-receptor mediated mechanism. Nafenopin has been found 
to bind to a specific saturable pool of binding sites in
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kidney cortex cytosol and that tissue levels of this protein 
correlated with the ability of nafenopin to induce renal 
peroxisome enzymes (Lalwani et al.,1987). A cytosolic receptor 
binding protein would provide a plausible explanation for 
tissue differences in responsiveness to peroxisome 
prolif erators (Rao and Reddy, 1987). As stated previously the 
existence of such a protein has not been verified in other 
laboratories and has not been accepted universally.
It is apparent that in "responsive" species a pattern of 
enzyme changes occurs in the liver of treated animals. 
Considerable rat strain and species differences were (observed 
in the renal response to ciprofibrate and of particular 
interest were changes in the level and activity of cytochrome 
P-452. In the rat the response to peroxisome prolif erators is 
largely tissue specific for the liver and one would assume the 
same for responsive species. j
7.4. MECHANISM OF INDUCTION OF TOXICITY IN DIFFERENT SPECIES
The different species investigated in my study have been 
classified as responsive (rat, mouse, hamster and rabbit) and 
non-responsive (guinea pig and marmoset). An hypothesis was 
presented (figure 7.1) to explain the induction of toxicity in 
the rat and this will now be discussed with reference to the 
other species examined.
Rapid absorption of ciprofibrate following administration was 
assumed in all species; in the marmoset peak plasma levels
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occurred between 2 and 4 hours post dose (Sterling-Winthrop, 
personal communication). Ciprofibrate (i.e. ciprofibric acid) 
is the active compound therefore possible species variation in 
metabolism are not relevant. Hepatomegaly was observed in the 
rat, mouse and hamster. The specific content of cytochrome 
P-452 was increased in the rat, mouse, hamster and rabbit but 
was not detected immunochemically in guinea pig or marmoset 
microsomes. The 11-hydroxy lation of lauric acid was slightly 
increased in the mouse and hamster however omega- hydroxylase 
activity was markedly induced in all responsive species. As 
described previously, an intra-hepatic accumulation of lipid 
could initiate the induction of cytochrome P-452 resulting in 
increased levels of medium and long chain dicarboxylic acids 
and a substrate influx into peroxisomes. An induction of 
peroxisomal beta-oxidation was demonstrated in the rat, mouse, 
hamster and rabbit. Carnitine acetyltransferase activity was
increased in all four species presumably to facilitate the 
transfer of fatty acyl substrates out of peroxisomes and into 
mitochondria. The specific activity of catalase was unchanged 
on treatment and glutathione peroxidase activity was decreased 
only in the rat and mouse.
If hepatocarcinogenesis in the rat is attributed to oxidative 
stress and lipid peroxidation arising indirectly from
increased peroxisomal beta-oxidation, it is conceivable that 
species exhibiting a similar peroxisomal induction could
develop liver tumours. Induction of microsomal and peroxisomal 
parameters in the hamster and rabbit are considerably lower 
than in the rat and mouse. Several peroxisome prolif erators
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including DEHP and DEHA induce liver tumours in rats and mice 
(Rao and Reddy,1987). The latency period and the incidence of 
tumours appeared to correlate well with the effectiveness of 
the compound to induce peroxisome proliferation. Decreased 
glutathione peroxidase activity may potentiate oxidative 
stress in the rat and mouse. Similarly sustained hepatomegaly 
of a hyperplastic nature may cause a mitogenic burden on the 
liver in these species. Two long term bioassays with DEHP were 
completed in Syrian golden hamsters using i.p. and inhalation 
routes of administration (Schmezer et al.,1988). There was no 
treatment related increase in tumour incidence indicating that 
hepatocarcinogenesis is restricted to the rat and mouse. If 
the above enzyme changes are relevant to the postulated 
mechanism of toxicity of peroxisome proliferation (figure 
7.1), then the balance of "activation" and "detoxication" 
enzymes are critically important. Thus an examination of the 
activity ratio of;
Omega-hydroxylation + Peroxisomal Beta-Oxidation + Carnitine 
Acetyltransferase Activities, versus 
Catalase + Glutathione Peroxidase Activities 
should provide an overall assessment of the validity of my 
hypothesis. As shown in table 7.1, there is a clear 
dose-dependent increase in this ratio in responsive species 
whereas the ratios are essentially unchanged in non-responsive 
species. The extent of activation is highest in the rat and 
mouse, the two species exhibiting hepatocarcinogenesis with 
treatment, whereas the non-responsive species (particularly 
the guinea pig and marmoset) are refractory to induction to 
their response to ciprofibrate. This is patently apparent in
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Table 7.1.
Species Differences in the Ratio of Activation to 
Detoxification in Control and Ciprofibrate Treated Animals 
Following Acute Exposure.
Species Dose Level Activation / Detoxication 
Ratio
Fischer
Rat
Mouse
Rabbit
Hamster
Control 
2 mg/kg 
20 mg/kg 
Control 
2 mg/kg 
20 mg/kg 
Control 
2 mg/kg 
20 mg/kg 
Control 
2 mg/kg 
20 mg/kg
3.01
43.67
60.12
3.34
26.70
66.88
9.63
15.93
32.66
5.21
7.75
15.29
Guinea
pig
Marmoset
Control 
2 mg/kg 
20 mg/kg 
Control 
20 mg/kg 
100 mg/kg
4.09
3.78
4.41
15.80
17.59
19.78
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the marmoset where the highest ciprofibrate dose was five 
times that in all other species.
In the guinea pig/ no enzyme changes were detected with 
ciprofibrate in my study. Similarly, nafenopin has been found 
to cause only comparatively small changes in palmitoyl-CoA 
oxidation and lauric acid 12-hydroxylation in the guinea pig 
as determined elsewhere (Lake et al.,1987). In contrast a 
4-week treatment period with tiadenol increased peroxisomal 
beta-oxidation 3.4-fold (Oesch et al.,1987), indicating that 
the guinea pig may be responsive to certain compounds, but as 
discussed previously this may be related to the structural 
analogy of this compound to fatty acids. Omega-lauric acid 
hydroxylation and carnitine acetyltransf erase activities were 
not determined in this latter study. In the marmoset a 4-fold 
increase in peroxisomal beta-oxidation was observed with both 
short term and chronic ciprofibrate administration. In these 
two species (omega-1)-hydroxylation of lauric acid was more 
extensive than the 12-hydroxylation of lauric acid. This 
indicates that in responsive species there is a regioselective 
difference in hepatic microsomal fatty acid metabolism in 
comparison to the non-responsive species. In responsive 
species, induction of cytochrome P-452 was observed, with it 
is assumed, a subsequent increase in long chain dicarboxylic 
acids initiating peroxisomal beta-oxidation and ultimately 
mitochondrial beta-oxidation. In the marmoset and guinea pig 
there would be no increase in long chain dicarboxylic acids 
and no substrate overload linked induction of peroxisomal and 
mitochondrial beta-oxidation enzymes. In the marmoset the
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slight increase in peroxisomal beta-oxidation is not initiated 
by products of microsomal oxidation of fatty acids. This 
apparent anomaly in the marmoset response may be explained by 
the different ability of the marmoset to handle lipids. In 
addition it must be emphasised that the increase in 
peroxisomal beta-oxidation in the marmoset was minimal 
compared to other responsive species commensurate with 
non-inhibited complement of the protective glutathione
peroxidase.
The lack of response in the guinea pig and marmoset may be due 
to a dose-dependent sensitivity phenomenon, absence \ of the 
putative cytosolic receptor or to a fundamental difference in 
lipid metabolism between species. With reference to 
peroxisomal beta-oxidation, the high dose level in the 
marmoset appears to correlate to the plateau on tfre dose 
response curve indicating that increasing the dose level would 
have little effect on this parameter (figure 5.16). It should 
be emphasised that this high dose level represented the
maximum tolerated dose in the marmoset. Induction of
peroxisomal beta-oxidation in the marmoset is not due to a 
dose dependent phenomenon. In the rat, sex differences in the 
hepatic response to peroxisome prolif erators have been 
observed (Reddy and Lalwani, 1983). In general the response was 
greater in male animals than females at the same dose level. 
By increasing the dose level the difference in response 
between male and female animals is abolished indicating a 
dose-dependent induction. With ciprofibrate the extent of
hepatomegaly in the Fischer rat and treatment-induced changes
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in glutathione peroxidase and omega- and (omega-1)-hydroxylase 
activities were the same in both sexes at the same dose level 
(Makowska et al., unpublished observations,1987).
In the rat, most of the very low density lipoproteins and 
chylomicra remnants are taken up into liver cells whilst in 
man and primates these are remodelled on the cell surface and 
re-exported into blood as low density lipoproteins (Cohen and 
Grasso,1981). Therefore in the guinea pig and marmoset there 
is no intra-hepatic accumulation of lipid associated with 
treatment, in accordance with the hypothesis presented in 
figure 7.1.
The lack of response in the marmoset is not due to low drug 
absorption (Sterling-Winthrop, personal communication), or to 
a difference in metabolic transformation as ciprofibrate is 
the active compound. On a theoretical basis, drug plasma 
levels and the extent of plasma protein binding at the low 
dose level in the rat (2mg/kg) and high dose level in the 
marmoset (80-100 mg/kg) were similar and would not therefore 
account for species differences in response. The lack of 
response in the guinea pig and marmoset would appear to be due 
to inherent species differences in induction probably related 
to species differences in hepatic lipid metabolism or genetic 
responsiveness.
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7.5. EXTRAPOLATION OF LABORATORY ANIMAL STUDIES TO PREDICT 
THE RESPONSE IN NON-HUMAN PRIMATES AND MAN.
The evaluation of the safety of chemicals in man is based 
largely upon the extrapolation of animal data to predict the 
likelihood of toxicity. A marked variability in response 
between species may exist and this may be attributed to both 
qualitative and quantitative differences. This raises 
questions concerning the validity of using animal models for 
the purposes of extrapolation. Detailed knowledge of the 
pharmacodynamic and pharmacokinetic profiles of the compound 
both in man and the comparative animal model is required. 
Evidence of toxicity in the animal model may be absent in man 
or alleviated by reducing both the dose and frequency of 
administration. In the rat, the ultimate expression of early 
toxicity is frequently carcinogenesis and the relevance of 
using rodent data in interpreting the possible carcinogenic 
risk to man is a major concern.
It is clear that the hepatic response to ciprofibrate in the 
rat is different to the response in the marmoset. In the 
previous sections the mechanisms of induction were described 
in an attempt to elucidate the cause of the apparent species 
specificity of ciprofibrate-induced liver changes. The 
differences in hepatic response between these two species 
cannot be attributed to the pharmacokinetic phase of drug 
action. The long half life of ciprofibrate in the rat has been 
attributed to extensive enterohepatic recirculation which has 
also been demonstrated with fenofibrate (Davison et al.,1975,
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Weil et al.,1987). This may explain the sensitivity of the rat 
to these compounds. In the marmoset elimination of 
ciprofibrate was biphasic (t 1/2 alpha is 4.5 hours, t 1/2 
beta is 8.2 hours). The half life of ciprofibrate in the 
marmoset is clearly shorter than in the rat.
In the rat peroxisome prolif erators produce a predictably 
similar pleiotropic response which includes hepatomegaly and 
induction of cytochrome P-452, carnitine acetyltransferase and 
mitochondrial and peroxisomal beta-oxidation enzymes. In
addition long chain acyl-CoA hydrolase and microsomal 
1-acyl-glycerophosphorylcholine acy 1-transferase activities
were induced in clofibrate treated rats and mice but not in 
treated guinea pigs (Kawashima et al.,1983 and 1984). A close 
link was established between bilirubin UDP-glucuronosyl-
transferase induction and increased catalytic activity of 
cytochrome P-452 (Fournel et al.,1985). Measurement of these 
latter enzymes in the marmoset would be of interest. These 
three enzymes would appear to be under coordinate regulation 
with microsomal, peroxisomal and mitochondrial parameters.
The administration of peroxisome prolif erators to rats is 
associated with a decrease in serum triglyceride levels giving 
rise to the term "hypolipidaemic agent". At high dose levels a 
reduction in serum cholesterol has been observed for example 
with clofibrate, bezafibrate and ciprofibrate (Dvornik and 
Cayen,1980). However hypocholesterolaemic drugs such as 
probucol reduce cholesterol levels but have no triglyceride- 
lowering effects (Cohen and Grasso,1981). The early liver
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changes observed with peroxisome prolif erators are absent in 
animals treated with hypocholesterolaemic compounds. This 
would correlate with the hypothesis that intra-hepatic lipid
accumulation initiates induction. Probucol acts by enhancing 
faecal excretion of bile acids while reducing cholesterol 
synthesis and slightly decreasing absorption of dietary
cholesterol (Miettinen,1972). It has been speculated that 
increased microsomal, peroxisomal and mitochondrial oxidation 
of fatty acids may be responsible for the hypolipidaemic
action of peroxisome prolif erators however the relative 
contributions have not been established. An increase in 
hepatic fatty acid binding protein (hFABP) has been observed 
with clofibrate treatment (Bass et al.,1985). This correlated 
with an increased rate of uptake and utilisation of free fatty 
acids by perfused liver following clofibrate treatment. It has 
been suggested that the early hypolipidaemic effect of 
clofibrate in rats and primates may be related to an enhanced 
hepatic oxidation of long chain fatty acids but this was not 
merely due to a reduction in esterification to complex lipids 
(Capuzzi et al.,1983). Bezafibrate administration may cause 
inhibition of hepatic fatty acid synthesis (Ayala et al.,1987) 
and inhibition of beta-hydroxymethylglutaryl CoA reductase, 
the rate limiting step in the formation of cholesterol from 
acetate in the liver (Monk and Todd,1987). The decrease in 
serum triglycerides in patients during bezafibrate treatment 
was reported to be due to an increased activity of skeletal 
muscle tissue lipoprotein lipase activity (Vessby et 
al.,1982). The mechanisms accounting for the hypolipidaemic
action need to be elucidated to provide a possible insight
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into species differences.
In figure 7.2. a scheme is presented to explain induction of 
microsomal, peroxisomal and mitochondrial enzymes in the rat 
under states of altered lipid metabolism. Diabetes and 
starvation cause increased lipase activity giving rise to 
medium and long chain fatty acids (Mortensen et al.,1986). An 
influx of fatty acid substrates into hepatocytes is predicted, 
initiating cytochrome P-452 induction. Omega-oxidation of 
sterate was stimulated 3 to 7-fold in starved and diabetic
rats (Bjorkhem,1973). A 2-fold increase in the level and 
catalytic activity of cytochrome P-452 has been observed in 
streptozotocin-diabetic rats (Sharma et al.,1988b). The 
omega-hydroxylase products of cytochrome P-452 could induce 
peroxisomal beta-oxidation enzymes. Increased peroxisomal 
enoyl-CoA hydratase activity and peroxisomal palmitoyl-CoA 
oxidation has been observed in diabetic and starved rats 
(Hertz and Bar-Tanna,1987). Peroxisomal proliferator acyl-CoA 
derivatives, such as clofibroyl-CoA, may act as the reactive
intermediate initiating induction (Berge et al.,1987, and 
Caldwell, 1984). However it should be pointed out that
elevation of long chain acyl-CoA seems not to be involved in 
the mechanism of induction of the beta-oxidation enzymes since 
induction of mRNA for enoyl-CoA hydratase : 
beta-hydroxyacyl-CoA dehydrogenase preceded the rise in long 
chain acyl-CoA (Fukami et al.,1986).
DNA-damage may arise from acylglucuronide metabolites of 
peroxisome prolif erators such as clofibrate (Faed and
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Figure 7.2.
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McQueen,1978). Acyl or ester glucuronides are distinguished 
from the more common "ether-type" by their susceptibility to 
nucleophile substitution which is due to the presence of the 
unsaturated carbonyl group in the molecule (Faed,1984). Acyl 
migration may take place resulting in intra-molecular 
rearrangement of the conjugate with covalent binding capacity 
(Wells et al.,1987). The 1-0-acyl-glucuronide of clofibrate is 
formed in vivo in the rat, mouse, guinea pig, rabbit and man 
(Caldwell and Emudianughe,1979, Caldwell et al.,1979, Sinclair 
and Caldwell,1982). This metabolite was shown to be an active 
chemical electrophile acylating albumin in vitro via 
trans-esterification and may represent a molecular mechanism 
of toxicity (Van Breeman and Fenselau, 1985). An acyl-linked 
mercapturic acid metabolite of clofibrate has been identified 
in human urine and the electrophilic properties may result in 
covalent interactions (Stogniew and Fenselau,1982). Aldehydes, 
epoxides and other lipid peroxidation products may be 
implicated in the development of hepatocarcinogenesis. 
Peroxisomal aldehyde dehydrogenase may function as a 
detoxification mechanism metabolising aldehydes into 
carboxylic acids (Turteltaub and Murphy,1987).
Tumour promoters such as the peroxisome prolif erators, may act 
directly on cell membranes. The phorbol ester, 12-0-tetra- 
decanoyl-phorbol-13-acetate (TPA), in rat cell culture, 
increased peroxisomal beta-oxidation, carnitine
acetyltransf erase, palmitoyl-CoA hydrolase and catalase 
activities (Lillehaug and Berge,1986). Phorbol esters interact 
with a high affinity saturable membrane receptor which appears
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to be a calcium and lipid binding protein kinase C. 
Phosphorylation of proteins by this kinase may modulate many 
cell regulatory functions including gene activation (Kensler 
and Trush,1984). An excellent correlation between tumour 
promoting activity of various compounds and their ability to 
induce ornithine decarboxylase (ODC) has been reported 
(O'Brien et al.,1975). The induction of this enzyme by 
peroxisome prolif erators does not appear to be a specific 
event associated with the development of preneoplastic foci 
and hepatocarcinogenesis but with sustained maintenance of 
hepatomegaly and increased liver cell proliferation (Izumi et 
al.,1981). ODC induction was not accompanied by an elevation 
in cAMP or increased activation of cytoplasmic cAMP-dependent 
protein kinases [types I and II] (Fukami et al.,1986).
The carcinogenic process in laboratory animals can be modified 
by genetics, age, sex and endocrine status and extrinsic 
factors such as mode and regimen of exposure, housing, 
nutrition and xenobiotic administration (Williams,1984). A 
high fat and low selenium diet has been shown to potentiate 
the initiation and promotion of aflatoxin B[l]-induced 
preneoplastic foci in rat liver (Baldwin and Parker, 1987). 
Hepatic glutathione peroxidase activity was decreased in 
patients with hepatocellular carcinomas (Corrocher et 
al.,1986). Chemical modulation of this enzyme may increase the 
carcinogenic risk in laboratory animals and man. However in 
neoplastic human adult lung tissues, glutathione peroxidase 
was unchanged or increased (Di Ilio et al.,1987).
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Treatment-induced changes may arise from modulation of growth 
factors/hormones. It has been proposed that TPA induces 
synthesis of a protein[s] similar in function to growth
factors (Levine,1982). This protein reacts with a cell 
membrane receptor leading to a growth factor stimulated
arachidonic acid metabolic cascade causally related to 
promotion. Arachidonic acid transformation may mediate tumour 
promotion by altering membrane fluidity (Levine, 1982). In 
mouse liver, the expression and repression of sex-dependent
testosterone hydroxylases are regulated pretranslationally by 
growth hormone (Noshiro and Negishi, 1986). The processes by 
which serum growth hormone mediates transcriptional regulation 
of hydroxylase genes through the cell membrane are unclear.
Steroids can serve as highly specific substrates for hepatic 
cytochrome P-450 enzymes and as hormone regulators of
isoenzyme expression (Waxman,1988). Growth hormone may act 
directly to activate cytochrome P-450 gene expression or 
indirectly, mediated by other endocrine factors such as 
somatomedians. The hyperplastic effect induced by peroxisome 
prolif erators while transient in the acute phase, may after 
chronic administration, induce constitutive cell cycling in 
some mononucleated cells by changing the expression of genes 
controlling differentiation in particular, those responsible 
for receptors to growth factors such as epidermal growth 
factor (Styles et al.,1987).
Hepatocarcinogenesis in laboratory animals may arise from 
activation of cellular oncogenes. An active cellular oncogene
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was demonstrated in hepatocellular neoplasms arising 
spontaneously in untreated 24-month old B6C3F1 mice (Fox and 
Watanabe,1985). Preliminary investigations with nafenopin 
indicated that treatment was associated with prolonged 
activation of cellular oncogenes (Bentley et al.,1987). A 
cellular gene termed "hap" has been isolated from human 
hepatocellular carcinoma and the sequence was similar to DNA 
binding hormone receptors (De The et al.,1987). This "hap" 
gene product may be a novel ligand-responsive regulatory 
protein whose inappropriate expression in liver may relate to 
hepatocarcinogenesis.
The hepatic response to ciprofibrate in the rat is 
characteristic of all peroxisome prolif erators. This suggests 
that there is a set of gene products or a "peroxisome- 
proliferator domain" which is under coordinate regulation. 
Increased catalytic activity correlates to transcriptional 
activation of the genes. The species difference in response 
probably reflects a different mechanism of induction and gene 
regulation. Gene dosage may be a critical factor.
The occurrence of peroxisome proliferation in non-human 
primates and man remains questionable. This study has shown 
the guinea pig and marmoset to be non-responsive. Peroxisome 
proliferation and induction of peroxisomal beta-oxidation 
enzymes does not occur with clofibrate in human hepatoma cell 
lines PLC/PRF/5 and SK-HEP-1 (Hertz et al.,1987). The 
assessment of chemical safety in man depends often upon 
laboratory animal studies. An added complication in human risk
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prediction is the use of excessively high doses in animal 
studies. This may affect the disposition of the compound as 
metabolic pathways can be dose-related or saturable. 
Understanding the potential role that cellular oncogenes may 
play in tumour development in animals used for long term 
studies is important for proper interpretation of data and
assessment of potential risk. In cases where there is evidence 
that the test compound is acting by non-genotoxic mechanisms 
to enhance liver tumour incidence under conditions of high 
exposure it seems likely that low exposure to humans does not 
represent a serious risk (ECETOC,1982).
The research presented in this thesis has shown that marked 
species differences in hepatic responses to ciprofibrate 
exist. It is equally clear that with ciprofibrate,
extrapolation from rat studies to predict the response in the 
marmoset is not scientifically accurate as the response in the 
rat is dissimilar to that in the marmoset. The response
between the marmoset and man is assumed to be more similar
than the relationship with rodents, with the inference that in 
man peroxisome prolif erators do not pose as a toxicological 
hazard.
SUGGESTIONS FOR FURTHER WORK
In the last few years considerable progress has been made in 
the study of peroxisome prolif erators. The pleiotropic 
response to administration appears to be tissue specific for 
the liver and induction is not associated with all species.
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Various mechanisms of induction (enzyme changes and 
hepatocarcinogenesis) have been proposed but further 
supportive experimental evidence is required.
The mechanism(s) of induced changes must be established in 
order to rationalise species differences in response. The 
chronological sequence of induction in different subcellular 
fractions must be ascertained and similarly the mechanism 
leading to the observed hypolipidaemic effect should be 
clarified. A greater understanding of gene structure and gene 
expression has been achieved recently with insight into gene 
regulation. It is anticipated that progress will continue and 
that techniques of molecular biology will be increasingly used 
in toxicology. At present cDNA probes to cytochrome P-452, 
glutathione peroxidase, fatty acyl-CoA oxidase and the 
peroxisomal bifunctional protein, are available in our 
laboratory and these should be used to study gene expression. 
The influence of peroxisome prolif erators on mRNA 
accumulation, transcriptional activation and DNA binding 
proteins of the genes coding for the above enzymes should be 
determined. The temporal aspects of gene expression in 
responsive species and tissues must be assessed. The ultimate 
goal of research into these compounds must be to delineate 
which changes in gene expression are a prerequiste for the 
final manifestation of toxicity.
A greater understanding of genetic regulation upon xenobiotic 
pretreatment would be attained and in addition recombinant DNA 
technology could play a role in clinical / toxicological
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diagnosis. Isolation and characterisation of human genomic 
cytochrome P-452, glutathione peroxidase and peroxisomal 
enzyme DNA will allow for more accurate risk assessment of 
these compounds in man.
f
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APPENDIX 1.
HAEMATOLOGY, CLINICAL BIOCHEMISTRY AND AUTOPSY PROCEDURES 
COMPLETED IN THE MARMOSET STUDIES.
Haematology ;
Red cell count, white cell count (including differential), 
haemoglobin, haematocrit and platelet count.
Clinical biochemistry ;
Aspartate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, lactate dehydrogenase, gamma-glutamyl 
transpeptidase, creatine kinase, total protein, urea, 
creatinine, cholesterol, triglyceride and bilirubin. Plasma 
hormones determined by radioimmunoassay; insulin and gastrin.
Autopsy procedures ;
Gross observations; examination of all external surfaces and 
orifice, macroscopic observation of organs in situ. 
Tissue for histological examination;
Adipose, adrenals, aorta, bone marrow (sternum), bladder, 
brain (medulla/pens; cerebellar cortex; cerebrum), eyes, gall 
bladder, heart, intestine (duodenum, jejunum, ileum, colon), 
kidneys, liver, lungs, lymph node (mesenteric and cervical), 
oesophagus, pancreas, pituitary, prostate, salivary gland 
(submaxillary), skeletal muscle (thigh), skin, spinal cord 
(cervical; mid-thoracic; lumbar), spleen, stomach, testes 
(with epididymes), thymus, thyroid and parathyroid, tongue, 
trachea and any gross changes c£ uncertain nature of tissue 
masses.
APPENDIX 2.
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TAXONOMY OF THE DIFFERENT SPECIES*
Terrestrial Vertebrates;
Class : Mammalia 
Order : Rodentia 
Sub-order : Myomorpha
for example - mouse and rat.
Class : Mammalia 
Order : Rodentia 
Sub-order : Hystricomorpha
for example - guinea pig and hamster.
Class : Mammalia
Order : Lagomorpha Duplicidentata 
for example rabbit.
Class : Mammalia 
Order : Primates 
Sub-order : Anthropoidea 
Infra-order : Platyrrhini 
Family : Hapalidae 
Species : Callithrix jacchus
Derived from Romer, (1966).
